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Abstract
The ELM erythroleukaemia system is unusual in that the erythroleukaemia cells 
growing in vivo in the spleen cannot be maintained in vitro except in contact with bone 
marrow-derived stromal cells. They are also unusual in that they retain the ability to 
undergo erythroid differentiation in response to physiological growth factors, such as 
Epo and IL-3. Clonal stroma-dependent ELM cells (ELM-D) have been isolated in the 
presence of stroma. By selecting for growth of ELM-D cells without stroma, a series of 
stroma-independent clones (ELM-Is) have also been obtained. They are more 
tumorigenic when injected into mice compared with their stroma-dependent parent. All 
of the stroma-independent clones, apart from one (i.e. ELM-I/1), are still able to 
differentiate into mature erythroid cells in response to Epo or IL-3. This particular cell 
line, that is blocked in differentiation, also displays the highest tumorigenicity in vivo. 
The ELM system therefore provides a unique opportunity to analyse the molecular 
nature of stromal control of erythropoiesis, and identify genetic events involved in 
confering stroma-independent growth, differentiation arrest and increased 
tumorigenicity.
The work presented in this thesis has demonstrated that, upon stroma-withdrawal, the 
majority of the ELM-D population dies out with characteristics of apoptosis. However, 
the fact, that a -globin expression in ELM-D cells is largely increased when the stroma is 
removed, indicates that ELM-D cells undergo erythroid differentiation in the absence of 
the stroma. Therefore, at least one mechanism whereby the stromal cells maintain the 
long-term growth of ELM-D cells is to prevent them from further maturation.
Gene expression and functional studies of the ELM system have revealed the following:
(1) The stroma-independent cells display an elevated expression of an ets oncogene, erg, 
at the mRNA level in comparison to ELM-D cells. However, only ELM-I/1 cells 
seem to express detectable level of the Erg protein.
(2) The expression of another ets oncogene, fli-1, in the ELM-I/1 cells is significantly 
activated at both mRNA and protein levels, but is absent in all the other ELM cells;
(3) The bcl-2 expression at the mRNA level in the stroma-independent cells is higher 
than that in ELM-D cells, especially in ELM-I/1 which is the only cell line wherein 
the Bcl-2 protein is expressed at a detectable level. Functional analysis indicate that 
over-expression of bcl-2 is not sufficient to induce differentiation arrest or increased 
tumorigenicity in ELM-I cells.
Finally, transient transfection assays have demonstrated that the Fli-1 protein can 
transactivate a partial bcl-2 promoter in a quail fibroblast cell line. The bcl-2 promoter 
activity is higher in ELM-I/1 cells, which express high levels of Fli-1 protein, than that 
in ELM-I/2 cells, which do not express fli-1 at all. This implies that Fli-1 may be 
responsible for the up-regulation of bcl-2 expression in ELM-I/1 cells. DNase I 
footprinting analysis has identified six binding sites for the ELM nuclear proteins within 
the minimum bcl-2 promoter region. However, gel retardation assays and “supershift” 
analysis using a Fli-1-specific antibody do not reveal the binding of Fli-1 to any of the 
six nuclear protein binding sites. The tentative conclusion is, therefore, that Fli-1 may 
transactivate the bcl-2 promoter by an indirect mechanism.
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PARTI: INTRODUCTION
1
CHAPTER 1: Haemopoiesis
Human peripheral blood constitutes 7% of body weight and about one-half blood 
volume is occupied by erythrocytes. Since erythrocytes and other blood cells have an 
average life span of 4 months or less, it has been estimated that, in human, 
approximately 3.7 x 1011 blood cells need to be produced per day to replace those lost 
by natural wastage. Injury, infection and haemotological stress increase this demand for 
cell production further. This generation of blood cells - haemopoeisis - is a multi-step 
process involving extraordinary self-renewal of rare haemopoietic stem cells, 
proliferative expansion of multi-lineage progenitor cells, progressive commitment of 
progenitors to single lineage differentiation, and consequent positioning of the cells 
within the tissue.
Regulation of haemopoiesis is mediated, at least in part, by a range of stimulatory and 
inhibitory growth factors that influence the haemopoietic stem cells, their more 
developmentally restricted progeny, or both. These include interleukins-1 to -11 (IL-1 to 
IL-11), haemopoietic cell colony-stimulating factors (CSFs), erythropoietin (Epo), 
thrombopoietin, stem cell factor (SCF, also known as c-kit ligand or mast cell growth 
factor), transforming growth factor p (TGF-p), macrophage inflammatory protein l a  
(MIPl-a), and various other growth factors such as the interferons (IFNs) and insulin­
like growth factors (IGFs) (Whetton and Dexter, 1993; D’Andrea, 1994). Many of these 
growth factors have overlapping biological activities and target cells, and different 
combinations of growth factors seem to have different biological effects.
In addition, the haemopoietic microenvironment (HM), especially stromal cells, also 
plays a pivotal role (Zipori and Tamir, 1989; Zipori, 1992). At the sites of haemopoiesis, 
that is, bone marrow, spleen and foetal liver, proliferation and differentiation of 
haemopoietic stem and progenitor cells occur in intimate contact with the stromal cells 
and the associated extracellular matrix (ECM). Electron microscopy revealed intimate 
interactions between haemopoietic cells and the stromal cells, which form secluded 
niches within HM. Although the exact role of the HM in determining haemopoietic stem 
and progenitor cell behaviour is not fully known, multiple possible functions have been 
theorised. As currently envisioned, the HM provides direct cell-cell contact between 
supporting and haemopoietic cells, provides anchorage for both growth factors and 
haemopoietic cells, supplies specific positive and negative growth regulatory factors, 
and probably provides for multiple cellular communications within what we have 
termed a “local area network”. Within this network, stromal cells probably play a key 
role by both producing growth regulatory proteins and secreting complex ECM proteins 
for stabilisation of growth factors in high local concentrations within the adherent layer
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of haemopoietic stem and progenitor cells. In particular, sequestration of growth factors 
on ECM components of stromal tissues and expression of membrane forms of growth 
factors may provide the basis for the formation of microenvironments (Zipori, 1992). 
The locally concentrated presentation of growth factors at the adherent stromal cell 
surface is thought to prime the stem and progenitors cells to respond to combinations of 
other local or circulating factors at physiologically relevant concentrations.
Relatively little is known about the differentiation-inducing activity of haemopoietic 
growth factors (HGFs) or microenvironment but two plausible models have been 
proposed, the instructive and stochastic models (D’Andrea, 1994), which might not 
necessarily be mutually exclusive, as agreed by the hybrid model, and exactly which 
model dominates may depend on cellular context, differentiation stage of the cells, the 
presence of other factors. The instructive model argues that binding of the HGFs to their 
receptors in combination with other components of the cellular microenvironment, such 
as cell adhesion molecules and (ECM), acts as an inducer of differentiation and 
determines lineage choice from multi-potent cells, presumably by influencing gene 
expression. In contrast, the stochastic model are based on the premise that multi-potent 
cells do not require exposure to external inducing stimuli to express the genetic changes 
that are presumably required for lineage restriction and argues that HGFs and HM 
simply permit the proliferation and development of these intrinsically committed cells 
and the subsequent expression of the mature cell phenotype.
In either model, HGFs and HM are proposed to act through a series of secondary 
messengers which transduce signals into the nucleus that lead to initiation of 
differentiation programs and co-ordinated, lineage-specific gene expression. Therefore, 
key transcription factors, including c-Myb, GATA-1, GATA-2, SCL/Tal-1, Rbtn2/LM02, 
Ikaros, Pax-5, PU.l, NF-E2 and EKLF, are essential for multiple aspects of 
haemopoietic development - from survival, proliferation, lineage commitment through 
terminal maturation (Orkin, 1995; Shivdasani et al., 1996; also see Section 2.2).
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CHAPTER 2: Erythropoiesis and “Erythroid-specific” 
Transcriptional Regulators
2.1. Erythropoiesis.
The earliest committed erythroid cell is a lineage-restricted product of a myeloid 
precursor, a cell derived from a pluripotent stem cell that has the potential to generate all 
other myeloid cells. There are two distinct types of committed erythroid progenitors, 
initially defined by the type of colony derived from such immature cells in semisolid 
methocel medium or fibrin clots. They are termed colony forming unit-erythroid (CFU- 
E), the mature progenitor, and burst forming unit-erythroid (BFU-E), the more primitive 
one (Figure 2.1). However, these two groups of cells probably represent two extremes of 
a continuum of development from the earliest unipotent progenitor cell to the mature 
erythrocyte. The CFU-E gives rise to a small colony of 10-50 mature, haemoglobinised 
cells within 2-3 days. On the other hand, the BFU-E develops into diffuse colony of tens 
to hundreds of CFU-E, each of which then forms a compact colony, resulting in “burst­
like” colonies containing thousands to tens of thousands of mature erythrocytes after 6- 
10 days. Under defined conditions, these two types of colonies appear with highly 
reproducible kinetics. This suggests that erythroid differentiation is a rigid program that 
involves a fixed number of cell divisions and, at the CFU-E stage, leads to dramatic, 
complex changes in gene expression as well as in cell shape and function (reviewed by 
Beug et a l , 1994).
Numerous studies over the years have yielded substantial insights into the molecular 
mechanisms whereby haemopoietic growth factors (HGFs) regulate erythroid 
differentiation. Using highly purified human CFU-E and BFU-E, it was shown that 
CFU-E require erythropoietin (Epo) and insulin-like growth factor 1 (IGF-1) and/or 
insulin for colony formation in fibrin clots (Sawada et a l , 1989); whereas BFU-E 
require human stem cell factor (SCF), the ligand for the receptor tyrosine kinase c-Kit, 
for growth and differentiation in culture (Dai et al., 1991). Studies employing purified 
BFU-E indicated that these cells are able to “count” generations (Sawada et a l,  1991; 
also see Figure 2.1): when the progenitors were first cultivated in liquid medium for 
increasing time periods and then assayed in fibrin clots for their remaining cell division 
capacity, the size of erythroid colonies obtained was inversely proportional to the 
number of cell doublings in suspension culture prior to colony formation in the fibrin 
clots. This, and work by others (Beug et a l, 1994), indicates that erythroid 
differentiation involves co-ordinated re-programming of gene transcription and specific 
alterations in cell cycle control. Upon differentiation induction, the CFU-E cells undergo 
five cell divisions during the first three days of differentiation and then arrest in G1
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Figure 2.1. Current view of normal erythroid differentiation as revealed by bone 
marrow colony assays and work on purified progenitors.
Two types of morphologically un-differentiated progenitors, the early BFU-E and 
its descendant, the more mature CFU-E, differentiate into post-mitotic erythrocytes 
via partially differentiated intermediates. The continuous increase in cell number, 
and the fact that both differentiation of BFU-E into CFU-E and terminal differen­
tiation of the latter may involve a strict cell division program able to “count” cell 
generations, are indicated at the right. The ability of retroviral oncogenes to induce 
continuous self-renewal (circular arrow) is also depicted (adapted from Beug et al., 
1994).
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(Beug et al., 1994). The final steps in the development of fully mature erythrocytes 
proceed in the absence of further cell divisions. Two important and active events occur 
in the first 16-24h after induction of differentiation. Firstly, the gene expression pattern 
of the cells was extensively re-programmed. The expression of genes characteristic of 
self-renewing cells (e.g. c-myb, c-kit and the oestrogen receptor gene) abruptly ceases, 
whereas expression of erythroid-specific transcription factors, such as GATA-1, GATA- 
2, SCL, NF-E2 (disccused in detail in Section 2.2), is strongly up-regulated, followed 
slightly later by the activation of numerous genes encoding late erythrocyte proteins 
(Beug et a l , 1994). Secondly, the cell proliferation rate increases drastically, as 
indicated by a reduction of cell cycle length from about 20 to 12h, which is almost 
entirely due to a shortening of the G1 period from 12 to 5 h, while S and G2 phase 
lengths are not affected (Beug et al., 1994). Contraction of cell cycle is accompanied by 
a decrease in cell volume from about 300 to less than 70 femtolitres. Measurements of 
amino acid incorporation versus cell size showed that the rate of protein synthesis 
normalised to cell volume remains constant (Beug et al., 1994). Thus cell size reduction 
seems to be a necessary consequence of G1 shortening in this case, as reduced 
production of cellular mass due to the shorter G1 phase could not be compensated for by 
a higher rate of protein synthesis. It is tempting to speculate that the progressive size 
reduction undergone by the maturing cells during the five “terminal differentiation 
divisions” is one of the mechanisms by which the differentiating cells “count” cell 
divisions (perhaps similar to those found in early embryogenesis). All these findings 
provide the first tentative evidence that erythroid differentiation, like myoblast 
differentiation, may involve control by a “master switch”, which not only completely re­
programs the pattern of gene expression, but also profoundly alters cell cycle control. It 
is logic to consider the possible existence of “master switch” as it is unlikely that HGFs 
regulate directly every details of commitment and/or differentiation sequence. They may 
merely initiate a self-sustaining genetic programme which is intrinsically determined by 
the cells of question.
In addition to HGFs, the microenvironment created by stromal cells is also essential for 
erythropoiesis (Zipori and Tamir, 1989; Zipori, 1992; also see Chapter 1). A series of 
studies carried out in Dr. M. Obinata’s laboratory demonstrated that stromal endothelial 
(Yanai et a l, 1989; Yanai et al., 1991) and epithelial-like cell lines (Ohneda et a l, 
1990), derived from mouse spleen and foetal liver, respectively, are able to support large 
erythroid colony formation and mimic erythropoiesis in vivo. The resulting mature 
erythrocytes and erythroblasts showing cytoplasmic budding were present in the large 
erythroid colonies generated on the stromal cell lines. This kind of in vitro 
microenvironment seems to be created by direct contact and/or short range 
communication between the erythroid progenitor cells and the stromal cell layer since 
large erythroid colonies were not formed if the progenitor cells were separated from the
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stromal cells by a diffusion chamber or a nucleopore filter. Supplementing with 
conditioned medium from the stromal cells did not surpport the colony formation, nor 
did various combinations of soluble growth factors such as IL-3, GM-CFS and Epo. The 
study was extended by examining the roles of adhesion molecules in erythropoiesis 
using blocking antibodies (Yanai et al., 1994). These adhesion molecules include very 
late antigen-4 and -5 (VLA-4 and VLA-5 integrins) and the ligands for VLA-4, vascular 
cell adhesion molecule-1 (VCAM-1) and fibronectin (FN). The data demonstrated that, 
although all of them can mediate adhesion of the erythroid progenitors cells to the 
stroma, formation of large erythroid colonies is only inhibited by the blocking 
antibodies against VLA-4 and VCAM-1. This implies that collaborative interaction 
between VLA-4 and VCAM-1 may be important in providing adequate signalling for 
the erythroid progenitor cells in the erythropoietic microenvironment. Consistent with 
this conclusion is the recent finding by Hamamura et a l (1996) who performed in utero 
treatment of mice with an anti-VLA-4 monoclonal antibody. They found that, although 
all haemopoietic cells in foetal liver expressed VLA-4, the treatment specifically 
induced anaemia, and it had no effect on the development of non-erythroid lineage cells, 
including lymphoids and myeloids. In the treated liver, almost no mature eiythroblasts 
were detected, although erythroid progenitors were present as judged by their ability to 
form erythroid colonies in vitro. These results indicate that VLA-4 plays a critical role 
in erythropoiesis specifically in vivo.
2.2. Transcriptional regulation of erythropoiesis by GATA-1, SCLITal-1 and 
related proteins.
As discussed in Chapter 1, haemopoiesis is the process by which blood cells acquire 
particular phenotypes as a result of co-ordinated, cell-specific gene expression. The 
pattern of gene expression within a cell is established, to a large extent, by cell-specific 
transcription factors that mediate the net effect of the variety of proliferation and 
differentiation signals which impinge on the cell. Hence, understanding the functions of 
transcription factors is essential to the study of haemopoeisis. In this section, 
transcriptional regulation of erythropoiesis by GATA-1, SCLITal-1 and the related 
proteins, such as LIM, Kriipple and Id  family proteins, will be discussed (reviewed by 
Bockamp et al., 1994; Orkin 1995; Shivdasani and Orkin, 1996; Green, 1996).
2.2.1. GATA-1.
GATA-1 is the first example of a family of zinc finger proteins that bind to the DNA 
sequence motif GATA. The GAT A family proteins share a conserved, cysteine-rich, 
metal-binding motif, which contains two finger domains and is essential for DNA 
binding. Structural and functional analysis of GATA-1 has also revealed a C-terminal
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activation domain capable of transactivating reporter constructs containing a GATA 
motif in fibroblasts (Martin et al., 1990). Within haemopoietic cells, expression of gata- 
1 is very abundant in erythroid cells, and is also present in megakaryocyte, eosinophil, 
mast cell lineages and multipotential progenitors. During differentiation, the gata-1 
mRNA level increases in some lineages including erythoid, whereas it decreases in 
others including granulocyte and monocytes (Bockamp et a l, 1994). Thus, GATA-1 
seems to play a role in differentiation of multiple blood lineages. More persuasive 
evidence in support of GATA-1 as a lineage-directing transcription factor has recently 
been provided by experiments in Myb-Ets- or v-vWyc-transformed myelomonocytic cell 
lines (Kulessa et a l, 1995). Over-expression of gata-1 in these cell lines reprograms 
these cells into eosinophils, thromboblasts and erythroblats. Gata-1-null embryonic 
stem (ES) cells do not produce mature erythroid cells when injected into mouse 
blastocysts, although gata-Tf' ES cells in those chimeric mice are fully able to develop 
into other haemopoietic lineages as well as other tissues (Pevny et a l, 1991; Simon et 
a l, 1992). The consequences of absence of gata-1 have been further defined by in vitro 
differentiation assays, which show a maturation arrest of erythroid precursors at the pro- 
erythrblast stage followed by apoptosis of these cells (Weiss et a l, 1994; Pevny et a l, 
1995; Weiss and Orkin, 1995). Thus, although a role for GATA-1 in lineage selection is 
possible, it is the survival and terminal maturation of erythroid precursors that appear to 
be critically dependent on GATA-1. Target genes for GATA-1 include the gata-1 gene 
itself, globin genes, and numerous other genes expressed specifically in erythroid and 
megakaryocyte lineages. Overall, an emerging theme for GATA-1 action appears to be 
that it promotes differentiation both by inducing differentiation-specific genes and by 
simultaneously suppressing genes involved in cell proliferation.
Modulation of GATA-1 activity has been shown to be the consequence of exposure to 
growth factors or differentiation inducers, and this occurs at various levels including 
transcriptional regulation, re-localisation, phosphorylation, and direct physical 
interactions. Baron and Farrington (1994) showed that pro-erythroblasts and mature 
erythroid cells contain a diffusible activity (TAG) capable of transcriptional activation 
of the gata-1 gene, and that this activity decreases during terminal differentiation of 
these erythroid cells. Briegel et a l (1996) demonstrated that, in primary erythroid 
progenitor cells, the GATA-1 protein is predominantly located in the cytoplasm; while 
induction of differentiation causes its rapid re-localisation to the nucleus, suggesting that 
nuclear translocation may constitute an important regulatory step in GATA-1 activation. 
Crossley and Orkin (1994) reported that GATA-1 is phosphorylated on 6 serines within 
its amino terminus in un-induced murine erythroleukaemia cells (MEL), and a 7th site 
becomes phosphorylated after the MEL cells are induced to differentiate by DMSO. The 
significance of the induced phosphorylation is still elusive as it does not influence
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DNA-binding affinity or sequence specificity, DNA bending, or transcriptional 
transactivation by GATA-1. Several proteins can modulate GATA-1 activity by direct 
physical contact and these include oestrogen receptor (ER) and the Krupple family 
proteins. Oestrogen is known to suppress erythropoiesis and induce apoptosis in 
erythroid cell lines in vitro. Recent evidence provided by Blobel et al. (1995) and Blobel 
and Orkin (1996) has shed light on the underlying molecular mechanisms. They 
demonstrated that oestrogen elicits its effects by inhibition of the transcriptional activity 
of GATA-1. Moreover, co-immunoprecipitation experiments demonstrated an 
association between GATA-1 and ER in a ligand-dependent manner. Merika and Orkin 
(1995) reported that GATA-1 activates transcription in a synergistic fashion with two 
Kriipple family factors, Spl and EKLF, by direct protein-protein interaction. Finally, 
nuclear localisation studies carried out by Elefanty et al. (1996) revealed specific bright 
foci of GATA-1 within the nucleus in erythroleukaemia cells, primary murine 
erythroblasts and megakaryocytes, in addition to diffused nucleoplasmic localisation. 
These foci, which were preferentially found adjacent to nucleoli or at the nuclear 
periphery, did not represent sites of active transcription or binding of GATA-1 to 
consensus sites in the p-globin loci. Interestingly, GATA-2 and GATA-3 proteins also 
localised to the same nuclear bodies in cell lines co-expressing gata-1, gata-2 or gata-3. 
This pattern of distribution is, thus far, unique to the GAT A transcription factors and 
suggests a protein-protein interaction with components of the nuclear bodies via the 
GAT A zinc finger domain.
2.2.2. SCLITal-1.
The scl/tal-1 (hereafter called set) gene was originally identified at the breakpoint of a 
chromosomal translocation in T-cell acute lymphoblastic leukaemia (Chen et al., 1990). 
Since then, three other related genes have been identified, LYL-1, NSCL and tal-2, all of 
which encode transcription factors that share a conserved basic helix-loop-helix (bHLH) 
motif. The scl expression is largely restricted to haemopoietic tissues, although some 
expression is seen in adult and developing brain and in endothelial cells. Within the 
haemopoietic system, scl is expressed in primitive multi-potent progenitors as well as in 
cells committed to the erythroid, mast, megakaryocytic lineages, but it is not found in 
several other cell types including T-cells, mature B-cells, or in many cell lines with 
granulocyte or monocyte characteristics.
Many lines of early evidence have implicated SCL as a positive regulator of erythroid 
differentiation and demonstrated that quantitative changes in the scl expression occur 
during normal erythroid and granulocyte/monocyte differentiation. For example, 
HMB A-induced erythroid differentiation of MEL cells results in biphasic modulation of 
the scl expression, with an early transient fall and a late rise in the scl mRNA (Green et
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a l , 1992). In contrast, HMBA-induced myeloid differentiation of K562 cells is 
accompanied by an early transient fall in the scl mRNA, which was initially recovered 
but subsequently followed by a late persistent down-regulation (Green et a l, 1993). 
Similarly, Epo-induced erythroid differentiation of FDCPmix A4 cells results in up- 
regulation of the scl mRNA, whereas growth factor-induced granulocyte/monocyte 
differentiation is accompanied by a marked decrease in the scl mRNA (Cross et a l, 
1994). Studies of the scl expression at the protein level in MEL cells during 
differentiation indicate that an early transient fall in the SCL protein is not required for 
erythroid differentiation (Murell et a l, 1995). Support for this concept has come from 
experiments involving over-expression of sense and antisense scl constructs. Exogenous 
expression of scl inhibits myeloid differentiation of Ml cells (Tanigawa et a l, 1993) but 
enhances erythroid differentiation of MEL cells (Apian et a l, 1992). Moreover, stable 
expression of antisense scl constructs inhibits erythroid differentiation of MEL cells 
(Apian et a l, 1992).
In addition, more recent data have also suggested a regulatory role of SCL in 
proliferation and anti-apoptosis. Leroy-Viard et a l (1995) reported a truncated form of 
SCL protein in a sub-clone of Jurkat T-cell line, which has a dramatically decreased 
DNA-binding activity to the SCL consensus sequence. It was found that the sub-clone 
exhibits premature apoptosis upon medium depletion or serum reduction when 
compared with the parental cells. Stable expression of the mutant SCL protein in Jurkat 
cells results in a phenotype that is similar to that of the mutant Jurkat subline, indicating 
that the truncated SCL protein behaves like a dominant negative mutant. Furthermore, 
Condorelli et al (1997) showed that in late myeloid progenitors and early leukaemic 
precursors, ectopic expression of scl induces a proliferative stimulus under sub-optimal 
culture conditions via an anti-apoptotic effect, which are accompanied by a marked 
inhibitory effect on differentiation. They also demonstrated that the proliferative effect 
of SCL depends on the integrity of the cell cycle checkpoints of the host cell, as 
observed for c-Myc and other oncogenes, and requires both DNA-binding and the 
heterodimerisation domains.
Although SCL is oncogenic in T-cells, the scl transgenic mice do not show any 
alterations in T-cell development and do not develop tumours (Robb et a l, 1995b). 
Neither does the transgene enhance tumorigenesis induced by infection with the 
Moloney murine leukaemia virus. The scZ-null mice die early in embryonic development 
and have no mature red blood cells (Robb et a l, 1995a; Shivdasani et al., 1995). Neither 
erythroid nor myeloid progenitors can be detected in yolk sacs, the normal source of 
haemopoietic progenitors in the early embryo. Analysis of chimeric mice demonstrated 
that the sc/-null ES cells make a substantial contribution to all non-haemopoietic tissues 
but do not contribute to any haemopoietic lineage (Porcher et a l, 1996; Robb et a l,
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1996). In vitro differentiation assays showed that both primitive and definitive 
haemopoietic cells are absent in the sc/-null embryonic bodies. Taken together, these 
results suggest that SCL functions very early in haemopoietic development, either in 
specification of ventral mesoderm to a blood cell fate, or in formation or maintenance of 
immature progenitors.
No target gene for SCL has been identified so far. Similar to GATA-1, the SCL activity 
also seems to be subject to the regulation by growth factors and differentiation inducers, 
and transcriptional control, phosphorylation and direct protein-protein interactions are 
three important mechanisms. Prasad et a l (1995) reported that Epo elicits a rapid, dose- 
dependent increase in the scl mRNA by increasing transcription of the gene and 
stabilising one of its transcripts. Furthermore, Epo also induces phosphorylation of the 
SCL protein, which results in an increase in DNA-binding activity. The full-length SCL 
protein binds a CANNTG element (E box) as a heterodimer with widely expressed E l 2 
and E47, both bHLH protein products of the E2A gene (Hsu et a l , 1991; Voronova and 
Lee, 1994). Such heterodimers may act by inhibiting the activation effects mediated by 
E l2 or E47 (Doyle et a l, 1994). More interesting is the subsequent demonstration of a 
direct interaction between SCL and a second T-cell oncoprotein, the L/M-domain 
protein LMO-2 (previously known as Rbtn-2 or TTG-2) (Valge-Archer et a l, 1994; 
Wadman et a l, 1994). This interaction may be physiological relevant because LMO-2 is 
co-expressed with scl in normal haemopoietic cells, and its “knockout” phenotype is 
remarkably similar to that of scl (Warren et a l, 1994). A final mechanism of the SCL 
regulation is mediated by another bHLH protein, Id. The Id  proteins lack the basic 
region for transactivation but retain the oligomerisation domain; thus, they can 
counteract the activating function of bHLH systems via Id/bHLH interaction and impede 
formation of bHLH/bHLH homo- or heterodimers. The Id  mRNA decreases in various 
cell lines when they are induced to differentiate (Benezra et a l, 1990), and over­
expression of Id suppresses muscle, myeloid and erythroid differentiation (Jen et a l, 
1992; Kreider et a l, 1992; Shoju et a l, 1994), suggesting that Id is a negative regulator 
of differentiation. Interestingly, Condorelli et a l, (1995) showed that the murine and 
human glutathione-S-transferase-/J2 polypeptides compete with the SCL/E2A-specific 
DNA-binding activity when added to nuclear extracts derived from erythroid culture 
cells, suggesting a functionally-important interaction of Id2 with the SCL/E2A complex.
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Chapter 3: Erythroleukaemia
3.1. Leukaemia and general mechanisms of leukaemogenesis.
Leukaemia results from uncontrolled proliferation or expansion of haemopoietic cells 
that do not retain the capacity to differentiate normally into mature blood cells 
(reviewed by Sawyer et al., 1991). The initiation and progression of leukaemia involve 
alterations in the normal homeostatic mechanisms used to regulate the self-renewal, 
proliferation, differentiation and apoptosis of blood cells. The study of leukaemogenic 
animal retroviruses, and the cloning of chromosomal translocation breakpoints from 
leukaemia patients, has led to identification of many proto-oncogenes involved in the 
development of leukaemia. These genes mainly encode growth factors, growth factor 
receptors, transcription factors and apoptotic proteins.
The first demonstration of the link between growth factors or their receptors and 
leukaemogenesis was the identification of the M-CSF receptor as the cellular 
counterpart of the v-fms oncogene of the Susan McDonough strain of feline sarcoma 
virus (Sherr et a l , 1985). The c-fms gene encodes a tyrosine kinase transmembrane 
receptor protein normally expressed in the monocyte-macrophage lineage that is 
dependent on its ligand M-CSF for activation of its kinase and growth-stimulatory 
properties. Its virally-encoded counterpart, v-fms, however, encodes a protein that has 
constitutive kinase activity. Mice reconstituted with v-fms-infected bone marrow 
develop malignancies of multiple haemopoietic lineages including erythroleukaemia, B- 
cell lymphoma and non-clonal myeloproliferative syndromes (Heard et al., 1987). 
Sequencing of the v-fms gene identified a point mutation that results in the constitutive 
kinase activity and analogous mutations were also detected in about 10% of patients 
with acute myeloid leukaemia and myelodysplastic syndromes (Ridge et al., 1990).
In addition to growth-regulating genes, genes involved in differentiation regulation, 
especially those encoding transcription factors, are also implicated in leukaemogenesis. 
As mentioned in Section 2.2.2, the T-cell leukaemia oncogene scl encodes a basic helix- 
loop-helix transcription factor and has been recently found to be essential for 
development of all haemopoietic lineages (Porcher et al., 1996; Robb et al., 1996). It is 
implicated in human T cell acute lymphoblastic leukaemia through its involvement in 
the t( 1; 14) chromosomal translocation and, more frequently, as a result of tumour- 
specific interstitial deletion on chromosome 1 (Finger et al., 1989; Apian et al., 1990). 
The consequence of both these chromosomal alterations is over-expression of scl in 
leukaemic cells, which is believed to induce differentiation arrest of cells at an early 
stage.
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Finally, dysregulation of apoptosis can also lead to leukaemia and this was demonstrated 
by the bcl-2 gene and its role in human lymphomagenesis. This gene was first described 
in association with the t(14;18) chromosomal translocation, which is characteristically 
present in 85% of follicular lymphomas and results in the transcriptional activation and 
over-production of the Bcl-2 protein (Tsujimoto et al., 1985; also see Chapter 5). It 
proved to be a novel proto-oncogene that exerts its effect by inhibiting apoptosis in a 
cell population that normally is destined to die. This results in a secondary expansion of 
cells that, though they may not be themselves malignant, have an increased 
susceptibility to subsequent transformation events.
In sum, alteration of proto-oncogenes disrupts the normal development and maturation 
of haemopoietic cells regulated by growth factors and the associated stromal cells, and 
leads to uncontrolled growth factor- or stroma-independent growth and blockade in 
differentiation and apoptosis. Several experimental models indicate that co-operation 
between these oncogenes are required to generate a full leukaemic phenotype. However, 
not all molecular changes associated with leukaemia progression involve activation of 
oncogenes or inactivation of tumour supressor genes. Certain virus do not harbour 
cellular oncogenes but contain viral proteins that can stimulate host cell growth by 
acting as “pseudoligands” for cellular growth factor receptors, which results in growth 
factor-independent growth. A typical example is gp55 of the env gene of spleen focus- 
forming virus (SFFV) that binds to and activates the Epo receptor, thereby inducing 
Epo-independent burst formation, confering Epo-independent growth to Epo-dependent 
cell lines, and promoting leukaemogenesis in vivo (Hankins et al., 1978; Ruscetti et al., 
1990; Li et al., 1990; also see Section 3.2)
3.2. Friend virus-induced erythroleukaemias.
Few of the murine retroviruses induce erythroleukaemia; most affect lymphoid cells or 
other myeloid lineages. However, the Friend virus (FV) specifically transforms erythroid 
progenitor cells (reviewed by Ben-David and Berstein, 1991). FVs are complexes of a 
replication-defective spleen focus-forming virus (SFFV) and a replication-competent 
Friend murine leukaemia virus (F-MuLV). The presence of F-MuLV in the FV 
complexes is required to provide functions necessary for the replicative life cycle of 
SFFV. Although F-MuLV alone does not induce diseases in adult mice, it does induce 
spenomegaly, severe anaemia and erythroleukaemia when inoculated into new-born 
BALB/c or NIH/Swiss mice. The erythroleukaemia induced by the various strains of FV 
are multi-stage malignancies characterised by the polyclonal proliferation of non- 
leukaemic erythroid progenitor cells, followed by a later stage in which there is clonal or 
oligoclonal expansion of malignant cells. Thus, the evolution of Friend leukaemia 
embraces the general principles of leukaemogenesis described above. This section will
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discuss the role of autocrine processes, the p53 tumour suppressor gene and members of 
the ets gene family. In addition, host genes that control susceptibility to FV will also be 
discussed in the light of advances in our understanding of their mechanisms of action.
3.2.1. Early events.
The early stages of the diseases induced by FV are associated with a marked increase in 
the number of erythroid progenitors (BFU-E and CFU-E) shortly after virus inoculation. 
These infected cells are not immortal or transplantable, have limited self-renewal 
capacity, and retain the capacity for terminal differentiation to mature red blood cells. 
The polyclonal expansion of erythroid progenitor cells is due to the env gene of SFFV 
which encodes a 55kDa glycoprotein (gp55). As mentioned above (see Section 3.1), 
gp55 binds to and activates the Epo receptor (Epo-R). By acting as a “pseudoligand” for 
Epo, gp55 can induce Epo-independent burst formation, confer Epo-independent growth 
to Epo-dependent cell lines and promote leukaemogenesis in vivo (Hankins et al, 1978; 
Ruscetti et a l , 1990; Li et al., 1990). These studies explain the molecular basis for the 
early polyclonal stage of Friend leukaemia and the erythroid specificity of the 
proliferative stimulus induced by SFFV. The importance of Epo-R in Friend leukaemia 
is reinforced by two observations. First, several F-MuLV-induced erythroleukaemia cell 
lines have been isolated in which the Epo gene is rearranged and amplified and which 
constitutively produce Epo (McDonald et a l , 1987; Hankins et a l , 1989), or in which 
the Epo-R gene has been activated by proviral insertion (Lacombe et a l, 1991). Second, 
infection of mice with retroviral vectors carrying either the Epo gene or an activated 
Epo-R gene leads to erythroblastosis strongly reminiscent of the early stages of Friend 
disease (Hoatlin et a l,  1990).
3.2.2. Late events.
However, expression of gp55, and therefore activation of Epo-R and polyclonal 
expansion of erythroid progenitor cells, is not sufficient to induce a truly malignant 
disease. Only at a later time after infection (4-8 weeks) do malignant clones emerge that 
are capable of transplantation in vivo and growth in semisolid or liquid medium in vitro. 
This suggests that additional events are required for leukaemic transformation. These 
events include both inactivation of the p53 tumour suppressor gene and activation of 
oncogenes that belong to the ets family of oncogenes. It was reported that approximately 
30% of leukaemic clones transformed by FV have an inactivated p53 gene as the result 
of internal deletions or SFFV proviral insertions (reviewed by Lane and Benchimol, 
1990). Many of these clones no longer retain a wild-type p53 gene, indicating that 
reduction to homozygosity frequently accompanies such inactivation events. The 
importance of p53 in the evolution of Friend leukaemia is also evident from studies on
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transgenic mice that express high levels of mutant forms of the p53 protein. In addition 
to displaying an increased spontaneous predisposition to a variety of malignancies, these 
p53 transgenic mice are more susceptible to the induction of the late stages of the 
leukaemia induced by FV (Lavigueru and Bernstein, 1991). Thus, inactivation of the 
p53 gene, either somatically after infection with FV or as the result of transgenic 
inheritance of dominant-negative alleles of p53, appears to be a central event in the 
emergence of the late stages of this leukaemia. These observations also imply that the 
accumulation of a specific set of mutational events, rather than the order in which they 
occur, is important for leukaemia induction.
In addition to inactivation of the p53 gene, a cellular proto-oncogene, spi-1 (SFFV 
proviral integration I), is activated through proviral insertion in 95% of 
erythroleukaemia induced by FV but not in other murine leukaemias (Moreau-Gachelin 
et al., 1988). The high frequency of spi-1 rearrangements in SFFV-induced leukaemic 
clones strongly implies that this locus is essential for transformation of erythroid cells 
during the progression of Friend disease. Spi-1 transcripts are highly expressed in the 
cell lines in which the spi-1 locus is rearranged (Moreau-Gachelin et al., 1990). Spi-1 
proved to encode a DNA-binding transcription activator that belongs to the ets oncogene 
family (Klemsz et al., 1990; the ets oncogene family is discussed in detail in Chapter 4). 
However, spi-1 is not rearranged or activated in the leukaemia induced by F-MuLV 
(Moreau-Gachelin et al., 1988). Instead, there is another highly preferred integration site 
for F-MuLV, termed fli-1 (Friend leukaemia integration i) , in over 75% of 
erythroleukaemia induced in either BALB/c or NIH/Swiss mice inoculated at birth with 
F-MuLV. Other haemopoietic neoplasms induced by F-MuLV, including myeloid and 
lymphoid tumours, do not show rearrangement of the fli-1 locus, nor have any of the 35 
erythroleukaemia cell lines induced by FV. Interestingly, fli-1 encodes another member 
of the ets family transcription factors (Ben-David et al., 1991; discussed in detail in 
Section 4.2). Taken together, these experiments suggest that activation of fli-1 or spi-1 
and inactivation of p53 are highly frequent and hence important steps in the evolution of 
Friend erythroleukaemia.
3.2.3. Three host genes - W. SI, and Fv-2 - that control susceptibility to Friend virus.
At least three host genes specifically control susceptibility to leukaemia induction by 
FV. Two of these genes, W and SI, were first identified on the basis of pleiotropic 
developmental defects: mice carrying W or SI mutations exhibit a dominant “white 
spotting” phenotype, anaemia and sterility. Earlier transplantation experiments suggest 
that the W locus controls an intrinsic property of the stem cells that give rise to 
melanocyte, erythrocytes and germ cells; while the SI locus affects the 
microenvironment in which these stem cells develop during embryogenesis and function
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in adult life. Consistent with these conclusions, subsequent results have shown that W 
encodes the c-kit receptor tyrosine kinase, while SI encodes the ligand for this 
transmembrane receptor, stem cell factor (SCF) (reviewed by Berstein et a l, 1991). In 
the light of these insights into the molecular basis of the W and SI phenotypes, it is 
interesting to speculate on the mechanisms of resistance of W and SI mice to FV. Both 
W and SI mutant mice have reduced numbers of erythroid progenitors, the likely cellular 
targets for transformation by FV, and thus resistance may reflect a reduction in the 
number of target cells. Alternatively, activation of the c-Kit signalling pathway may be a 
necessary event in erythroleukaemia induction.
Like the W locus, Fv-2 also determines a cell-autonomous, intrinsic property of the 
target cells, not their environment (Silver and Teich, 1981). By analysing strains of mice 
congenic for Fv-2, Del Rizzo et a l (1988) have shown that the majority of BFU-E 
erythroid progenitors from Fv-2n mice are not actively cycling, whereas a high 
proportion of BFU-E from Fv-2SS mice are. This difference in cell cycling status between 
Fv-2rr and Fv-2SS congenic mice is restricted to the BFU-E stage of erythroid 
differentiation. These observations are reminiscent of earlier experiments showing that 
cell cycling is required for successful execution of early steps in the retroviral life cycle, 
and suggest that Fv-2 may encode a novel cell type-specific regulator of the mammalian 
cell cycle.
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CHAPTER 4: The Ets Family of Proteins: Transcription Factors 
and Oncoproteins
The v-ets oncogene, the first member of the ets gene family, was discovered as part of a 
fusion protein with gag and myb expressed by the E26 avian erythroblastosis virus, from 
which it derives its name (E26 transformation-specific). Since then, more than 30 
related genes have been discovered and cloned from a variety of organisms ranging from 
humans to Drosophila, and these include c-ets-1, c-ets-2, elf-1, elf-2, elk-1, erg, E1AF, 
E4TF1, ERF, ERM, fli-1 , PEA3, SAP-1, spi-1 /PU.l, tel. In most family members, the 
conserved DNA-binding domain (the Ets domain) is located at the carboxyl terminus of 
the protein, with the exception of Elf-1, Elk-1 and SAP-1, where it is found at the amino 
terminus. The Ets domain, which covers approximately 85 amino acids has no structural 
homology to other known DNA-binding motifs, such as the zinc finger, homeodomain, 
leucine zipper or helix-tum-helix motifs, but has limited homology to the DNA-binding 
domain of the c-myb oncogene product. This chapter will first discuss the general 
features of the Ets protein family (reviewed by Crepieux et a l, 1994; Hromas and 
Klemsz, 1994; Wasylyk et a l, 1993; MacLeod et a l, 1992; Seth et a l, 1992), followed 
by a more detailed description of those that are directly relevant to the work presented 
by this thesis (i.e. Fli-1 and Erg).
4.1. General features of the Ets family of proteins.
4.1.1. Tissue distribution.
The Ets proteins are expressed in a wide variety of tissues and the pattern of tissue- 
specific expression varies among different family members. For example, c-ets-1 is 
expressed preferentially in adult lymphoid tissue, with high levels in the thymus, and at 
lower levels in the lung and spleen. In contrast, c-ets-2 is expressed in almost every type 
of tissues and cell lines tested. Elk-1 is expressed only in the lung and testis. Spi-11 PU.l 
is found to be expressed primarily in the B-cells and myeloid cells.
4.1.2. The Ets proteins as transcription factors.
DNA-binding activity. The Ets proteins have been found to bind specifically to 
sequences containing an invariant core motif GGAA/T in the middle of lObp of DNA. 
The flanking sequences are variable and there is growing evidence that they help 
determine which Ets protein will bind. The DNA-binding activity of the Ets proteins is 
mediated by the conserved Ets domain which, on its own, appears to be sufficient for 
specific DNA-binding. Nuclear magnetic resonance (NMR) structural analyses have
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determined that the Ets domain displays a “winged helix-tum-helix m otif’ (Donaldson 
et al., 1996), demonstrating that the Ets domain is compact and highly well folded. 
Nevertheless, this minimal DNA-binding domain is modulated by the remainder of the 
protein (see below). Intramolecular inhibitory domains. The activity of some of the Ets 
proteins as transcription factors is negatively regulated by an intramolecular mechanism. 
Studies of deletion mutants and natural variants of c-Ets-1 (Lim et a l, 1992) indicate 
that the flanking regions negatively regulate the Ets domain, since N-terminal deletion 
mutants display higher binding activity than the full-length protein, so as deletions of 
residues C-terminal to the Ets domain. These studies led to a model of two inhibitory 
regions working together to sterically mask the DNA-binding surface. These inhibitory 
domains can be relieved by association with accessory factors. Transactivation 
domains. Expression of the Ets proteins activates transcription from multimerised DNA 
motifs, suggesting that they contain activation domains. The transactivation domains 
reside in non-conserved regions and act independently from DNA-binding domains, c- 
Ets-1 and c-Ets-2 fused to heterologous DNA-binding domains are able activate through 
the corresponding heterologous motifs (MacLeod et a l, 1992). The Ets proteins as 
components o f the general transcription machinery. In addition to the role of Ets 
family members as classical activators that stimulate transcription from a distance, they 
may also have a primary role in the formation of transcription initiation complex on 
minimal core promoters containing or lacking the TATA sequence. It has been reported 
that recombinant Spi-11 PU.l can bind to TFIID (Hagemeier et al., 1993), the TATA-box 
binding protein that stimulates RNA polymerase II to initiate transcription. Moreover, 
some ets motifs are located close to the transcription initiation site in a number of 
promoters that lack a TATA element, and these have been shown to be important for 
transcription. It is possible that the Ets proteins may be a component of the "general 
transcription complex" that forms on certain promoters around the start site. This may 
give them a primary switching role during differentiation or in phases of the cell cycle.
The Ets family members regulate a wide spectrum of target genes in response to 
different cellular signalling pathways (see Section 4.1.4). This ability to mediate diverse 
cellular processes is achieved, at least in part, through co-operation with other groups of 
transcription factors. Co-operation can affect DNA-binding or transactivation activity, 
which may result in transcriptional activation or repression. Co-factors that physically 
interact with the Ets proteins. A number of transcription factors have been shown to 
physically interact with the Ets proteins and form ternary or quaternary complexes at the 
recognition sites. These include serum response factor (SRF), the c-Fos/c-Jun complex, 
NF-EM5, Pax-5, retinoblastoma binding factor 1 (.RBF-1), MafB, retinoblastoma protein 
(Rb), Rbtn-2. Among those are SRF and the c-Fos/c-Jun complex that have attracted the 
most attention. SRF binds to a motif adjacent to the eto-like motif. Elk-1 (Hipskind et 
al., 1991), SAP1 (Dalton and Treisman, 1992) and Fli-1 (Watson et al., 1997) can
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recognise and interact with the SRF bound to the DNA, and form a stable ternary 
complex. In some cases, the c-Fos/c-Jun complex also requires co-operation with 
certain Ets proteins, such as c-Ets-1 (Bassuk and Leiden, 1995), c-Ets-2 (Wu et al., 
1994), Elf-1 (Wang et al., 1994) and Erg (Buttice et al., 1996), via direct protein-protein 
interactions for transactivation. In the case of transactivation of the polyomavirus 
enhancer by c-Ets-1 and the c-Fos/c-Jun complex, cooperativity is not mediated at the 
level of DNA binding (Wasylyk et al., 1990). Direct interactions with some 
transcription factors can also lead to repression of the Ets protein activity. MafB, an AP- 
1 like protein, binds to the DNA-binding domain of c-Ets-1 via its basic region or 
leucine-zipper domain (Sieweke et al., 1996), and this represses the ability of c-Ets-1 to 
transactivate either a synthetic promoter containing Fto-binding sites or the promoter of 
transferrin receptor. In addition, unphosphorylated Rb can also reduce the transcriptional 
stimulating activity of Elf-1 in inactive lymphocytes by direct physical conatct. Upon T- 
cell activation, Rb is phosphorylated and subsequently dissociates from the complex, 
which restores the Elf-1 activity immediately (Wang et al., 1993). Finally, a novel Ets 
family member, Elf-2, has been recently reported to bind to Rbtn-2, a T-cell oncoprotein 
that belongs to the LIM  family of transcription factors, though the significance of this 
interaction is unclear (Wilkinson et al., 1997). Other co-factors. The Ets proteins can 
also cooperate with a number of other factors, such as c-Myb, C/EBPa. However, the 
mode of these interactions have not been established. For example, c-Ets-2 does not 
activate the mim-1 promoter unless c-Myb is also present (Dudek et al., 1992). 
Furthermore, c-Myb can synergise with either c-Ets-1 or c-Ets-2 to transactivate the 
promoter of an early myeloid gene (Shapiro, 1995). The nature of such co-operation is 
not known and a direct interaction between c-Myb and c-Ets-1 or c-Ets-2 has not been 
documented. Finally, the Ets family member also seem to co-operate with one another in 
gene activation. Hume et a l (1997) reported that Spi-11 PU.l and c-Ets-2 can 
synergistically transactivate the c-fms promoter. Moreover, ERF has been identified as 
an Ets repressor factor that exhibits strong transcriptional repressor activity on 
promoters that contain an Fte-binding site (Sgouras et al., 1995).
4.1.3. The Ets proteins as oncoproteins.
The v-Myb-Ets fusion protein in E26 induces erythroblastosis. Various lines of 
evidence show that v-Ets is responsible for the erythroblastosis induced by the avian 
acutely transforming retrovirus, E26. E26, which expresses a v-Myb-Ets fusion protein, 
causes a mixed erythroid and myeloid leukaemia with a predominance of the former, 
whereas AMV, that expresses only v-Myb, induces myeloid leukaemia. The 
temperature-sensitive mutant of E26, tsl.lE26, with a point mutation in the v-Ets DNA- 
binding domain, is temperature-sensitive in vitro for erythroid but not myeloid 
transformation.
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Activation by proviral insertion. Two different ets genes, fli-1 and spi-11 PU.l, are 
activated by proviral insertion, and the activation is found to be responsible for virally 
induced murine erythroleukaemia (also see Section 3.2.2, 4.2 and 4.3). Proviral 
integration by the Friend murine leukaemia virus (F-MuLV) and the spleen focus- 
forming virus (SFFV) into flanking sequences activates expression of the fli-1 and spi­
l l  PU.l genes, respectively.
Activation by chromosomal translocation. Chromosomal translocations involving the 
ets oncogenes have been associated with both haemotological and solid tumours. In 
many cases, chimeric proteins are created as a result of fusion between the two genes 
located at the sites of the breakpoint. For example, the human c-ets-1 and c-ets-2 genes 
are translocated in certain types of acute leukaemia from chromosomes 11 to 4 and from 
21 to 8, respectively. Approximately 85% and 10% of the human Ewing’s sarcomas and 
the related tumours are recurrently associated with t(ll;22) and t(21;22) chromosomal 
translocations which result in the production of aberrant fusion proteins EWS/Fli-1 and 
EWS/Erg, respectively (Delattre et al., 1992; Sorensen et al., 1994). The fusion proteins 
consist of the amino terminus of EWS, a putative RNA-binding protein, fused to the 
carboxyl terminus of Fli-1 or Erg including the Ets domain. EWS/Fli-1 and EWS/Erg 
also display the biochemical attributes of a transcription factor. Accumulating evidence 
suggests that EWS/Fli and EWS/Erg may disrupt normal growth and differentiation by 
acting as aberrant transcription factors that inappropriately activate and/or repress the 
expression of target genes. This may also underlie the mechanism whereby another 
fusion protein of two transcription factors, the Ets protein Tel and AML1, contributes to 
paediatric acute lymphoblastic leukaemia (ALL) (Shurtleff et al., 1995). A second 
chromosomal translocation in ALL, t(9;12), fuses Tel to a tyrosine kinase, Abl 
(Papadopoulos et al., 1995). In addition, Tel is also involved in the t(5;12) translocation 
associated with chronic myelomonocytic leukaemia (CMML), which results in the 
amino terminus of Tel being coupled to the tyrosine kinase domain of PDGF (Golub et 
al., 1994; Carroll et al., 1996). Both Tell Abl and 7W/PDGF fusion proteins have an 
elevated tyrosine kinase activity, which is thought to be the consequence of constitutive 
dimerisation that is mediated by the helix-loop-helix domain of Tel that is retained in 
the fusion proteins.
In vitro transformation by the Ets proteins. The role of ets gene family members as 
oncogenes has been tested in classical transformation experiments in which over­
expression of the Ets genes, such as c-ets-1, c-ets-2, erg or fli-1, in NIH-3T3 mouse 
fibroblasts generates transformed foci in low serum conditions. These transformed cells 
grow in soft agar and form tumours in nude mice (Wasylyk et al., 1993).
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4.1.4. The functions of Ets proteins in development and co-ordinated regulation of cell 
proliferation, differentiation and apoptosis.
Attempting to assess the biological functions of Ets proteins from the identity of their 
target genes is a difficult quest, given that many members appear to be expressed in an 
array of tissues, where they may regulate common or specific target genes. To date, a 
large number of Ets protein target genes have been determined (see Table 4.1). 
However, caution must be exercised with regard to defining genuine target genes as, in 
many cases, only putative is/s-binding sites are identified in the promoters of genes of 
interest; furthermore, in vitro transactivation activity does not always correlate with an 
in vivo function. As can be seen in Table 4.1, the Ets protein target genes can be 
classified into six categories: growth factor and growth factor receptors, oncogenes and 
tumour suppressor genes, genes involved in or regulating extracellular matrix (ECM) 
interactions (e.g. integrins and metalloproteinases), lymphoid-specific genes, viral 
enhancers, and genes encoding cytoskeleton components. This suggests that the Ets 
proteins may play a role in co-ordinated regulation of growth and differentiation in 
response to growth factors and differentiation inducers, in lymphoid development and 
functions, and in viral infectious cycles. Additionally, the involvement of Ets proteins in 
the transcription of metalloprotease genes should be emphasised. Metalloprotease genes 
are involved in the degradation of ECM and many of them, such as those encoding 
stromelysin 1, collagenase and urokinase plasminogen activator (pPA), contain Ets- 
binding sites in their regulatory flanking sequences. Furthermore, c-Ets-1 (Wasylyk et 
a l , 1993; Buttice and Kurkinen, 1993; Nerlov et al., 1992), Erg (Buttice et al., 1996) 
and E1AF (Kaya et al., 1996) are able to transactivate the promoters of those genes in 
vitro. Moreover, transfection of the non-invasive human breast cancer cell line with the 
E1AF expression plasmid results in induction of invasive and motile activities, 
accompanied by an increase in the type IV collagenase (MMP9) gene expression (Kaya 
et al., 1996). Tumours derived from the E1AF transfectants are highly invasive and 
produce MMP-9. Elevated expression of E1AF and MMP-9 were also observed in 
several invasive tumour cell lines. Take together, this suggests that the Ets proteins play 
a role in co-ordinating events that lead to the degradation of ECM, an important process 
in vasculogenesis, angiogenesis, and tumour cell growth, invasion and metastasis.
Clues with regard to the functions of Ets proteins are also obtained in situations where 
the ets gene expression is manipulated, either in cell lines in vitro or in the entire 
organisms in vivo. Over-expression of spi-11 PU.l in Friend virus-induced murine 
erythroleukaemia (MEL) cells leads to differentiation inhibition and, as a result, these 
cells can no longer induce p-globin expression in response to DMSO (Yamada et al.,
1997). Intriguingly, over-expression of spi-11 PU.l also inhibits growth and, in 
conjunction with DMSO treatment, induces apoptotic cell death. Although it is
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Table 4.1. List of genes whose promoters contain putative ^ -b in d in g  sites and/or can 
be transactivated by the Ets proteins (in italic).
Growth factors and growth factor receptors Oncogenes and tumour
GM-CSF suppressor genes
G-CSF c-ets-1
IL-2, -3, -4 and -6 c-ets-2
NGF a  subunit c-fos
GM-CSF receptor a c-myc
CSF-1 (or M-CSF) receptor (c-fms) c-myb
Thrombopoietin receptor (MPL) JunB
Vascular endothelial growth factor receptor (Fit-1) spi-1 /PU.l
Transferrin receptor p53
Macrophage scavenger receptor Rb
Genes involved in or regulating extracellular Genes encoding cytoskeleton
matrix (ECM) interactions proteins
integrin CD1 lc vimentin
integrin CD 18 Endo A/B (type II/I karetin)
integrin a4
collagenases
stromelysin 1
urokinase plasminogen activator (pPA)
Lymphoid-specific genes Viral enhancers
T-cell receptor a  chain Adenovirus E l A enhancer
T-cell receptor f  chain EBVearly cytoplasmic antigen
IgH HIV-1 LTR
IgK HTLV-1 LTR
MHC class IH2-K gene MSVLTR
MHC class II gene I-A3 Polyoma enhancer
CD4 SV40
Others
GATA-1
CD34 (a stem cell antigen)
Mim-1
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puzzlying how Spi-1/PU. 1 can inhibit growth and differentiation at the same time, and 
how a protein that inhibits growth and induces apoptosis can induce 
erythroleukaemia, the results suggest a role of Spi-11 PU.l in co-ordinated regulation of 
cell growth, differentiation and apoptosis. Consistent with this theme, but contradictory 
to the data, are the studies by Delgado et al. (1994) who demonstrated that inhibition of 
the spi-11 PU.l expression in MEL cells by antisense oligonucleotides results in a 
significant decrease in proliferation and cloning efficiency of those cells. Furthermore, 
this anti-proliferative effect is not related to an apparent maturation of the 
erythroleukaemic cells. Targeted disruption of the normal spi-1/PU.l gene in vivo also 
suggests that it is required in the development of multiple haemopoietic lineages and, 
therefore, it may act at the level of multipotential progenitors (Scott et al., 1994; 
McKercher et al., 1996). In contrast, targeted inactivation of c-ets-1 by the RAG-2'a 
complementation system and murine embryonic stem (ES) cells containing homozygous 
deletion of the c-ets-1 gene (ets-PA) demonstrated that the functions of c-Ets-1 are 
restricted to lymphoid development and functions (Bories et al., 1995; Muthusamy et 
al., 1995). Ets-l^'-RAG-I^' chimaeric mice display markedly decreased numbers of 
mature thymocytes and peripheral T cells, which show a severe proliferative defect in 
response to multiple activation signals and demonstrate increased rates of spontaneous 
apoptosis in vitro. In contrast, B-cells are present in normal number in the e t s - F mice, 
but a large proportion are IgM plasma cells. These findings suggest that c-Ets-1 is 
essential for the maintenance of the normal pool of resting T- and B-lineage cells.
4.1.5. Regulation of the Ets functional activity.
A variety of growth modulators and differentiation inducers affect the Ets activity, and 
this regulation is controlled mainly at three levels: the initiation of transcription, post- 
translational modification and protein stability.
Transcriptional regulation. It has been reported that the c-ets-1 and c-ets-2 gene 
expression is modulated at the transcriptional level in response to growth factors and 
during T-cell activation. Gilles et al. (1996) demonstrated that c-ets-1 is an early- 
response gene of TNFa and IL-la, since it undergoes a rapid (within lh) and long- 
lasting (19h) increase upon stimulation with these cytokines. In contrast, bFGF, EGF 
and PDGF are mainly delayed stimulators. In T-cells, the expression of c-ets-1 is highest 
in quiescent cells and decreases following T-cell activation (Bhat et al., 1990). 
Conversely, the c-ets-2 expression increases from a low level following T-cell activation 
and reaches the maximum level l-2h after induction. The mechanism of co-ordination 
of the expression of these genes is unclear.
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Phosphorylation. Various growth factors and differentiation inducers modulate Ets 
protein activity by eliciting a series of signalling pathways, and one of the most 
important consequences is phosphorylation of the proteins which can lead to a change in 
DNA-binding or transactivation activity. Alternatively, phosphorylation appears 
necessary for the recruitment of co-activators in order to transactivate efficiently, as is 
the case for Spi-11 PU.l (Pongubala et al., 1993). Numerous studies suggest that various 
Ets proteins are direct targets of the Ras/RaflMAP kinase signalling pathway. 
Expression of Ha-Ras can induce phosphorylation of c-Ets-1 (Yang et a l, 1996; 
Wasylyk et al., 1997), c-Ets-2 (Yang et al., 1996; Wasylyk et al., 1997), Elk-1 (Marais 
et al., 1993), ERM  (Janknecht et al., 1996) and PEA3 (Ohagan et al., 1996) by 
activating MAP kinase family proteins, which subsequently strongly activates their 
transactivation activity. Interestingly, Elk-1, in turn, stimulates MAP kinase 
autophosphorylation and activity (Rao and Reddy, 1993b), and this is mediated by direct 
interaction between the two proteins (Rao and Reddy, 1994). Consistent with the role of 
Ras signalling pathway in regulating Ets family members is the fact that several 
dominant negative mutants of the Ets proteins (c-Ets-1, c-Ets-2 and Spi-1 /PU.l) can 
revert the transformed phenotypes of NIH3T3 fibroblasts due to ras over-expression, 
including morphology, anchorage independent growth, saturation density, growth in low 
serum and tumour formation in nude mice (Wasylyk et al., 1994). In addition to the 
MAP kinase family, the Ets proteins can also be phosphorylated by PKC (Erg and Spi­
l l  PU.l), PKA (ERM), cdc2/cyclin B kinase (ERF) and possibly Ca2+-dependent 
calmodulin kinase (c-Ets-1, c-Ets-2 and Elf-1). It is worthwhile mentioning that 
phosphorylation can also negatively regulate the functional activities of Ets proteins. 
Phosphorylation of c-Ets-1 can inhibit its DNA-binding activity and its ability to restore 
mitogenic response of a cell line expressing a mitogenically defective CSF-1 receptor 
(Rabault et al., 1996). As mentioned above, phosphorylation of c-Ets-1 can also enhance 
its transactivation activity. Therefore, the consequence of c-Ets-1 phosphorylation, in 
terms of activation or repression, may be dictated by biological and cellular contexts. 
Finally, phosphorylation of ERF, an Ets repressor factor, can also decreases its 
transcriptional repressor activity (Sgouras et al., 1995).
Protein stability. Finally, protein stability is another level at which the Ets family 
members are regulated. The half-life of c-Ets-2 is increased from 20min to 140min 
following phorbol ester stimulation of protein kinase C (Fujiwara et al., 1988). The 
PEST sequence (regions rich in Pro, Glu, Ser and Thr) are found in many Ets proteins, 
such as Erg, c-Ets-1, c-Ets-2, Fli-1 and Spi-1 /PU.l, and may play a role in protein 
turnover. The PEST sequences are located between putative transactivation domains and 
DNA-binding domains and cleavage may create a DNA-binding domain free from the 
regulatory restraints imposed by amino-terminal domains.
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4.2. Fli-1.
The mouse fli-1 gene was originally identified as the proto-oncogene insertionally 
activated in 75% of erythroleukaemia cell clones induced by Friend murine leukaemic 
virus (see Section 3.2.2 and 4.1.3). The human homologue of fli-1 is rearranged in 
Ewing’s sarcoma (see Section 4.1.3) and neuroepithelioma as a result of reciprocal 
chromosomal translocation. Expression of the fli- l  transcripts is present at high levels in 
spleen and lymphoid tissues, such as thymus, and is also detectable in ovary, bone 
marrow and heart tissue (Nunn et al., 1983; Watson et a l, 1992). In haemopoeitic cell 
lines, fli- l  is expressed in a number of T-cells (CEM, Molt-4, Jurkat), B-cells (P3HR1) 
and erythroleukaemic cells (HEL, JK-1, TMK) (Nunn et al., 1983; Watson et al., 1992; 
Klemsz et al., 1993). No expression of the fli- l  mRNA is detectable in two of the 
erythroleukaemia cell lines, K562 or RM10 (Klemsz et al., 1993).
Fli-1 is a sequence-specific transcriptional activator by virtue of its ability to activate the 
transcription of a reporter gene that is linked to the Fli-1 target sequences. Like other 
Ets proteins, DNA-binding of Fli-1 is mediated by the conserved Ets domain (Figure 
4.1a). Deletion analysis revealed the presence of two antonomous transcriptional 
activation domains, one at the amino-terminal region (amino-terminal transcriptional 
activation or ATA), and the other at the carboxy-terminal region (carboxy-terminal 
transcriptional activation domain or CTA) (Rao et al., 1993a; Zhang et al., 1993). The 
Fli-1-specific region (FLSR) and the conserved Ets domain are between these two 
transactivation domains. Interestingly, PEST sequences are found in these two 
transactivation domains, which may be important in regulating functional activity of the 
Fli-1 proteins (Rao et al., 1993). Recently, both Fli-1 and EWS/Fli-1 are found to 
recognise serum response element (SRE) and form a ternary complex with a second 
protein, serum response factor (SRF), in the promoters of c-fos and egrl (Magnaghi- 
Jaulin et al., 1996; Watson et al., 1997). Very few of the Fli-1 target genes have been 
identified although DNA-binding sites for Fli-1 have been identified in a number of 
lymphoid cell-specific genes. However, it has been reported that the human Fli-1 
protein can transactivate the HIV LTR core enhancer and the gata-1 promoter (Hodge et 
al., 1996; Seth et al., 1993), the latter being consistent with a role of Fli-1 in the 
regulation of erythropoeisis. Recent reports by Athanasiou et al. (1996) and Deveaus et 
a l (1996) further extend the functions of Fli-1 to a role in controlling differentiation and 
gene expression along the megakaryocyte/platelet pathway. Athanasiou et a l (1996) 
discovered an elevated expression of fli-1 in K562 cells induced to undergo 
megakaryocytic differentiation by phorbol ester. Moreover, over-expression of f li- l  in 
those cells caused a higher level of spontaneous differentiation along megakaryocytic 
and erythroid lineages. Furthermore, Deveaus et a l (1996) demonstrated that Fli-1 can
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Figure 4.1. Schematic representation of the functional domains of the Fli-1 (a) and 
Erg (b) proteins.
(a) Fli-1
ATD FLSR EBD CTD
PEST seq. PEST seq. PEST seq.
(b) Erg-1, Erg-2 and Erg-3
Erg-3
ATD ERSR/NRTD EBD CTD
PEST seq. PEST seq.
Erg-2
Erg-1 wzmm
ATD: Amino-terminal transactivation domain 
CTD: Carboxy-terminal transactivation domain 
EBD: fe-binding domain
PEST seq.: sequences rich in proline, glutamine, serine and threonine 
that are important in the regulation of protein stability 
FLSR: Fli-1-specific region 
ERSR: £rg-specific region 
NRTD: Negative regulatory transactivation domain
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transactivate the promoter of thrombopoietin receptor, whose ligand specifically 
controls megakaryocytic differentiation.
Consistent with the high levels offli-1 expression in the thymus and spleen, two recent 
reports from Dr. A. Bernstein’s laboratory using a transgenic approach further confirm 
that Fli-1 plays a vital role in lymphoid development and the associated immune 
functions, and the induction of erythroleukaemia by Friend virus. The first report 
detected a defect in thymus development and a delay in Friend virus-induced 
erythroleukaemia in mice that expressed a truncated mutant Fli-1 protein (Melet et al., 
1996). The second report demonstrated that the fli-1 transgenic mice develop a high 
incidence of a progressive immunological renal disease, and ultimately died of renal 
failure caused by tubulointerstitial nephritis and immune-complex glomerulonephritis 
(Zhang et a l, 1995). The hypergamma-glubulinemia, splenomegaly, B-cell hyperplasia, 
accumulation of abnormal CD3+B220+ T lymphoid cells and CD5+b220+ B-cells in 
peripheral lymphoid tissues, and detection of various autoantibodies in the sera of 
diseased fli- l  transgenic mice suggest the involvement of an immune dysfunction in the 
pathogenesis of the renal disease. In addition, splenic B-cells from the transgenic mice 
exhibit increased proliferation and prolonged survival in vitro in response to mitogens, 
suggesting that programmed cell death is perturbed. Interestingly, transgenic mice 
overexpressing bcl-2, an anti-apoptosis gene (see Chapter 5), in B-cells also exhibit a 
similar enhanced antibody response and prolonged survival in vitro, and they develop a 
systemic autoimmune disease in vivo (Strasser et al., 1991). These similarities between 
the fl i- l  and bcl-2 transgenic mice indicate that these two proteins may have similar 
functional end points. It is possible that they act through distinct pathways which 
converge at some point. Alternatively, they may be part of the same pathway and, in this 
scenario, it is possible that Fli-1 may lie upstream of Bcl-2 and regulate its activity, 
directly or indirectly.
4.3. Erg.
The erg gene was identified by screening a cDNA library of human Colo-32 cells (a 
colon tumour-derived cell line) with a human c-ets-2 cDNA (Rao et al., 1987; Reddy et 
al., 1987), and it was subsequently found to be involved in chromosomal translocations 
associated with human Ewing’s sarcoma (Sorensen et al., 1994; also see Section 4.1.3) 
and myeloid leukaemia (Shimizu et al., 1993). In parallel with the involvement of erg in 
tumorigenesis, it proves to be a proto-oncogene capable of transforming NIH-3T3 
mouse fibroblast cells in vitro (Hart et al., 1995). It codes for three proteins, Erg-1, Erg- 
2 and Erg-3, as a result of differential splicing, alternative polyadenylation and also 
alternative usage of the initiation codon (Rao et al., 1987; Reddy et al., 1987; Prasad et 
al., 1994). The erg gene is expressed at high levels in transformed cells, and its
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transcripts of ~3.2-3.6kb and ~5kb can be detected in various cell lines, such as Colo- 
32, KG-1 and Molt-4 (Rao et a l , 1987; Reddy et al., 1987; Prasad et a l , 1994).
All Erg proteins proved to be sequence-specific transcriptional activators (Reddy and 
Rao, 1991; Prasad et a l, 1987). Structural analysis of the Erg proteins (Siddique et a l, 
1993) indicates that, like Fli-1, they also have two transactivation domains (ATD and 
CTD) residing at the amino- and carboxyl-terminus of the proteins (Figure 4.1b). 
Between ATD and CTD are the isrg-specific region (ERSR) and the Ets domain. It is 
worthwhile noting that, overall, the human Erg and Fli proteins show 80% homology 
throughout the coding regions, whereas within the 84-amino acid Ets domain there is 
98% sequence identity (Ben-David et a l, 1991). As the Ets domain is responsible for 
sequence-specific DNA-binding activity, it is likely that Erg and Fli-1 have similar 
sequence specificity. On the other hand, the ERSR of Erg proteins shows no homology 
to FLSR of Fli-1, suggesting that this region may dictate the functional differences 
between Erg and Fli-1 (Prasad et a l, 1994). The downstream cellular genes regulated by 
Erg are also poorly documented. However, it has been reported recently that Erg can 
transactivate the human collagenase 1 promoter when recruited by c-Fos/c-Jun at the 
promoter (Buttice et a l, 1996). Collagenase 1 belongs to a family of matrix- 
metalloproteinase (MMPs) that are extracellular enzymes, which degrade connective 
tissues and basement membranes and are expressed widely during growth and 
development. In mature adults, however, MMPs are rarely expressed except in places of 
diseases or active tissue-renewal/remodelling. For example, many MMPs are expressed 
in human tumours and are thought to play a critical role in several stages of tumour 
progression: tumour growth, tissue invasion and metastasis. Therefore, the fact that the 
Erg proteins regulate the collagenase 1 expression provides intriguing possibilities with 
regard to the molecular mechanisms of oncogene action. Like many other Ets proteins,
Erg proteins are phosphoproteins. Phosphorylation of Erg-2 can be stimulated by
2+
phorbol ester or activation of protein kinase C (PKC) but not by Ca ionophore 
treatment (Murakami et a l, 1993), which, in turn, may modulate the functional activity 
of the protein.
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CHAPTER 5: Bcl-2 and Other Apoptosis Proteins
5.1. Programmed cell death and apoptosis.
Programmed cell death is an inconspicuous yet prevalent phenomenon in complex 
multi-cellular organisms, by which single cells are deleted from the midst of living 
tissues. The decision to die is made cell-autonomously and the cell is an active 
participant in its own death. With few exceptions, cellular death is accomplished by a 
process with a structural stereotype, termed apoptosis, that strongly suggests a common 
underlying mechanism. Apoptosis is regulatable and is of fundamental importance to 
tissue development and homeostasis. Dysregulated apoptosis is important in the 
pathogenesis of several important human diseases including neoplasia, and recognition 
of the defects involved is prompting development of new therapeutic strategies. The 
consistent morphological, cellular and molecular changes accompanying apoptosis 
include plasma membrane blebbing, cytoplasmic vacuolisation, chromatin condensation, 
DNA fragmentation, and the formation of membrane-enclosed structures termed 
“apoptotic bodies” that are extruded into the extracellular milieu (Wyllie et al., 1980; 
Savill et al., 1993). Recognition of these cellular corpses and their removal by 
phagocytosis are carefully controlled and occur without disturbance to tissue 
architecture or function and without initiating inflammation (Savill et al., 1993).
Apoptosis can be induced by a variety of means such as DNA damage, growth factor 
deprivation, Fas/TNF/Reaper, loss of adhesion, oxidative stress or developmental cues 
(Rowan and Fisher, 1997). These triggers can then activate various positive and 
negative apoptotic modulators (e.g. p53, c-Myc, the Bcl-2 family of proteins, cell cycle 
regulators, transcription factors) and the interplay between them defines the net cellular 
outcome (life or death). In the event a cell chooses to die, apoptotic machinery will be 
activated. Emerging evidence indicates that apoptosis utilises some of the same signal 
transduction mediators previously implicated in other physiological cellular responses, 
including intracellular Ca , protein kinases and phosphatases, cAMP, lipids, pH and 
oxidative radicals (McConkey and Orrenius, 1996). A breakthrough in understanding 
apoptosis came in the recognition that, in all known instances of apoptosis, a family of 
cysteine proteases related to the IL-ip-converting enzyme (ICE) becomes activated and 
executes apoptosis through specific cleavage of substrates, now popularly know as death 
substrates (Martin and Green, 1995). One of the first recognised and common class of 
death substrates are endo-exonuclease precursors whose proteolytic cleavage causes 
enzymatic activation (Fraser 1994). Seeing apoptosis as a proteolytic process has 
revolutionised the way apoptosis is detected and studied, and apoptosis is now
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commonly measured as proteolytic enzyme activity which facilitates the development of 
these cell-free apoptosis systems.
5.2. The Bcl-2 family of proteins.
Bcl-2 is the founding member of an expanding family of proteins involved in the 
regulation of apoptosis. The human bcl-2 gene was identified at the breakpoint site of 
the t(14; 18) chromosomal translocation, which is associated with follicular lymphoma 
and results in the transcriptional activation and over-production of the 26 kD Bcl-2 
protein (Tsujimoto et a l , 1985). It proved to be a novel proto-oncogene: although Bcl-2 
alone does not stimulate cell proliferation or cause transformation, it co-operates with c- 
Myc (Vaux et a l , 1988; Fanidi et a l , 1992) and members of the Ras family (Reed et a l , 
1990) to transform cells. Transgenic mice that overexpress bcl-2 display increased 
tumour development (Korsmeyer 1995). In particular, when the bcl-2 transgenic mice 
were mated to the c-myc transgenic mice, a rapidly emerging undifferentiated 
haemopoietic leukaemia occurred, demonstrating the potent synergy of this oncogene 
combination (Strasser et a l , 1990). Being an oncoprotein, Bcl-2 proved to have novel 
unusual properties acting to promote survival rather than proliferation in cellular assays 
(Vaux et a l 1988; Hockenbery et a l , 1990). A rapid succession of experiments 
demonstrated that Bcl-2 acts as an inhibitor of apoptosis in most of in vivo and in vitro 
systems with few exceptions (Reed 1994; Vaux et a l, 1992).
The Bcl-2 protein has a fairly wide tissue distribution within adult tissues, including 
lymphoid, haemopoietic, epithelial and neural tissues (Hockenbery et a l , 1991). 
However, within these tissues, the bcl-2 expression is limited to distinct cell types or 
topologic areas, and appears to be expressed in cells that are rapidly dividing and 
differentiating into mature components. Bcl-2 is expressed more widely in foetal tissues, 
most notably in the central nervous system, where most populations of neurons express 
bcl-2 at relatively high levels (Veis-Novack and Korsmeyer, 1994). Within the cells, the 
Bcl-2 protein is located in nuclear and endoplasmic reticulum membranes and the outer 
membranes of mitochondria (Hockenbery, 1995). The 6c/-2-deficient mice complete 
embryonic development and appear normal during the first week after birth (Veis- 
Novack et a l, 1993). Their spectrum of haemopoiesis is initially normal, so as 
development of most organs determined by histological analysis. Thus, the Bcl-2 
activity is not absolutely required for embryogenesis and development. However, 
abnormalities (including growth retardation, polycystic kidney disease, abnormal hair 
pigmentation, fulminant apoptosis of the thymus and spleen, and an almost complete 
loss of lymphocytes) develop over time and the mice die young. This illustrated that 
Bcl-2 may have its most dramatic role in maintaining homeostasis in adult tissues.
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Since the cloning and characterisation of bcl-2, a number of genes that share sequence 
homology with bcl-2 have been isolated, which include bcl-x, box, mcl-1, A l , bag, bak 
(Nunez and Clarke, 1994; Farrow and Brown, 1996). Members of this family and its 
interacting partners have been central to models that attempt to explain the mechanisms 
of apoptosis in mammalian cells. The homology among the Bcl-2-related proteins is 
concentrated in two regions, termed BH1 and BH2, which turn out to be important for 
homo- and hetero-dimerisation (Yin et al., 1994). As it will be discussed below (see 
Section 5.4), homo- and hetero-dimerisation among the Bcl-2 family proteins play a 
pivotal role in the regulation of their functional activities. In addition, proteins of the 
Bcl-2 family contain a stretch of hydrophobic amino acids at their C-termini, which 
appear important for attachment to intracellular membranes (Nunez and Clarke, 1994). 
Indeed, 2?c/-2-related proteins are found at similar locations in the cell as Bcl-2 (Farrow 
and Brown, 1996). It is conceivable that, in each location, the cellular targets of Bcl-2 
family proteins are different, but are coupled to a common effector.
5.3. Transcriptional regulation of the bcl-2 expression.
Although bcl-2 is subject to both tissue-specific and developmental regulation, little is 
known about the molecular mechanisms controlling its expression. Characterisation of 
its genomic organisation revealed that bcl-2 consists of three exons, with the second and 
third exons separated by extremely large, 225kb intron (Negrini et al., 1987; Seto et a l, 
1988). Two promoters are responsible for the initiation of bcl-2 transcription (Figure 
5.1). The predominant promoter, PI, is a GC-rich, TATA-less promoter that displays 
multiple start sites and includes several consensus binding sites for the Spl transcription 
factor. This promoter structure is somewhat surprising for a developmentally regulated 
gene and is more commonly associated with constitutively expressed genes. The second 
promoter, P2, is located approximately 1.4kb downstream from the first, and includes 
both a CCAAT box and TATA element.
The unusual feature of the bcl-2 gene is characterised by the very long (5’ about 1.4kb 
and 3’ about 5.1 kb) untranslated regions (UTR) surrounding the relatively short coding 
region. More interestingly, the 5’ and 3’ UTRs are highly homologous between human 
and mice with 66% and 60% nucleotide sequence homology, respectively. It is 
conceivable that the UTRs might play a role in transcriptional regulation of the gene. 
Indeed, Young and Korsmeyer (1993) took advantage of the differential expression of 
bcl-2 within the B-cell lineage and identified a novel negative regulatory element (NRE) 
in the human bcl-2 5’ UTR that decreased expression from the bcl-2 PI promoter or 
heterologous promoters. Most of the negative regulatory activity of the 1.4kb NRE has 
been mapped to the 271 bp region immediately upstream of the ATG start codon, and so 
this region is considered as the minimum NRE (see Figure 5.1). The minimum NRE
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contains the bcl-2 P2 promoter, an octamer mitif, and a cluster of putative Ete-binding 
sites (Figure 5.1). However, the NRE activity is similar in pre-B-cell and mature B-cell 
lines, that display different bcl-2 expression at the transcriptional level. It was 
subsequently reported that p53 can down-regulate bcl-2 transcription via this element 
(Miyashita et al., 1994). Interestingly, Frampton et a l (1996) identified several Myb- 
binding sites within the minimum NRE whereby v-Myb up-regulates bcl-2 transcription. 
Therefore, although the NRE activity is an important determinant of the differential 
expression of bcl-2, it alone does not explain the developmental control of bcl-2 
transcription. At least one other mechanism emerging is the interplay between various 
positive and negative transcription factors that are able to bind to the NRE and control 
transcription of the gene.
Figure 5.1. Schematic representation of the bcl-2 promoter.
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Exon 1 Exon 2
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PI: Promoter 1 
P2: Promoter 2
NRE: Minimum negative regulatory element 
ORF: Open reading frame 
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* : Putative Ete-binding site
5.4. Mechanisms and regulation of the Bcl-2 functional activities.
Bcl-2 can inhibit apoptosis in a variety of cells and tissues across divergent phyla in 
response to a variety of stimuli. This indicates that Bcl-2 must act at a final common 
pathway that operates in all forms of apoptosis and appears to be evolutionarily 
conserved. The mechanism whereby Bcl-2 inhibits apoptosis is not clear but more and 
more direct evidence have arisen from recent discoveries. The first clue has come from 
studies of Hockenbery et al. (1993) and Kane et al. (1993), who postulated that Bcl-2 
inhibits cell death by acting as an antioxidant or inhibiting the generation of oxygen free
•  ^  Iradicals. Shimizu et al. (1996) also showed that induction of apoptosis by a Ca 
ionophore or hypoxia results in increased levels and activity of active ICE-like cysteine 
proteases, the inhibition of which reduces the extent of cell death. Interestingly, over­
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expression of bcl-2 or bcl-xi inhibits apoptosis and the activation of ICE-like proteases, 
indicating that Bcl-2 and BcI-xl act upstream of these proteases. Marin et al. (1996) 
suggested that the anti-apoptotic effects of Bcl-2 may, in part, be to prevent a sustained 
increase in nuclear and cytosolic Ca following apoptosis induction.
Regulation of the Bcl-2 functional activity can occur at either 
transcriptional/translational or post-translational level. It has been well established that a 
variety of growth factors can act as survival factors and prevent apoptosis in certain 
growth factor-dependent cells. In the case of IL-2, IL-3 and GM-CSF, it was reported 
that they do so by up-regulating bcl-2 expression at the mRNA and protein levels (Duke 
and Cohen, 1986; Rinaudo et al., 1995; Bradbury et a l, 1994). Kinases appear to be 
required for this activity since either herbimycin A, a protein tyrosine kinase inhibitor, 
or inhibitors of protein kinase C block the ability of IL-2 and IL-3 to up-regulate bcl-2 
expression and induce apoptosis (Rinaudo et al., 1995; Otani et al., 1993). In addition, 
there is evidence that growth factors induce the bcl-2 expression through activation of 
the Ras signalling pathway (Kinoshita et al., 1995). Stromal cells can also regulate the 
bcl-2 expression in a stroma-dependent pro-B cell line. When removed from stromal 
cell cultures, the pro-B cells rapidly lose the bcl-2 mRNA expression, which is 
coincident with immediate initiation of apoptosis (Gibson et al., 1996). More direct 
evidence with regard to regulation of bcl-2 expression comes from studies of p53 and v- 
Myb. It has been reported that p53 induces apoptosis by decreasing the bcl-2 expression, 
and mice deficient in p53 exhibit an increase in the Bcl-2 protein in several tissues 
(Miyashita et al., 1994b). Frampton et al. (1996) reported that v-Myb up-regulates bcl-2 
and suppresses apoptosis in myeloid cells. More importantly, both p53 and v-Myb 
appear to act directly on the bcl-2 promoter (Miyashita et a l, 1994a; Frampton et a l, 
1996; also see Section 5.3).
In addition to modulate bcl-2 expression, the Bcl-2 activity can also be regulated, and 
this occurs either by phosphorylation or interaction with other proteins. Haidar et al. 
(1995) reported that Bcl-2 can be phosphorylated on serine, and the phosphorylated 
protein can no longer protect cells from apoptosis. One way to induce Bcl-2 
phosphorylation is by microtubule depolymerisation (Haidar et a l, 1997) and, hence, it 
was proposed that Bcl-2 may act as “guardian of microtubule integrity”. Bcl-2- 
interacting proteins include the itas-related protein, R-Ras p23, and the Bcl-2- related 
protein Bax. Identification of R-Ras as Bcl-2-interacting partner provides evidence of a 
putative component of a signal transduction pathway involved in the regulation of 
apoptosis (Femandez-Sarabia and Bischoff, 1993), but direct evidence is lacking with 
regard to how this interaction may regulate the anti-apoptotic activity of Bcl-2. On the 
other hand, it has been reported that interaction of Bcl-2 with Bax abolishes its anti- 
apoptotic activity (Oltvai et a l,  1993). When Bcl-2 is in excess, Bcl-2 homodimers
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dominate and cells are protected. When Bax is in excess Bax homodimers dominate and 
cells are susceptible to apoptosis (Figure 5.2). Thus, the ratio of Bcl-21 Bax represents a 
cell-autonomous rheostat that pre-determines a cell’s life or death response to an 
apoptotic stimulus. Of note, with the rapid increase of identification of Bcl-2 family 
members and their protein partners, more and more proteins are being found that 
interact directly with either Bcl-2 or Bax or both (Farrow and Brown, 1996), and so our 
understanding of the roles of Bcl-2 family members is rapidly changing and the above 
picture is very simplified.
5.5. The roles of Bcl-2 family proteins in regulating proliferation and 
differentiation.
Although Bcl-2 family proteins were initially identified as regulators of apoptosis, recent 
evidence suggests that they may also play a role in co-ordinating cell proliferation and 
differentiation. Miyazaki et a l (1995) demonstrated that Bcl-2 mediates IL-2 signalling 
in conjunction with either the c-fos/c-jun induction pathway involving src family protein 
tyrosine kinases or the c-myc induction pathway. Marvel et a l (1994) suggested a direct 
involvement of Bcl-2 in cell cycle events, based on their demonstration that over­
expression of bcl-2 results in a delay in re-entry into cell cycle after growth factor 
withdrawal, implying that Bcl-2 function may antagonise a critical event in G0/G1 
transit after a period of quiescence.
The involvement of Bcl-2 in regulating differentiation was first implied by its 
expression pattern within tissues. As mentioned above (see Section 5.2), the bcl-2 
expression in adult tissues appears to be restricted in cells that are rapidly dividing and 
differentiating into mature components. Such cells include stem cells of the crypts of the 
gut epithelia or the skin, and early haemopoietic progenitors. In some cases, the bcl-2 
expression declines in cells as they mature, or at stages when cells may be eliminated. 
For example, bcl-2 is down-regulated during keratinocyte or myeloid differentiation 
(Hockenbery et a l, 1991), and also transiently during B- and T-cell differentiation at a 
stage when such cells are prone to undergo clonal elimination by apoptosis (Gratiot- 
Deans et a l, 1993; Merino et a l, 1994). Furthermore, down-regulation of the bcl-2 
expression in a epidermal keratinocyte cell line using an antisense approach results in a 
spontaneous epidermal differentiation (Marthinuss et a l, 1995). However, an up- 
regulation of bcl-2 expression has also been documented in differentiating cells. Zhang 
et a l (1996) reported that the bcl-2 expression increases in Paju cells, a human neural 
crest-derived tumour cell line, that are induced to undergo neural differentiation in 
response to phorbol ester. Over-expression of the bcl-2 cDNA induces extensive neurite 
outgrowth, even in low serum concentrations, together with an increased expression of a 
neuron-specific enolase; whereas Paju cells expressing the antisense bcl-2 cDNA
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Figure 5.2. A pre-set rheostat model as to how the ratio of Bcl-2/Bax determines the 
life or death response of a cell following a programmed cell death (PCD) signal.
PCD
Signal
On/Off
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construct do not undergo spontaneous neural differentiation. Similarly, in a myeloid 
precursor cell line, expression of the bcl-2 family member, A l, is stably increased during 
myeloid differentiation induced by G-CSF (Lin et a l , 1993). Finally, expression of 
another bcl-2 family member, mcl-1, undergoes an early rapid increase (l-3h) followed 
by a later gradual fall in a human myeloid leukaemia cell line, ML-1, undergoing 
myeloid differentiation (Kozopas et a l , 1993). It appears, therefore, that quantitative 
changes in expression of bcl-2 family members is required in various differentiation 
processes. The up- or down-regulation of bcl-2 family members in different 
differentiation processes may reflect a difference in the mechanisms whereby 
differentiation is regulated.
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Chapter 6: The ELM Erythroleukaemia System
6.1. Erythroleukaemia induced by X-ray irradiation.
A disease with the characteristics of an erythroblastic leukaemia, termed the ELM 
erythroleukaemia, was induced after a long delay in a female C3H mouse by X-ray 
irradiation of 300 Rads when the animal was 10 weeks old (Figure 6.1) (Itoh et al., 
1988a). Hepatomegaly, spenomegaly and anaemia were noticed after a ten month 
latency. Subsequent passage in vivo in the spleen generated erythroleukaemia within two 
weeks of injection, implying selection for more leukaemogenic cell clones during these 
early passages. Cytological analysis of peripheral blood from animals with a well- 
developed leukaemia showed that it consisted almost entirely of erythroid cells at 
different stages of differentiation. It is unusual for irradiation to induce erythroid 
malignancies in mice: usually cells from the lymphoid and other myeloid lineages are 
affected, and the genetic background of the irradiated host, to some extent, determines 
the nature of the haemotological malignancies formed (Janowski and Boniver, 1986; 
Mole, 1986). In some cases, leukaemia progression involves the production of 
recombinant endogenous retroviruses that are leukaemogenic in other non-irradiated 
host animals. Itoh et a l (1988a) performed a number of experiments that appeared to 
exclude any endogenous or exogenous retroviral involvement in the ELM tumour. First, 
both cell-free medium from short-term ELM spleen cell cultures and ultra-sonicated 
ELM cells failed to induced erythroleukaemia in 8-10 week-old C3H mice, 
demonstrating that no leukaemogenic retroviruses are being produced by the cells. 
Second, reverse transcriptase (RT) activity, which is present in retrovirus-producing 
cells, was not detected in the spleen and liver of mice with advanced ELM 
erythroleukaemia: the same assay had been used effectively to detect RT activity in 
Friend virus-infected cells (Ono et al., 1984). These results distinguished ELM from 
Friend and Rauscher virus-induced erythroleukaemias and implied that the X-ray 
irradiation was the sole factor involved in initiating this malignancy, presumably by 
generating mutation in cellular genes. Autocrine growth factor production has been 
recorded in a number of haemopoietic malignancies (Sawada et a l, 1986; Meeker et a l, 
1990). However, conditioned medium from short-term ELM leukaemic spleen cell 
cultures failed to increase erythroid burst formation from normal bone marrow cells, 
demonstrating that erythroid stimulatory factors, such as Epo, were probably not 
produced by the leukaemic cells as a result of these putative mutations (Itoh et a l, 
1988a).
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6.2. Long-term growth in vitro supported by stromal cells.
Attempts to culture the spleen cells in vitro from the ELM tumour proved to be difficult, 
and even with IL-3, GM-CSF or Epo supplements, no cell lines could be established. 
This is quite distinct from the late stages of Friend erythroleukaemia, from which cell 
lines are readily generated even in the absence of growth factors. However, after an 
initial decrease in viability, ELM cells grew well on the stroma, initially on bone 
marrow-derived primary stromal cells, then later, on a bone marrow-derived stromal cell 
line, MS-5 (Itoh et a l, 1988b and Figure 6.1). Single cell-cloning of those leukaemic 
cells grown on stroma gave rise to the ELM-D cell line, with the “D” representing the 
stroma-dependence of the erythroleukaemia cells. The MS-5 cells are pre-adipocytes 
established after 900 Rads X-ray irradiation of a long term bone marrow culture 
(LTBMC) (Itoh et al., 1988b; Suzuki et a l, 1992). They are capable of supporting the 
adhesion-dependent growth of haemopoietic stem cells and their progeny for greater 
than two months in LTBMC (Itoh et a l, 1989). Electron microscopic analysis showed 
that ELM-D cells adhere intimately to the stromal cells, with regions of extremely close 
contact (-10 Angstroms).
The stroma-dependence of ELM-D cells was rigorously tested by serial re-cloning 
experiments in the presence or absence of stromal cells. Clonal growth of ELM-D cells 
in the presence of stromal cell is very efficient but can be reduced by a factor of 104 
when the feeder layer was omitted. However, during the first couple of weeks of 
cloning, many large colonies would arise that later disintegrate. The frequency of true 
stroma-independent variants is <2 x 10'5 (Prof. W. Ostertag, personal communication). 
These results confirmed that ELM-D cells show a genuine dependence on the stroma for 
long-term growth and survival, but are capable of proliferative cell expansion for a short 
term without stroma (2-3 weeks). Further evidence indicates that this stroma- 
dependence strictly requires direct cell-cell contact: (1) the long-term growth of ELM-D 
cells can not be supported by a cocktail of soluble growth factors including IL-3, GM- 
CSF and SCF, nor can conditioned medium from ELM-D/MS-5 co-cultures or MS-5 
cells; (2) the long-term growth of ELM-D cells, when grown separated with the stromal 
MS-5 cells via an agar layer, is not maintained.
Dependence on specific growth factors for the survival and proliferation of leukaemic 
cells in vitro has been demonstrated in many studies, but the use of stromal cells to 
support growth has rarely been recorded. Bearing in mind the importance of the stromal 
cells in the maintenance of haemopoiesis (see Chapter 1 and Section 2.1), such stroma- 
dependent cell lines as ELM-D cells provide a unique and appropriate means of stromal 
cell investigation in vitro because: (1) morphological and kinetic analysis can easily be
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performed on the cell populations; and (2) deletion and reconstitution experiments of 
putative functional stromal cell components can be carried out.
6.3. Stroma-independent derivatives.
As mentioned above (see Section 6.2), the ELM-D cell population contains a small 
proportion of cells that can grow without stromal cells and the frequency of occurrence 
of stroma-independent clones is approximately 2 x 10’5. Fifteen stroma-independent 
ELM cell lines have been established by cloning or growth of ELM-D cells in the 
absence of stroma (Itoh et a l , 1988b and Figure 6.1), which are termed ELM-I cells 
with the “I” representing the stroma-independent growth of these cells. ELM-I/1 was 
derived from the non-adherent cell population from a dense culture of ELM-D cells 
grown on feeders for seven weeks. ELM-I/2 arose after culturing the ELM tumour cells 
(that had been passaged in vivo) directly in vitro in the absence of stromal cells. The 
remaining ELM-I cell lines were independently derived from the clonal ELM-D cell 
line, by selection for growth in suspension in the presence (eleven cell lines) or absence 
(1/5 and 1/6) of GM-CSF. However, continued growth of those eleven cell lines proved 
not to be dependent on GM-CSF. In this thesis, ELM-I/1, 1/2, 1/5 and 1/6 cells were 
routinely used.
6.4. Tumorigenicity and differentiation capacities.
The original ELM tumour can be passaged in vivo. Subsequently, a comparison of 
tumorigenicity of stroma-dependent and -independent ELM cells was performed by Itoh 
et a l (1988b) and Nibbs (unpublished data). This was carried out by injecting cells via 
the tail vein into syngenic C3H mice that had been immuno-suppresed by irradiation 
with 300 Rads of y-rays. Mice were sacrificed 15-20 days post-injection and their 
spleens weighed as a measure of leukaemogenicity. It proved that all the ELM cells 
tested (ELM-D, ELM-I/1, 1/2, 1/5 and 1/6) cause splenomegaly in mice and this is 
accompanied by liver enlargement. In addition, spleens from mice injected with ELM 
cells are also significantly paler than those from normal animals, indicating that severe 
anaemia might be induced in those mice. Most interestingly, ELM-I/1 cells consistently 
show the highest tumorigenicity, with the spleens up to eight times that of a normal 
spleen; whereas spleens from mice injected with other ELM cells are 2-3 times above 
the normal level. Moreover, mice injected with the ELM-I/1 cells also appear least 
healthy prior to sacrifice.
In parallel with these in vivo tumorigenicity assays, differentiation capacity of ELM cells 
was also tested in response to physiological growth factors, Epo and IL-3 (Nibbs et a l , 
1993). The results showed that all of ELM cells apart from one (ELM-I/1) undergo
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erythroid differentiation, indicated by an increase in the a-globin mRNA, in response to 
either Epo or IL-3. However, ELM-I/1 cells are insensitive to Epo or IL-3 induction. 
Later studies carried out by Dr. N. Leslie in our laboratory showed that ELM-I/1 cells 
can neither be induced to undergo erythroid differentiation by chemical inducers such as 
DMSO and HMBA. Taken together, ELM-I/1 cells seem to be blocked in differentiation 
and this may be associated with their high tumorigenicity in vivo.
6.5. Genetic characterisation.
Attempts were made to define the genetic changes responsible for the different 
phenotypes within the ELM system with regard to stroma-dependence, differentiation 
capacity and tumorigenicity (Nibbs et a l , 1993). At the p53 locus, in both the primary 
tumour and all the ELM cell lines derived from it, one copy of the gene has been lost 
whereas the other contains an 18bp deletion, implicating its mutation as an early step in 
the development of the leukaemia. However, the mutation of p53 found in these cells is 
not sufficient to confer stroma-independent growth or induce differerentiation arrest.
Although none of the ELM cells express the c-ets-1, c-ets-2 or spi-llPU.l mRNA, 
changes in gene expression of another two ets family members, erg and fli-1 , were 
identified (Nibbs et al., 1993). Only very low or undetectable levels of the erg mRNA 
are present in the primary leukaemic cells or ELM-D cells, whereas all the ELM-I 
variants have moderate levels of erg expression. Upon stroma-withdrawal, ELM-D cells 
show an elevated expression of the erg mRNA, yet, ELM-I cells do not down-regulate 
the erg mRNA when grown in contact with the stroma. This implies that up-regulation 
of erg expression seems to be important for stroma-independent growth and this seems 
to be made permanent in the ELM-I mutants.
The fli-1 expression at the mRNA level is not detectable in any of the ELM cell lines 
apart from one (ELM-I/1), in which the fli-1 expression is significantly up-regulated. 
Surprisingly, it was found that the fli-1 gene region is rearranged not only in the ELM- 
I/1 varient espressing^/7z'-7, but also in the primary tumour and all the ELM cells derived 
from it. The rearrangment is due to the insertion of an unexpected retrovirus inserted 
upstream of one fli-1 allele, but this does not result in fli- l  gene activation in any of the 
ELM cell lines except ELM-I/1. It appears, therefore, that insertion at the f li- l  locus may 
be an important event in the evolution of this erythroleukaemia. The fact that the tumour 
cells are monoclonal with respect to this insertion implies that it was selected for during 
tumour development. There are precedents in other systems for such insertion being 
selected because of activation or inactivation of adjacent genes. In the ELM leukaemia, 
inactivation seems unlikely, since there is no evidence for fli-1 expression in normal 
erythroid progenitors. Furthermore, only one allele appears to be affected by mutation in
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the ELM tumour. There seem to be two plausible interpretations of the data involving 
gene activation by retroviral insertion. First, fli-1 could have been activated in the 
original tumour but then became inactivated during subsequent passages in vivo, i.e.,fli- 
1 expression was required for initiation of the leukaemia but not for its subsequent 
maintenance. Alternatively, the retroviral insertion upstream of the fli-1 gene could be 
activating another important gene nearby. A further question concerns the mechanism 
whereby fli-1 becomes expressed uniquely in ELM-I/1 cells. No structural differences 
have been detected at the fli-1 locus between ELM-I/1 and other ELM cell lines, 
although it cannot be excluded that small sequence changes may be affecting expression 
of the fli-1 gene. Alternatively, ELM-I/1 may express certain transcription factors absent 
from other ELM cell lines that permit fli-1 transcription.
6.6. Aims and objectives
As discussed above, the ELM system consists of a series of erythroleukaemic cell lines 
that are different in their stroma-dependence, differentiation potential in response to 
physiological growth factors, and tumorigenecity in vivo. Thus, the ELM system not 
only provides us a very useful cellular system that allows us to identify the cellular and 
molecular mechanisms of stroma-dependent growth, but also is an in vitro model of 
tumour progression and enables us to identify genetic changes involved in the 
occurrence of stroma-independent growth, differentiation arrest and increased 
tumorigenicity.
There were mainly three parallel aims of this project. The first aim was to characterise 
cellular and molecular events in ELM-D cells upon stroma-withdrawal in an attempt to 
understand the nature of stroma-dependent growth and the underlying molecular 
mechanisms. In particular, experiments were performed to determine whether apoptosis 
is the form of cell death that occurrs in ELM-D cells in the absence of stroma, and if 
genes that regulate apoptosis, such as bcl-2, may play a role in regulating stroma- 
dependent growth.
The second aim was to identify genetic changes that were associated with different 
phenotypes of ELM cells. The genes to be examined can be classified into three 
categories: (1) genes involved in the induction of erythroleukaemia {erg and fli-1)', (2) 
genes involved in the control of cell survival, especially when in the absence of survival 
and proliferation signals that are normally present (bcl-2 and bcl-x); and (3) genes that 
play a crucial role in the regulation of erythroid differentiation (gata-1 and scl). If any 
particular gene appeared to be associated with a particular phenotype then functional 
work would be carried out to perturb gene expression by either over-expression or 
antisense approaches.
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The third aim was to dissect the molecular mechanisms responsible for differentiation 
arrest and increased tumorigenicity associated with ELM-I/1 cells, especially in light of 
the fact that the fli-1 mRNA is significantly up-regulated in this particular cell line.
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PART II: METHODS AND MATERIALS
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CHAPTER 7: Methods
7.1. Cell culture.
7.1.1. Culturing of mammalian cells in vitro.
All the ELM cell lines (Itoh et a l,  1988) and the MS-5 stromal feeder cells (Itoh et al., 
1989) were maintained in Minimal Essential Medium (a-MEM) in 5% (v/v) C 02 at 
37°C. a-MEM, containing deoxyribonucleosides and ribonulceosides, is supplemented 
with 16% (v/v) or 8% horse serum and 4mM glutamine. This medium will be referred to 
as the ELM growth medium hereafter. In long term cloning experiments, during which 
chances of contamination were significantly high, lOOpg/ml of streptomycin and 
37.5pg/ml penicillin were included.
MS-5 cells or ELM-D cells growing on live MS-5 cells were passaged as follows. Cells 
were washed with PBS (137mM NaCl, 3mM KC1, lOmM Na2HP04, 2mM KH2P 0 4, 
pH7.4) and then removed from the flask by treating with a 0.25% trypsin solution and 
incubating at 37°C for approximately 5min. After trypsinisation, 9 volumes of fresh 
ELM growth medium was added to dilute and thereby inhibit the trypsin. The resulting 
cell suspension was directly transferred into new flasks. All the stroma-independent cell 
lines of the ELM system (i.e. ELM-I cells) grow to some extent attached to the bottom 
of the tissue culture flasks. On passage, they were scraped off from the flasks using 
Disposable Cell Scrapers (Costar) and re-seeded at a density of 105 per ml in the fresh 
ELM growth medium.
The HL60, K562, KG-1 and Molt-4 cells were maintained in DMEM containing 10% 
(v/v) foetal calf serum and 4mM glutamine in 5% C 02 (v/v) at 37°C. Since they are also 
suspension cells, and thus were passaged in a similar way as ELM-I cells.
The Q2BN cells were grown in DMEM containing 8% (v/v) foetal calf serum, 2% (v/v) 
heat-inactivated horse serum, 4mM glutamine, 0.375% (v/v) sodium bicarbonate, 1 mM 
sodium pyruvate and lOmM HEPES buffer in 5% C 02 (v/v) at 37°C. This DMEM 
medium with supplement will be referred to as the Q2BN medium hereafter. The Q2BN 
cells were passaged as described for ELM-D/MS-5 cells.
7.1.2. Cell storage.
Stocks of cells were stored in liquid nitrogen. To freeze cell stocks down, cells were 
harvested as above, resuspended to a final concentration of 107 cells per ml in growth
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medium containing 10% (v/v) DMSO and then dispensed into l-2ml Nunc cryotubes 
and stored at -70°C for 24h in a well insulated container to give a rate of 1°C per min. 
Tubes were then transferred to liquid nitrogen for long-term storage.
To thaw frozen cell stocks, cells were placed in a 37°C water bath. As soon as they were 
thawed, they were diluted in 20ml of growth medium at 37°C and centrifuged for 5min 
at l,200rpm in a MSE Centaur benchtop centrifuge. Cell pellets were then resuspended 
in fresh tissue culture medium and seeded into a tissue culture flask.
7.2. Growth curve analysis of ELM-D cells.
The ELM-D cells were grown to confluence on the stromal cells. They were then shaken 
off from the stroma, counted by a haemocytometer and diluted at a density of 105 per 
ml. 5ml of such cell suspension were aliquoted into the T25 flasks that had been seeded 
with 5 x 105 MS-5 feeder cells. At each time point, ELM-D cells were shaken off from 
the stroma and counted in a similar way. Each time course was performed in triplicates.
7.3. Cell viability assays
Cell viability assays were carried out using the trypan blue exclusion method (Sigma) 
which is based on the permeability changes of the cytoplasmic membrane that occur 
concomitantly with cell death, so that dead cells can uptake trypan blue and appear blue. 
To perform the assays, cell suspension was mixed with an equal volume of a trypan blue 
solution (Sigma) and the mixture was then incubated at room temperature for 5min. At 
the end of incubation, the number of blue cells and the total number of cells were 
counted using a haemocytometer.
7.4. Serial re-cloning of ELM-D cells.
In the serial re-cloning experiments, ELM-D cells were cloned on MS-5 cells irradiated 
with 17,000Rads of y-rays from an Alcyon II Teletherapy Unit containing a 60Co source. 
It has been demonstrated that the lethally irradiated stromal cells almost cease 
proliferation but can support the growth of ELM-D cells for up to 2-3 weeks before they 
disintegrate. The MS-5 cells were seeded in 96-well plates (Nunc) at a density of 2- 
3x10 cells per well. After irradiation, the medium was replaced with lOOpl of fresh 
medium. To clone ELM-D cells, they were grown on the irradiated MS-5 cells to sub­
confluence when they were shaken off from the stroma, counted using a 
haemocytometer and then re-seeded into 96-well plates containing irradiated stroma in 
such a way that there were 1, 3, 10 and 30 cells in 200pl of the ELM medium per well. 
At about day 10 after cloning, lOOul of fresh medium were added into each well with
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care. After 2-3 weeks, the number of clones that grown out were counted and at least 8- 
10 clones picked and subsequently re-cloned as above. The cloning effiency was 
calculated as the number of clones grown out divided by the total number of cells 
seeded initially.
7.5. Staining ELM-D cells with Giemsa.
Approximately l-2xl05 cells in suspension were centrifuged onto microscope slides in a 
Cryo-Tek cytospin centrifuge at 500rpm for 5min, washed once with PBS (see Section
7.1.1) and fixed in ice-cold 70% ethanol for lmin. The fixed cells were then stained 
with a Giemsa solution (0.4% (w/v) in buffered methanol solution, pH6.8, Sigma) for 
5min, washed 2-3 times with dH20 , dried and finally mounted under coverslips with 
Depex.
7.6. Differentiation induction in vitro.
Cells were grown to sub-confluence, harvested and then re-seeded in the ELM growth 
medium at a density of 105 cells per ml plus either no additional growth factors or 
lU/ml of recombinant human EPO (Boehringer Mannheim). Culture were incubated for 
3h, 6h or 1-5 days and the RNA extracted (see Section 7.9.3).
7.7. Transient and stable transfection of Q2BN and ELM cells.
7.7.1. Transient transfection of Q2BN cells by the calcium phosphate precipitate 
method.
Calcium phosphate-mediated transfection of the adherent Q2BN cells was carried out as 
described in Sambrook et a l (1989). 24h before transfection, exponentially growing 
Q2BN cells were harvested by trypsinisation and re-plated at a density of 2x105 cells per 
5ml per 60mm dish (Nunc). They were incubated for 20-24h in 5% (v/v) C 02 at 37°C in 
a humidified incubator. Calcium phosphate-DNA precipitation was carried out as 
follows (the amounts given are sufficient for triplicate transfections): 770pl of DNA 
solution in O.lxTE (lxTE: lOmM Tris.HCl , ImM EDTA (pH8.0)) was added into 
109pl of 2.46M CaCl2 and mixed well, then 875pl of 2xHBS (2xHBS: 280mM NaCl, 
lOmM KC1, 1.5mM Na2P 0 4, 12mM glucose and 50mM HEPES (pH7.9)) was added 
with mixing by pipetting up and down rapidly 6 times. The mixture was left at room 
temperature undisturbed for exactly 20min, then 0.5ml of the calcium phosphate-DNA 
precipitate solution was transferred into each 60mm dish containing Q2BN cells in 5ml 
medium. After 24h incubation at 37°C, the medium was removed and 5ml of fresh 
medium added at 37°C. Assays for transient expression were carried out 24h later.
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7.7.2. Transfection of ELM cells by electroporation.
24h before transfection, ELM cells were seeded at a density of 4xl05 cells per ml. For 
electroporation, cells were harvested, spun down and resuspended at a density of 
2.5x105 cells per ml in ELM growth medium. 200pl of such cell suspensions containing 
5xl06 cells were used for each electroporation. 40pl of 0.5pg/pl DNA solution in lxTE 
(see Sction 7.7.1) were gently mixed with the cell suspension in a electroporator cuvette 
and then equilibrated to room temperature for lOmin. For generation of stably 
transfected ELM cells, electroporation was carried out at 960pF and 260V using a 
BioRad Gene Pulser with a capacitance extender. For transient expression assays, a 
much improved transfection efficiency was desired and this was achieved, to a limited 
extent, by using a Flowgen EasyjecT Plus electroporator at 1050pF and 280V. After 
electroporation, cells were immediately transferred to 6-well plates (Nunc) in 10ml of 
medium at 37°C and then incubated for 48h when transient expression assays (see 
Section 7.7.4) or selection of stably transfected cells (see below Section 7.7.3) were be 
carried out.
7.7.3. Selection of stably transfected ELM cells.
48h after electroporation, ELM cells were cloned in 96-well plates in the ELM growth 
medium containing lOOpg/ml of streptomycin, 37.5pg/ml penicillin and 80mg/ml G-418 
sulphate (Sigma) to select for cells expressing the transgene. Cells were plated by end­
point dilution so that there were 300, 1000, 3000 cells in 200pl of medium per well. 
Such large number of cells were required because the transfection efficiency was very 
low and furthermore electroporation tends to cause large extent of cell death. Ten days 
later, lOOpl of the growth medium containing appropriate antibiotics and G418 were 
added into each well with great care so as not to disturb the clones that might have 
already grown up. Another 5-10 days later, clones were counted and selected for 
expansion and further analysis.
7.7.4. Luciferase assays.
Luciferase assays were performed at 20°C throughout using a Luciferase Assay System 
purchased from Promega. Growth medium was removed from the cells which were then 
washed twice in PBS (see Section 7.1.1). The minimal volume of cell lysis reagent was 
added to the cells (e.g. 250pl for a 60mm culture dish in the case of adherent Q2BN 
cells or lOOpl for each transfection in the case of ELM suspension cells) and the mix 
was incubated at 20°C for 10-15min. In the case of Q2BN cells, cells were scraped off 
from the culture dish using Disposable Cell Scrapers (Costar) and the cell lysates
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transferred to microfuge tubes. Samples were spun at 14,000rpm in an Eppendorf 
microfuge for 2-3min and the supernatants then transferred to fresh microtubes. The 
luciferase activity of 2 0 pl of cell lysates was measured by a luminometer.
7.7.5. B-galactosidase assays.
30-60pl of the cell lysates prepared as described above (see Section 7.7.4) were added 
into Solution I (40mM NaH2 P 0 4, 60mM Na2 HP04, lOmM KC1, ImM MgCl2  and 
50mM p-mercaptoethanol) followed by 0.1ml of Solution II (40mM NaH2 P 0 4, 60mM 
Na2 HP0 4  and 2mg/ml ONPG) and the mixture was incubated at 37°C for 30-90min 
depending on transfection efficiency. The reaction was stopped by the addition of
0.25ml of 1M Na2 CC>3 and the absorbance at 420nm determined by a DU® 650 
spectrophoto-meter (Beckman) was a measure of p-galactosidase activity.
7.8. Tumorigenicity assays in vivo.
To test the tumorigenicity of the ELM cell lines, cells were grown to sub-confluence and 
harvested. The viability of the cells was measured by the trypan exclusion method (see 
Section 7.3) and then 1-I.5xl0 7 cells in 0.2ml of PBS were injected via the tail vein into 
recipient C3H mice that had been immuno-suppressed by irradiation with 300Rads of y- 
rays from rays from an Alcyon II Teletherapy Unit containing a 60Co source. After a 
latency period of about 2-5 weeks depending of the cell types, some animals became 
sick due to splenomegaly, when all the mice were sacrified. The spleens were removed 
after disecting any visible connective tissue. A group of 9 control mice of similar age, 
which had been injected with 0.2ml PBS (see Section 7.1.1), were also included.
7.9. Preparation of oligonucleotides, mammalian genomic DNA and total RNA.
7.9.1. Purification and precipitation of nucleic acid samples.
To remove protein contaminants, a combination of phenol-only (OOH), phenol- 
chloroform (OOH/CHC13) (50:50 (v/v) mix) and chloroform (CHCI3 ) extractions were 
used. Phenol was prepared according to Sambrook et al. (1989). CHC13 was saturated 
with dH2 0 . To extract proteins, an equal volume of these solutions was added to nucleic 
acid samples, vortexed and the layers separated by centrifugation either for 15min at 
3,000rpm at 20°C in a Sorvall® Centrifuge RC3C (DuPont) using the swing-out rotor 
H6000A/HBB6 (large samples) or for lOmin at 14,000rpm in an Eppendorf microfuge. 
Nucleic acids remained in the upper aqueous layer.
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Nucleic acids were precipitated by the addition of 1/1 Oth volume of 3M NaAc (pH5.2) 
and then 3 volumes of ethanol. This was mixed by vortexing and then precipitation 
carried out at -20°C for 0.5-lh. The nucleic acid was pelleted by centrifugation at 4°C 
for 25min at 3,000rpm in a Sorvall® Centrifuge RC3C using the swing-out rotor 
H6000A/HBB6 or for 15min at 14,000rpm in an Eppendorf microfuge. The pellets were 
washed once with ice-cold 75% ethanol, centrifuged again as above, air dried, and then 
re-suspended in the appropriate buffer.
7.9.2. Preparation of oligonucleotides.
Oligonucleotides were synthesised on an Applied Biosystems model 381A DNA 
synthesiser according to manufacturers’ instructions. 5’ trityp groups were removed by 
the machine and the DNA immobilised on a column. The DNA was eluted in 29% (v/v) 
ammonia by passing the solution through the column once every 5min for lh. This 
solution was sealed in a glass vial and incubated at 55°C overnight to deprotect the 
oligonucleotides. Oligonucleotides were precipitated by adding 1ml of butan-l-ol to 
100-150pl of the ammonia stock, the mixture incubated at 20°C for 10-15min and the 
oligonucleotides pelleted for 5-10min at 14,000rpm in an Eppendorf microfuge. The 
supernatant was discarded and the butanol was removed by a speedivac. The dried 
pellets were resuspended in lOOpl of lxTE buffer (see Section 7.7.1). Oligonucleotides 
were quantitated as described in Section 7.9.4.
7.9.3. Preparation of genomic DNA.
Cells were resuspended in lxTE (see Section 7.1.1) to a final concentration of 5x10 
cells per ml and 10 volumes of extraction buffer (lOmM Tris.HCl (pH8.0), O.lmM 
EDTA (pH8.0), 0.5% (w/v) SDS and 20pg/ml DNase-free RNase) added. After a 60min 
incubation at 37°C, samples were mixed gently on a Stuart TR-2 tube rotator and 
proteinase K added to a final concentration of 0.1 mg/ml. This was gently mixed and 
incubated at 50°C for 3h, swirling periodically. After cooling to room temperature, the 
protein fragments were removed by two phenol extractions. DNA was then ethanol 
precipitated (see Section 7.14.1) and collected by spooling it onto a clean Pasteur pipette 
moulded into a hook-shape over a Bunsen. The DNA pellets were allowed to air dry for 
15min and then slowly resuspended at 4°C for 3 days in a volume of lxTE (see Section
7  •7.1.1) such that 1ml was used for every 2x10 cells in the original sample. This solution 
was then dialysed in lxTE (see Section 7.1.1) for 18h at 4°C to remove any remaining 
salt and ethanol, and was stored at 4°C. The DNA concentration was determined 
spectrophotometrically (see section 7.9.4).
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7.9.4. Preparation of total RNA.
Total cellular RNA was prepared using the TRIzol method (Gibco), following the 
manufacturer’s instructions. Cells were grown to sub-confluence and harvested followed 
by centrifugation at l,200rpm for 5min in a MSE Centaur benchtop centrifuge. After 
removed of growth medium, the cells were lysed by dispersing the cell pellets in TRIzol 
Reagent at a density of 5-10xl06 cells per ml followed by incubation at 20°C for 5min. 
Then 0.2ml of chloroform per 1ml of TRIzol was added and samples vortexed 
vigorously for 15sec and the incubation continued at room temperature for 2-3min. 
Samples were then centrifuged at 14,000rpm in an Eppendorf microfuge at 4°C for 
15min and the upper colourless aqueous phase containing RNA was transferrred to a 
fresh tube. The RNA was precipitated by incubating with 0.5ml of isopropanol per ml of 
TRIzol Reagent at RT for lOmin. Samples were then centrifuged as above for lOmin 
and RNA pellets washed with ice-cold 75% ethanol using at least 1ml of 75% (v/v) 
ethanol per ml of TRIzol Reagent. RNA was spun down as above, the pellets air dried 
for 5min and dissolved in a buffer containing lOmM EDTA (pH8.0), 1% (w/v) SDS and 
lpg/pl proteinase K. To facillitate dissolving, RNA samples were incubated at 55-60°C 
for 5-10min.
To avoid degradation by contaminating RNases, a number of precautionary steps were 
taken. First, plastic rather than glass ware was preferred for handling and storage of 
solutions. All tubes were autoclaved before use. Second, all solutions including ddH20  
were pre-treated with 0.1% (v/v) DEPC, an irreversible inhibitor of RNases, and 
autoclaved. Treatment with DEPC was carried out in a fume hood for 3h at 37°C or 
overnight at room temperature. Third, the buffer used to dissolve RNA contains SDS 
and proteinase K and this serves to inhibit any residual RNases or those that carried over 
during subsequent handling of the samples. Finally, all solutions were pre-cooled in ice 
and all manipulations and centrifugations were carried out at 4°C. The concentration 
was determined sepctrometrically (see Section 7.9.4.)
7.9.5. Quantitation of DNA and RNA.
Nucleic acid concentrations were determined spectrophotometrically. 3 pi of the sample 
was added to 300pl of dH20  and absorbance (A) readings taken at 260nm and 280nm in
a quartz cuvette using a DU 650 spectrophotometer (Beckman). dH20  was used as the 
blank for quantitating DNA samples. The blank for RNA samples was prepared by 
adding 3pi of RNA dissolving buffer into 300pl dH20. An A260 value of 1 was taken to 
be equivalent to 50pg/ml of plasmid or genomic DNA, 40pg/ml of RNA and 20pg/ml of 
oligonucleotide. The A260/A28o ratio was used as a measure of purity: samples giving a
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ratio less than 1.75 were further purified by <£>OH/CHCl3 extraction (see Section 7.12.1), 
ethanol precipitation and the A26o/A28o ratio re-assessed.
7.10. PCR from genomic and plasmid DNA.
The concentrations of DNA template used in PCR reactions were 40ng/pl for genomic 
DNA and 2ng/pl for plasmid DNA in lx  TE (see Section 7.7.1). 5pi were used for 
amplification. The primers used are listed in Table 7.1.
Table 7.1. Oligonucleotide primers for PCR from genomic DNA.
Name Sequence Position"
gata-1 F CTCAGAACCCTTGCCCCAGTTTGTGGATTC 101
gata-1 R AGTGGGGCGATCACGCTGGTGCTGCTGGTG 1271
bcl-2 FI ACAGTAAGTTCTTTGCACAGGAATTTTGTT 1303
bcl-2 R1 CCTTCCCCGAAAAGAAGCTGCAGGTACAAC 1791
bcl-2 F2 TAACTTCCTAGGTCGTCCCGCCTCTTCACC 1491
bcl-2 R2 TCTCCCGGTTATCATACCCTGTTCTCCCGG 1831
a The positions of the primers are based on the gata-1 mRNA and bcl-2 genomic 
sequences published by Tsai et a l (1989) and Negrini et al. (1987), respectively.
7.10.1. PCR using Tag DNA polymerase.
Amplification of partial gata-1 fragment from genomic DNA was carried out by 
polymerase chain reactions (PCR) using Taq DNA polymerase. The PCR reaction mix 
was set up as follows:
ddH20  29pl
1 Ox PCR Reaction Buffer (Gibco) 5pi
25mM MgCl2 3pl (final 1.5mM)
2mM dNTPs (Pharmacia) 2.5 pi
DNA template 5 pi
forward primer (140ng/pl) 2.5pl
reverse template (140ng/pl) 2.5pl
Taq DNA polymerase (1 OU/pl,Gibco) 0.5pl
The mixture was mixed thoroughly and 50pl mineral oil added to prevent evaporation. 
The reactions were carried out in a Perkin-Elmer Thermal Cycler 480 with the following 
program:
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No. of programs Temperature Time Cycles
1 95°C 2min 1
2 95°C lmin 25-30
55°C 1.5min
72°C 2min
3 72°C lOmin 1
4 4°C hold -
The products were electrophoresed on an agarose gel (see Section 7.11.2) and the
appropriate sized fragments were purified using the FMC SpinBind DNA Recovery 
System (see Section 7.11.3). PCR products generated using Taq DNA polymerase were 
cloned by the TA Cloning® System (see Section 7.12.7).
7.10.2. PCR using Pfu DNA polymerase.
Amplification of the partial bcl-2 promoter was carried out by polymerase chain 
reactions (PCR) using Pfu DNA polymerase. The PCR reaction mix was set up as 
follows:
ddH20 32.5pl
lOx cloned Pfu buffer (Stratagene) 5 pi
2mM dNTPs (Pharmacia) 2.5pl
DNA template 5 pi
forward primer (140ng/pl) 2.5pl
reverse template (140ng/pl) 2.5pl
Pfu DNA polymerase (2.5U/pl, Stratagene) lpl
The rest of the procedure was similar to that using Taq DNA polymerase apart from that 
the extension temperature was 42°C instead of 55°C (see above Section 7.10.1). PCR 
products generated using Pfu DNA polymerase were cloned by the pCR-Scrip™ 
.Amp.SK(+) Cloning kit (Stratagene, see Section 7.12.8).
7.11. Restriction digest and agarose gel electrophoresis of plasmid DNA.
7.11.1. Restriction digest.
Small quantities of plasmid DNA (<2pg) were digested in the appropriate buffer in a 
total volume of 20pl using 1-10 units of enzymes per ug of DNA, depending on the
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enzyme used and the number of sites present. Larger, preparative digests were carried 
out proportionately larger volumes. For double digests, suppliers’ information was 
consulted and the most appropriate buffer used. Reaction mixes were incubated for 2-3h 
at 37°C and then terminated by the addition of l/6th volume of 6x DNA gel-loading 
buffer (6x buffer: 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% 
glycerol).
7.11.2. Agarose gel electrophoresis.
DNA fragments were resolved on non-denaturing agarose gels containing ethidium 
bromide for subsequent visualisation under UV luminator. In general, 1% (w/v) agarose 
gels were used, but smaller fragments (100-400) were separated on 2-4% gels. Gel 
mixes containing the appropriate amount of agarose in lxTAE (50xTAE: 2M Tris, 
50mM EDTA and 57.1ml/l glacial acetic acid) were heated in a microwave oven to 
dissolve the agarose, and then cooled to 60°C when ethicium bromide was added to 
5pg/ml and the mix was poured into appropriate gel former. Gels were allowed to set at 
room temperature and installed into the electrophoresis tank in lxTAE buffer. Samples 
containing the DNA gel-loading buffer (see Section 7.11.1) were loaded and 
electrophoresed at around 100V. Molecular weight standards used include the lkb 
ladder and Hae Ill-digested bacteriophage 0x174 fragments. A photograph was taken of 
the gel with a polaroid camera, using a TF-35M UV luminator (Vilber Laurmat).
7.11.3. Purification of DNA fragments from agarose gels.
DNA fragments separated from agarose gel were purified using the SpinBind DNA 
Recovery System (FMC) following manufacturer's instruction. This system is able to 
recover DNA fragments from agarose gel ranging in size from 20bp to 5,000bp with an 
effective DNA capacity from 20ng to 30pg. Briefly, the volume of gel slices containing 
the DNA fragments of interest were estimated as its weight and 3 volumes of Binding 
Solution (7.2M Nal, 20mM DTT and 0.1M sodium phosphate (pH6.0)) added. The 
samples were incubated at 20°C for 10-15min or until the gel slices were completely 
dissolved and then were loaded into the SpinBind unit attached to microfuge tubes and 
incubated for lmin at RT to allow the solution to wet the membrane uniformly. The 
units were the centrifuged at 14,000rpm for 15sec in an Eppendorf microfuge. The 
filtrates in the microfuge tube were were re-applied to the Spin-Bind units and re- 
centrifuged as above. Finally, the binding process was repeated once more to ensure 
maximum binding of the samples. After the binding procedure, the SpinBind units were 
washed using 400pl of Sodium Iodide Wash Buffer (4.8M Nal, 20mM DTT and 
0.066M sodium phosphate (pH6.0)) and spinning as above. The wash solution was 
discarded. The units were further washed three times using 400pl of ice cold High 
Ethanol Wash Buffer (50mM Tris.HCl, ImM EDTA (pH8.0) and 80% (v/v) ethanol).
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At the end of the washing, the empty units were spun at the maximum speed for 45 sec 
to remove any remaining ethanol wash buffer and then air dried for 2min. The SpinBind 
units were transferred to fresh microfuge tubes and 50pl of 65°C DNA elution buffer 
(either lxTE or dH20) applied, and spun as above for 15sec to recover the DNA 
samples.
7.12. Recombinant DNA techniques.
7.12.1. Host cells.
For propagating plasmids, DH5a E.coli cells were grown at 37°C either on inverted 
1.5% (w/v) agar L-broth plates (L-broth: lOmg/ml bacto-tryptone, 5mg/ml bacto-yeast 
extracts, 171mM NaCl, pH7) or in Terrific broth (12mg/ml bacto-tryptone, 24mg/ml 
bacto-yeast extracts, 0.4% glycerol, 17mM KH2P 0 4 and 72mM K2HP04) liquid 
medium supplemented with Amphicillin at a final concentration of 50pg/ml. Liquid 
cultures were grown in a New Brunswick G25 incubator shaker with a speed of 250rpm.
7.12.2. Preparation of competent cells.
To prepare competent DH5a cells, 2ml of an "overnight culture" was used to inoculate 
200ml of L-broth (plus the necessary antibiotics), and then incubated at 37°C until the 
absorbance at 650nm was 0.5 units above an L-broth blank. These logarithmically 
growing cells were harvested by centrifugation at 2,000rpm for lOmin at 4°C in an IEC 
Centra-8R centrifuge. The pelleted cells were resuspended in 80ml of RFI solution 
(lOOmM RbCl, 50mM MnCl2, 30mM KAc, lOmM CaCl2, 15% (v/v) glycerol, pH5.8), 
incubated on ice for 2h, pelleted as above and then resuspended in 16ml of RFII solution 
(lOmM MOPS, lOmM RbCl, 75mM CaCl2 and 15% (v/v) glycerol). After incubating on 
ice for 15min, 0.8ml aliquots were transferred into 2ml Nunc cryotubes, frozen in a dry 
ice/ethanol bath and finally transferred to -70°C for storage.
7.12.3. Removal of protruding 3’ termini from DNA fragments that have been digested 
with restriction enzymes.
In a 20pl reaction, 0.2-5 pg of DNA were digested with the appropriate restriction 
enzymes (see Section 7.11.1). At the end of the digestion, lpl of 2mM dNTPs was 
added followed by 1-2U of bacteriophage T4 DNA polymerase per pg of DNA, and the 
reaction mix incubated at 12°C for 12min, after which all the enzymes present in the 
reaction were inactivated by either heating to 75°C for lOmin or the addition of equal 
volume of lxTE (pH7.6, also see Section 7.7.1) followed by phenolxhloroform 
extraction and DNA precipitation (see Section 7.9.1).
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7.12.4. Ligation of DNA fragments into plasmids.
Apart from when using the pCR-Script™.Amp.SK(+) cloning kit (see Section 7.12.8), 
ligation of DNA fragments into plasmids was carried out as follows. DNA fragments of 
interest obtained by either PCR (see Section 7.10) or restriction enzyme digest were 
purified as described in Section 7.11.3 and ligated to the desired linearised plasmid 
DNA as follows:
5x Reaction Buffer (Gibco, containing PEG) 2pl
DNA fragment lOOng
linearised plasmid DNA 50-1 OOng
T4 DNA ligase (Gibco, lU/pl) lpl
ddH20  make up to lOpl
The mixture was incubated at 12°C overnight, 40pl of either lxTE (see Section 7.7.1) or 
ddH20  added to dilute out PEG (which can interfere with transformation) and 5 pi used 
for transformation (see below Section 7.12.5)
7.12.5. Transformation of bacteria.
Apart from when using the pCR-Script™.Amp.SK(+) cloning kit (see Section 7.12.8), 
transformation was carried out as follows. To propagate circular plasmid DNA in E.coli 
(see Section 7.12.1), l-5pl plasmid DNA (l-10ng) were added into 50-100pl of 
competent bacteria DH5a cells, mixed by gentle swirl, and incubated on ice for 20min 
followed by heat shock at 42°C for exactly 45 sec and then incubated again on ice for 
another 2min. Then L-broth (see Section 7.12.1) was added to make up the volume to 
0.5-lml and the content was incubated at 37°C for lh  in a incubator New Brunswick 
G25 incubator shaker with a speed of 250rpm. 10-lOOpl of baterial culture were then 
plated using a sterile glass spreader onto 1.5% (w/v) agar L-broth plates (see Section
7.12.1) containing 50pg/ml ampicillin. When blue/white selection was desired, 25pl of 
X-gal (40mg/ml stock in dimethylformamide) was also spread on top of agar plates. The 
plates were then incubated at 37°C overnight. In the case of blue/white selection, white 
colonies were chosen for further analysis.
7.12.6. Bacterial glycerol stocks.
The DH5a cells transformed with useful plasmids were stored as glycerol stocks for 
future retrieval. Stationary cultures in liquid medium were mixed with an equal volume
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of a 30% (v/v) glycerol/L-broth solution (see Section 7.12.1), cooled on ice and then 
frozen at -70°C.
7.12.7. Cloning PCR products using TA-cloning kits.
This takes advantage of the non-template dependent activity of Taq DNA polymerase 
that adds a single deoxyadenosine to the 3’ ends of duplex molecules. These 3’ A- 
overhangs are used to insert the PCR product into a vector which contains 3’ T- 
overhangs at its insertion site. Ligation and transformation were carried out as described 
above (see Sections 7.12.4 and 7.12.5).
7.12.8. Cloning PCR products using pCR-Script™.Amp.SK(+) cloning kit.
As /y«-generated blunt-ended PCR fragments did not contain sites for restriction 
enzyme Srf, they were cloned using a pCR-Script™.Amp.SK(+) cloning kit (Stratagene). 
Ligation mix was prepared as the following order:
pCR-Scrip. Amp. SK(+) cloning vector (1 Ong/pl) 1 pi
pCR-Scrip 1 Ox reaction buffer 1 pi
lOmMrATP 0.5pl
PCR product 2-4pl
Srf restriction enzyme (5U/pl) 1 pi
T4DNAligase lpl
ddH20  m akeuptolO pl
The ligation mix was mixed gently and incubated at 20°C for lh, then heat-inactivated 
at 65°C for lOmin, and then stored on ice and ready for transformation into E.coli 
supercompetent cells supplied with the kit.
Duing transformation, 40pl of the supercompetent E.coli cells were pipetted into pre­
chilled 15-ml Falcon 2059 polypropylene tube and 0.7pl of the p-mercaptoethanol 
added to yield a final concentration of 25mM. The mixture was swirled gently and 
placed on ice for lOmin, swirling gently every 2min. 2pl of the DNA sample was then 
added into the bacteria, swirled gently and incubated on ice for 30min. The 
transformation mixture was heat-pulsed at 42°C for 45 sec and then incubated on ice for 
another 2min. Then 0.45ml of pre-heated (42°C) SOC medium (20mg/ml bacto- 
tryptone, 5mg/ml bacto-yeast extract, 8.6mM NaCl, 2.5mM KC1, lOmM MgC12, 20mM 
glucose, pH7) was added and samples were incubated at 37°C for lh  with shaking. 
Finally, 50pl, lOOpl, 150pl and 190pl of the transformation mixture, together with 25pl 
of X-gal (see Section 7.12.5) and lOpl of ITPG (200mg/ml stock in ddH20) were plated
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out on agar plates containing ampicillin. The plates were incubated at 37°C overnight 
and white colonies picked. For the control insert, X-gal and ITPG were not necessary 
and the antibiotic used was 30pg/ml of chloramphenicol instead of ampicillin.
7.13. Isolation of plasmid DNA.
7.13.1. Mini-preparations of plasmid DNA.
One step ‘miniprep’ method for the isolation of plasmid DNA was carred out according 
to Chowdhury (1991). 1.5ml of overnight bacterial culture in Terrific broth (see Section
7.12.1) was harvested in a microfuge tube and spun at 14,000rpm in an Eppendorf 
microfuge for 30sec. 1ml of supernatant was discarded, 0.5ml of PCI 
(phenol:chloroform:isoamylalcohol = 25:24:1) added and the mix vortexed and then 
transferred to a Eppendorf mixer for 5-10min. Samples were spun at 20°C for 5min and 
the upper aqueous layer transferred to fresh microfuge tubes containing an equal volume 
of isopropanol. After mixing thoroughly by vortexing, plasmid DNA and RNA was 
pelleted by centrifugation as above for lOmin. The pellets were washed twice with ice- 
cold 75% (v/v) ethanol, air dried and re-suspended in 20pl of lxTE (see Section 7.7.1) 
containing 20pg/ml RNaseA.
7.13.2. Large scale preparation of plasmid DNA.
30ml of overnight bacterial culture of E.coli in Terrific broth (see Section 7.12.1) were 
harvested in a 50ml-Falcon tube and spun at 4,000rpm for lOmin at 4°C using a Sorvall 
Centrifuge RC3C using a H6000A/HBB6 swing-out rotor. The supernatant was 
discarded and the bacterial pellets re-suspended in 5ml Resuspension Buffer (50mM 
Tris.HCl (pH8.0), 10mM EDTA (pH8.0), and lOOpg/ml RNase A), mixed well by 
vortexing, and then 10ml of Lysis Buffer (200mM NaOH and 1% SDS) added, and the 
tubes were turned upside down gently for a few times to achieve a homogeneous lysate 
without shearing the bacterial genomic DNA. Then 7.5ml of Neutralisation Buffer (3M 
KAc (pH5.5)) was added, mixed well, and centrifuged as before. The supernatant was 
filtered through 2 layers of gauze, 0.6 volume of isopropanol added, and the contents 
mixed by vigorous shaking before pelleting the plasmid DNA and bacterial RNA by 
centrifugation as before. The pellets were dissolved in lxTE (see Section 7.7.1) 
containing lOOpg/ml RNase and the mix was incubated at 37-55°C for 30min. At the 
end of the incubation, an equal volume of PEG solution (1.6M NaCl and 13% PEG) was 
added to precipitate plasmid DNA. The contents were mixed thoroughly by vigorous 
shaking, the DNA pellets recovered by centrifugation as before, and re-dissoved in 
0.4ml lxTE (see Section 7.7.1) by repeated pipeting. PCI extraction (see Section 7.13.1) 
was performed twice to get rid of PEG and DNA precipitated (see Section 7.9.1).
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7.14. DNA sequencing.
PCR products were sequenced using cycle sequencing. They were sequenced on both 
strands using the same primers used in the initial PCR reaction. 3.2 pmols of primer was 
added to approximately lpg of DNA and the total volume made up to 12pl with RQ 
grade ddH20 . To this mixture was added 8pi of the Dyedeoxy Terminator Cycle 
Sequencing Prism Kit (Applied Biosystems). Reactions were carried out in a Perkin- 
Elmer 9600 thermal cycler using using 25 cycles 96°C for 15sec, 50°C for lsec and 
60°C for 4min or in a Perkin Elmer Thermal Cycler 480 using 25 cycles 96°C for 30sec, 
50°C for 15 sec and 60°C for 4min. The resultant DNA products were precipitated (see 
Section 7.9.1) and dissolved in 3-4pl of loading buffer (5x: 5 parts deionised formamide 
and 1 part 50mM EDTA containing 30mg/ml blue dextran). Running and analysis of 
sequencing gels was expertly performed by Robert MacFarlane (Beatson Institute, 
Glasgow, UK) as follows. Samples were run on a 6% polyacrylamide gel (made from a 
stock with 40% acrylamide and 2.1% bis-acrylamide) in lxTBE buffer TBE (90mM 
Tris, 90mM boric acid and 2mM EDTA (pH8.0)) using an Applied Biosystem ABI 
373A DNA Sequencer at 30W for 12h. Gels were analysed using 373A software version 
1.2 . 1.
7.15. Northern blotting analysis.
7.15.1. Electrophoresis of RNA samples.
20pg of RNA was ethanol precipitated (see Section 7.9.1) and the pellets resuspended in 
22pl of RNA sample buffer which contained the following:
2pi 5x formaldehyde gel-running buffer (5x FGRB: 0.1M MOPS (pH7.0),
40mM NaAc and 5mM EDTA (pH8.0))
3.5pl formaldehyde (40.6%, v/v) 
lOpl formamide (>99%)
2pl lOx formaldehyde gel-loading buffer (lOx FGLB: 0.25% (w/v) 
bromophenol blue, 50% (v/v) glycerol and ImM EDTA (pH8.0))
4.5pl ddH20
The RNA samples, with 5pg of RNA size markers analysed in parallel, were denatured 
by incubation at 65°C for 15min followed by immediate chilling on ice. They were then 
loaded in 1.1% (w/v) agarose gel containing 6.5% (v/v) formaldehyde in lxFGRB and 
electrophoresis was carried out in lxFGRB (see above) at 80mM for 3-4h. At the end of 
electrophoresis, RNA gels were stained for 5min with an acridine orange dye solution
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(15ug/ml in 3% (v/v) formaldehyde and lOmM Tris.HCl (pH6.8)) and then washed a 
few times in lx  FGRB (see above). 28s, 18s and low molecular weight RNA were 
visualised under a TF-35M UV luminator and this could give a rough idea with regard 
to the quality and loading of RNA samples.
7.15.2. Blotting of RNA gels.
Following electrophoresis, RNA gels were rinsed in dH20  for 5min, followed by 
soaking in 20xSSC (3M NaCl, 0.6M sodium citrate, pH7.0) for 20-60min. Then they 
were transferred to Hybond™ N nylon membrane (Fingerprint grade) by capillary action 
overnight in 20xSSC. After transfer, the membrane was air-dried and UV cross-linked 
using a UV Stratalinker™ 1800 UV cross-linker. Lanes containing RNA markers were 
fixed in 0.5% acetic acid for 5-10min and then stained with 0.04% (w/v) methylene blue 
in 0.5M NaAc (pH5.2) for 5-10min.
7.15.3. Random-primed radiolabelling of DNA probes.
All DNA probes used for hybridisation to Northern blots were labelled with [a-
T9PJdCTP using a random-priming kit (Boehringer Mannheim) according to the 
manufacturer’s instructions. Briefly, lOOng of probe in 8pl lxTE (see Section 7.7.1) was 
denatured by boiling at 100°C for 5min and chilling on ice immediately. To the 
denatured probe, the following were added:
lOx hexanucleotide mix 2pl
The reaction mix was incubated at 37°C for 30min. Unincorporated nucleotides were 
removed by gel filtration on a Sephadex G-50 column equilibrated in PBS (see Section
7.1.1). To prepared the columns, concentrated G-50 in PBS containing 0.02% (w/v) 
sodium azide was pipetted into the Disposable Chromatography Columns. The column 
was then attached to a microfuge tube and placed in a Falcon 15ml-tube which was then 
centrifuged at lOOOrpm in a Sorvall Centrifuge RC3C using a H6000A/HBB6 swing-out 
rotor at 4-10°C for 6min to compress the column. The eluted PBS solution was 
discarded and the centrifugation process was repeated once more. Then the elutent was 
discarded and a fresh microfuge was attached to the column. Before purification of the 
probe, 80pl of lxTE (see Section 7.7.1) was added to the above 20pl reaction mix after 
incubation at 37°C and the mixture was applied to the centre of the column and the 
radio-labelled probe was recovered by centrifugation as above. The eluent containing
Klenow enzyme (lOU/pl, Gibco)
0.5mM dNTPs (dATP+dGTP+dTTP) 
[<x-32P]dCTP (10nCi/nl)
3 pi 
5 pi 
2pl
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the radio-labelled probe was boiled for 5min and then chilled immediately on ice to 
denature the probe.
7.15.4. Hybridisation of blots to the radiolabelled DNA probes.
The membranes were prehybridised in a 42°C shaking water bath for l-3h or overnight 
depending on the strength of the signals expected. Hybridisation buffer contained 
5xSSPE (20xSSPE: 3M NaCl, 0.2M NaH2P 04, 25mM EDTA, pH7.4), 50% (v/v) 
formamide, 5xDenharts (50xDenhardts: 1% (w/v) Ficoll-400, 1% (w/v)
polyvinylpyrroli-done, 1% (w/v) BSA, 0.5% (w/v) SDS and lOOpg/ml denatured salmon 
sperm DNA. Following prehybridisation, radio-labelled probe was boiled for 5min, 
chilled on ice and added to the hybridisation buffer. The membrane was subsequently 
hybridised overnight under the conditions described above. After hybridisation, the 
membranes were washed under increasingly stringent conditions as follows: twice in 
2xSSPE, 0.1% (w/v) SDS at 20°C for lOmin, once in lxSSPE, 0.1% (w/v) SDS at at
20°C for lOmin and finally 2-3 times in O.lxSSPE, 0.1% (w/v) SDS at 65-68°C for 10-
( § )15min. The membranes were then exposed to a Kodak X-OMAT AR imaging film at 
-70°C for the required time.
7.15.5. Stripping blots of the radiolabelled probes.
The radio-labelled probe was stripped from the blots by placing in boiling 0.1% SDS 
and shaking until the solution cooled to room temperature. The blots were then 
hybridised to another probe as described in Section 7.15.4.
7.16. Scanning autoradiographs and quantitation of hybridisation signals by 
densitometry.
Autoradiographs were scanned by laser densitometer (Molecular Dynamics) and image 
analysis carried out using the PDQuest and Quantity 1 software from Protein Databases 
Inc.
7.17. Preparation of protein extracts.
7.17.1. Preparation of total protein extracts for Western blotting analysis.
Cells were grown to sub-confluence, harvested and washed thoroughly in ice-cold PBS. 
After removal of all the supernatant by aspiration, cell pellets were dispersed in ice-cold 
suspension buffer with freshly added proteinase inhibitors (lOOmM NaCl, lOmM 
Tris.HCl (pH7.6), ImM EDTA (pH8.0), ImM PMSF, lpg/pl aprotinin, lug/ul leupeptin
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and 5mM NaF). As soon as possible, an equal volume of 2x SDS gel-loading buffer (2x: 
lOOmM Tris.HCl (pH6.8), 5% (w/v) SDS, 0.02% (w/v) bromophenol blue and 20% 
(v/v) glycerol) was added with freshly added p-mercaptoethanol (80pl per ml of 2x SDS 
gel-loading buffer). The samples were boiled for 5-10min and then, if necessary, 
sonicated twice with 5sec each time using a MSE Soniprep 150 ultra-sound sonicator. 
After sonication, samples were centrifuged in a microfuge for lOmin at 4°C and the 
supernatant was transferred to fresh tubes. They were ready for use directly in SDS 
polyacrylamide gel electrophoresis (see Section 7.18.1)
7.17.2. Large scale preparation of nuclear protein extracts for gel retardation and DNA 
footprinting analysis.
The ELM-I/1 and 1/2 cells were cultured at 105 per ml in 2 litre roller bottles containing 
200-300ml medium that had been saturated with 5% (v/v) C 02 air, and then placed on a 
New Brunswick RollaCell roller at 37°C. When the cell number had reached 
approximately 109, cells were pelleted by spinning at 1700 rpm (860g) for lOmin at 4°C
in a H6000A/HBB6 swing-out rotor using the Sorvall® centrifuge RC3C. The pellets 
were washed once with ice-cold PBS and resuspended in a hypotonic TMS solution 
(5mM Tris.HCl, 2.5mM MgCl2 and 125mM sucrose, pH7.5) at a density of l-2x l07 
cells per ml containing freshly added proteinase inhibitors (0.5mM benzamidine, lOmM 
p-glycerophosphate, 2mM levamisole, 0.5mM PMSF, lOmM sodium butyrate, 5mM 
sodium ortho vanadate (pH8.0) and lpg/ml each of aprotinin, bestatin, leupeptin and 
pepstatin). All the TMS solution used in the following steps contained all the proteinase 
inhibitors mentioned above. The suspension was centrifuged as above and the pellets 
resuspended in TMS/Triton (TMS with 0.05% (v/v) Triton-100) at a density of 2xl07 
per ml, to lyse the cytoplasmic membrane and release the nuclei. The nuclei were 
recovered by centrifugation at 800rpm (180-200g) for 5min at 4°C and washed 1-2 times 
with ice-cold TMS. The pellets were then resuspended in 50ml ice-cold TMS and 0.1ml 
of aliquot was used to check the amount of DNA in the nuclei preparation as follows. 
0.1ml of the sample was mixed with 0.9ml of dH20  and 9ml of 1M NaOH, the mixture 
was sonicated briefly to solubilise the DNA and the absorbance at 260nm was 
measured. The rest of the sample was centrifuged as above and the pellets resuspended 
in ice-cold TMS to give a the final DNA concentration of 5-10mg/ml. 1/10th volume of 
4M NaCl was added dropwise into the sample on ice with stirring, followed by stirring 
on ice for another lOmin and then centrifugation in a SS34 fixed-angled rotor using the
Sorvall® RC-5B Superspeed Centrifuge at 17,000rpm for 15min at 4°C. The 
supernatant was transferred into 30ml ultracentrifuge tubes and ultracentrifuged in a
T1270 rotor using Sorvall® OTD- ComBI Ultracentrifuge at 35,000rpm for lh  at 4°C. 
Then 0.45g of ammonium sulphate was added to per ml of the supernatant to precipitate
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proteins. The mixture was vortexed to dissolve the salt and then stirred on ice for
30min. Proteins precipitates were recovered by spinning in a SS34 fixed-angled rotar
®using a Sorvall RC-5B Superspeed Centrifuge at 15,000 rpm for 20 min at 4°C and the 
pellets dissolved in the minimum amount of a E50 solution (50mM (NH4)2S 04, 5mM 
MgCl2, 20mM HEPES (pH7.9), O.lmM EDTA, 0.1% (w/v) Brij-35, 20% (v/v) glycerol) 
with freshly added ImM DTT and proteinase inhibitors (see above). The samples were 
then dialysed overnight at 4°C in lx  storage buffer (50mM NaCl, 5mM MgCl2, 20mM 
HEPES (pH7.9), O.lmM CaCl2, O.lmM EDTA (pH8.0) and 20% glycerol) with freshly 
added ImM DTT and proteinase inhibitors (see above). The next day, the samples were 
ultracentrifuged in a TLA100.3 rotor using the Beckman centrifuge TL100 at 35,000rpm 
for lh  at 4°C. The supernatant was aliquoted into sterile microfuge tubes and 
immediately frozen on dry ice.
For Western blot analysis (see Section 7.18), the appropriate amount of protein extract 
was mixed with lx  SDS loading buffer (see Section 7.17.1) and denatured by boiling for 
5-10min. The samples were then ready for use in SDS polyacrylamide gel 
electrophoresis (see Section 7.18.1).
7.17.3. Quantitation of protein extracts.
The concentrations of protein extracts were determined by the Pierce BCA potein assay
reagents following manufactures’ instruction. The working reagent was prepared by
mixing 50 parts of Reagent A with 1 part of Reagent B (Reagents A and B were
supplied by the company). 0.1ml of protein samples or each of the BSA protein
standards was added to 2ml of the working reagent and the mixture was incubated at
60°C for 45min. After incubation, all samples were cooled to room temperature before
®the absorbance at 562nm was measured using a DU 650 spectrophotometer.
7.18. Western blotting analysis.
7.18.1. SDS-polvacrylamide gel electrophoresis of protein samples.
Denatured protein samples in lx  SDS loading buffer (see Section 7.17.1 and 7.17.2) 
were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in the 
appropriate percentage (5-15%) of acrylamide resolving gels containing 0.1% (w/v) 
SDS, 0.1% (w/v) APS, 0.04% TEMED in 376mM Tris.HCl (pH8.8). 5% acrylamide 
stacking gels, containing the same concentration of SDS, APS and TEMED, were made 
in 76mM Tris.HCl (pH6.8). Gels were prepared from a stock with 30% (w/v) 
acrylamide and 0.8% (w/v) bis-acrylamide. Electrophoresis was carried out in lx
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protein-gel tank buffer (lOx PGTB: 2M glycine, 1% (w/v) SDS and 250mM Tris.HCl 
(pH8.0)) at 150-200V.
7.18.2. Blotting of protein gels.
At the end of SDS-PAGE, protein gels were blotted onto ECL nitrocellullose membrane 
using a KEN EN TEC Semi Dry Protein Blotter according to manufacturer’s 
instructions. Briefly, the transfer units were assembled as follows: (1)6 layers of 3MM 
filter paper soaked in anode solution I (0.3M Tris, 20% (v/v) methanol, pH 10.4) were 
placed on the anodic graphite plates; (2) on top of the 6 layers, 3 layers of 3MM filter 
paper soaked in anode solution II (25mM Tris, 20% (v/v) methanol, pH10.4) were 
placed; (3) these were followed by an ECL nitrocellulose membrane, pre-rinsed in 
dH20 , and then the protein gel; (4) finally, 6 layers of 3MM filter paper that soaked in 
cathode solution (40mM 6-amino-n-hexanoic acid, 20% methanol, pH7.2) were placed 
on top of the protein gel. After each step of layering, bubbles were squeezed out gently 
using a glass rod. Finally, the transfer unit was covered with the cathode plate and the 
blotting was carried out at a constant current of 0.8mM/cm of gel for lh  at room 
temperature. Blots were then air dried and ready for the ECL detection of proteins of 
interest.
7.18.3. Detection of proteins using the ECL system.
The membranes were incubated in a blocking solution (5-10% (w/v) dairy milk powder 
in lx  Tris-buffered saline-Tween (lxTBS-T: 20mM Tris, 137mM NaCl and 3.8mM 
HC1, pH7.6, plus 0.1% (v/v) Tween 20)) at 4°C overnight or at RT for l-2h with 
constant vigorous shaking. After blocking, the blots were washed in lxTBS-T (see 
above) as follows: two brief rinses at RT, one wash at RT for 15min with constant 
vigorous agitation and finally two washes at RT for 5min. Then the membranes were 
incubated with a 1:1-2,000 dilution of the primary antibody in TBS-T containing 5-10% 
(w/v) dairy milk power at RT for lh  or 4°C overnight with constant vigorous agitation. 
At the end of the incubation, the membranes were washed as described above and then 
incubated with a 1:5,000 secondary antibody in TBS-T containing 5-10% (w/v) dairy 
milk power at RT for lh  with constant agitation. The membranes were then washed 
again as described above and antibody binding detected using the ECL system 
(Amersham). Equal volumes of detection solution I and II were mixed and the mixture 
placed onto the membranes with protein-side up After incubation for exactly lmin, the 
membranes were wrapped in Saran Wrap and exposed to a Fuji Medical X-ray imaging 
film for appropriate length of time.
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7.18.4. Immuno-depletion of antibodies by the control antigen peptides.
The specificity of the primary antibody, rabbit-anti human Erg antibody, was tested by 
incubating the original antibody solution with 50pg of the Erg control peptides on ice 
for 30min prior to use in Wester blotting. The control peptides were the antigens that 
were used to generate the antibody.
7.19. In vitro transcription-translation.
In vitro transcription and translation of the Fli-1 protein were carried using the TNT 
T7 Quick Coupled Transcription/translation System (Promega) following the 
manufacture’s instructions. The following reaction components were assembled:
TNT® T7 Quick Master Mix 40pl
[35S]methionine (lOpCi/pl, Amersham) 4 pi
DNA template lpg
nuclease-free ddH20  make up to 50pl
The reaction was incubated at 30°C for 90min. The radioactive translation products 
were analysed on an SDS-polyacrylamide gel as follows. 5pi aliquot was added to 20pl 
of lx  SDS-sample buffer (see Section 7.17.1). After denaturation by boiling at 100°C
for 2min, the samples were then analysed by SDS-PAGE (see Section 7.18.1). At the
®end of the electrophoresis, the gel was dried down and exposed to a Kodak X-OMAT 
AR imaging film for 6-16h at RT. For producing non-radioactive translation products, 
lpl of ImM methionine was substituted for the [ S]methionine for gel retardation 
assays (see Section 7.20.3).
7.20. Gel retardation assays.
7.20.1. Preparation of double-stranded oligonucleotides.
250pmols of each complementry oligonucleotide were added to a solution containing 
0.1M NaCl in lxTE (see Section 7.7.1) in a total volume of lOOpl. The mixture was 
boiled in a water bath for lOmin and then left to slowly cool down to RT in the water 
bath. The concentration of the annealed double-stranded oligonucleotides was 
2.5pmols/pl.
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7.20.2. Preparation of probes.
5'-end labelling of double stranded oligonucleotides was carried out as previously 
described by Plumb et al. (1989). 2pi (5pmols) of double-stranded oligonucleotide 
annealed as described above was 5'-[ P]-end labelled in the following reaction:
1 pi 1 Ox kinase buffer (Gibco)
0.5pl lOOmM DTT 
1 pi 20mM spermidine (Sigma)
2.5pl ddH20
2pl [y-32P] dATP (lOpCi/pl, Amersham)
lp l T4 polynucleotide kinase (lOU/pl, Gibco)
The above mixture was incubated at 37°C for 60min and then 68°C for lOmin to 
inactivate the enzyme. Any ragged ends of the oligonucleotdes were then filled in by 
adding the following to the end-label reaction, followed by incubation on ice for lh:
lp l lOx TA (0.33M Tris.Ac (pH7.9), 0.66 KAc, 0.1 MgAc2, 5mM DTT and 
1 mg/ml BSA)
4pl 2.5mM dNTPs (Pharmacia)
4pl ddH20
1 pi Klenow enzyme (1 U/pl) (Gibco)
The oligonucleotides were then precipitated by adding 8pl of 1M NaCl, 1.5pl of 
lOmg/ml calf liver tRNA, 300pl of ethanol and cooling at -20°C for lh. The mixture 
was spun for 15min in a microfuge and the pellet resuspended in 30pl of lx  DNA gel- 
loading buffer (see Section 7.11.1). The labelled oligonucleotides were then 
electrophoresed in a lxTBE (see Section 7.14), 8% (w/v) polyacrylamide gel (prepared 
from a stock with 40% acrylamide and 2.1% bis-acrylamide at 100-150V for l-2h in
lxTBE running buffer. The gel was exposed to a Kodak® X-OMAT®AR imaging film 
for 2min, the film developed and the radiolabelled oligonucleotides excised from the gel 
by aligning the autoradiograph with the gel. A second exposure was then taken to ensure 
the oligonucleotides had been removed. The gel slice was then incubated at 37°C 
overnight in 1ml lxTE (see Section 7.7.1). To estimate the amount of unlabelled 
sequence used in competition experiments it was assumed that 80% of the 
oligonucleotides was recovered during the procudure, giving a concentration of labelled 
oligonucleotides of 4pmols/ml.
The sequence of the oligonucleotides used in gel retardation analysis are shown in Table
7.2.
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Table 7.2. Oligonucleotides for gel retardation analysis.
Name Sequence (Ets-binding sites were boxed) Referecnes
E74 GATCTCTAGCTGAATAACCGGAAGTAACTC
ATCCTAGGATC
Reddy and Rao, 1991.
mE74 GATCTCTAGCTGAATAACCCAAGTAACTCA
TCCAGGATC
Reddy and Rao, 1991.
Ets3 ATACTCCAGAAGGAGGAAGCCAGTAGACAA O’Prey etal., 1993
Fli TGAAACCGGAACTGGGC Bosselut etal., 1993
Pea3 GATCCTCGAGCAGGAAGTTCGAGATC Wasylyk et al, 1990.
PU1 GATCCATAACCTCTGAAAGAGGAACTTGGT
TAGGTGATC
Klemsz et al., 1990.
FP1 AAGTAGACTGATATTAACAAAGCTTAATA
AATAATGTACCTCATG
FP2L ACCTCATGAAATAAAAAGCAGAAAGGAAT
TTGAATAAAAATTTCCTGCATCTCATGC
FP2S AAGCAGAAAGGAATTTGAATAAAAATTTCC
TGCATCTCATGC
FP3 TCATGCCAACGGGGAAACACCAGAATCAAGT
GTTCGGTGTAACTAAAGACACCCCTTCATCC
A
FP4 CCAAGAATGCAAAGCACATCCAATAAAAGA
GCTGGATTATAACTATTCTTT
FP5 GTCGGGACTTGAAGTGCCATTGGTACCTGC
AGCTTC
FP6 TTCTTTTCGGGGAAGGATGGCGCAAGCCGG
GAGAAC
7.20.3. DNA:protein binding reactions and gel electrophoresis.
The DNArprotein binding reaction was carried out in the following mix in a total 
volume of 15pi:
nuclear extract (0.1-5pg)
lp l of 1 mg/ml poly(dl-dC) (Pharmacia)
un-labelled double-stranded competitors (5pmols for 25Ox) (when applicable) 
lx  storage buffer (see Section 7.17.2) with freshly added proteinase inhibitors 
ImM PMSF and lpg/pl aprotinin
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The reaction mix was incubated on ice for 20-3 Omin and then 5(4,1 of labelled 
oligonucleotides (~20fmols) was added and the mix was incubated at 20°C for a further 
30min. Samples were electrophoresed in a 5% (w/v) polyacrylamide 0.25xTBE (lxTBE 
see Section 7.14) gel (prepared from a stock with 40% acrylamide and 2.1% bis- 
acrylamide) for 2h at 150V at 4°C, after pre-running the gel for lh  under the same
conditions. At the end of the electrophoresis, the gel was dried and exposed to a Koda
X-OMAT® AR imaging film.
7.20.4. “Supershift” analysis using antibodies.
In “supershift” analysis, 2pl of pre-immune serum or anti-serum were included in the 
DNA-protein binding mix prior to addition of probes. Incubation and gel electrophoresis 
were carried out as described above.
7.21. DNase I DNA footprinting analysis.
DNase I DNA footprinting analysis was carried out essentially as described by Plumb 
and Goodwin (1988).
7.21.1. Preparation of probes.
50pg of plasmid DNA was digested with an appropriate restriction enzyme in a total 
volume of 100(4,1 for 2-3h (see Section 7.11.1). At the end of the the digestion, 20(4,1 of 
calf intestinal alkaline phosphatase (lU/pl, Boehringer Mannheim) and the incubation at 
37°C was continued for another 30min. Then, 10(4,1 of 10% (w/v) SDS, 5pi of 2M NaCl 
and 5pi of EDTA (pH7.5) was added and the mixture heated at 68°C for 5min to 
inactivate the enzyme. The DNA was extracted with PCI and ethanol precipitated (see 
Section 7.13.1). The pellets were dissolved in 45pl of a solution containing lOOmM 
Tris.HCl and ImM EDTA (pH8.0). 7pl of such dephosphorylated DNA (approximately 
7pg) was used for each 5’-end labelling reaction as follows.
The following reaction mix was set up:
dephosphorylated DNA (~lpg/pl) 7 pi
lOx Kinase Buffer (Gibco) 3 pi
50mM DTT 3 pi
20mM spermidine 3 pi
ddH20 l lp l
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The mixture was heated at 70°C for 5min to denature the ends of the DNA and then 
quickly chilled at -20°C. It was then thawed on ice and 5|_il of [y-32P]dATP (1 Op.Ci/jj.1), 
Amersham) and 0.7pl of T4 polynucleotide kinase (lOU/pl, Gibco) were added and 
incubated at 37°C for lh  before adding lp l of 0.2M EDTA (pH7.5) and incubation at 
70°C for lOmin to inactivate the enzyme. Then lOOpl of TE (see Section 7.7.1) was 
added and the mixture deproteinised by PCI extraction (see Section 7.9.1). The aqueous 
phase was transferred to a fresh microfuge tube and lOpl of 4M NaCl, 3pi of calf liver 
tRNA (lOmg/ml, Boehringer Mannheim) added, and the DNA was precipitated with 3 
volumes of ethanol (see Section 7.9.1). The pellets were dissolved in 90pl of TE (see 
Section 7.7.1), lOpl of 1M KAc added and the DNA was re-precipitated with ethanol as 
above. The DNA pellets were then dissolved in 17pl of ddH20  and the second 
restriction enzyme digest carried out in the appropriate buffer in a total volume of 20pl 
for 2h. At the end of the incubation, 5 pi of 6x DNA gel-loading buffer (see Section
7.11.1) was added and the 5’ labelled probe separated from the rest of the plasmid by 
agarose gel electrophoresis using a 1-1.5% agarose gel made from a stock of 40% 
acrylamide and 2.1% bis-acrylamide (see Section 7.11.2). The gel was exposed to a
Kodak® X-OMAT®AR imaging film for 5min, the film developed and the 
radiolabelled oligonucleotides excised from the gel by aligning the autoradiograph with 
the gel. A second exposure was then taken to ensure the oligonucleotides had been 
removed. The probe was then purified using the Spin-Bind® DNA Recovery System for 
Agarose gel see section (7.11.3) and the DNA was eluted into lOOpl of ddH20 .
7.21.2. DNA:protein binding reactions.
The DNA:protein binding reaction mix, containing lOOpg of nuclear protein extract, 
6ug of poly(dl-dC) and l-3ul of 5’-end labelled purified probe in a total volume of 
lOOpl made up with lxSB (see 7.17.2), was incubated on ice for 90min. In the control 
reaction, nuclear protein extract was replaced by lxSB.
7.21.3. DNase I digestion of DNA-protein complexes.
The DNA:protein complex was then digested briefly with DNase I as follows. As DNA 
fragments were extremtely sensitive to DNase I, minor inconsistence in handling could 
cause large differences in the extent of digestion. To circumvent this problem: all 
handlings were kept as consistent as possible; the reactions were carried out one by one 
and, in addition; and various amounts of DNase I were used in each experiment. Briefly, 
0.5pl, l.Opl and 1.5pl of DNase I working dilution (~0.27pg/ml) was added to each 
sample, the mixture was vortexed rapidly and incubated at room temperature for exactly 
30sec. At the end of the incubation, lOOpl of footprint STOP buffer (82.4mM Tris.HCl, 
8.2mM EDTA, 106mM NaCl, 1% (w/v) SDS, 66ug/ml calf liver tRNA and 0.4mg/ml
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proteinase K, pH8.0) was added and the samples were uncubated at 37°C for 30min. 
The DNA was then denatured at 90°C for 2min and deproteinised by 2x PCI extraction 
(see Section 7.13.1) followed by lx  chloroform extraction (see Section 7.9.1). Then 
15pi of 5M LiCl was added and the DNA was precipitated by the addition of 3 volumes 
of ethanol. The DNA was pelleted by spinning the samples at 14,000rpm in an 
Eppendorf microfuge and the pellets were washed once with ice-cold 75% (v/v) 
ethanol. After air-dry, the pellets were dissolved in 4-8pl of lx  Sequencing Gel Sample 
Buffer (0.025% (w/v) bromophenol Blue, 0.025% (w/v) Xylene Cyanol FF and 95% 
(v/v) formamide), denatured at 90°C for 3min and then immediately chilled at -50°C.
7.21.4. Sequencing-gel analysis of the digested probes.
DNase I digested and deproteinised DNA samples were separated in 6% denaturing 
polyacrylamide gels containing 42% (w/v) urea and the electrophoresis was carried out 
at 66 watts (~1600 Volts) for 2-3h at room temperature after pre-running the gels for lh  
under the same conditions. The polyacrylamide gels were prepared from a stock solution 
with 40% acrylamide and 2.1% bis-acrylamide.
7.21.5. Localisation of footprints by A+G chemical sequencing.
The positions of footprints within the promoter were localised by utilising A+G
32chemical sequencing reactions (Papavassiliou, 1994). 9.5pl of P-labelled probe were 
mixed with 0.5pl of calf liver tRNA (lOmg/ml) and 1.5pl of 88% (v/v) formic acid. The 
reaction mix was incubated at 37°C for 14min, chilled on ice and 150pl of freshly 
prepared 1M aqueous piperidine added to cleave the DNA at 90°C for 30min. At the end 
of the incubation, the samples were chilled on ice and precipitated by the addition of 
lml of butan-l-ol followed by spinning at full speed in a microfuge for 2-5min. The 
pellets were resuspended in 1% SDS and reprecipitated with lml of butan-l-ol as above. 
The pellets were dried in a Heto Vac speedivac (Inter Med) for 5min, resuspended in 10- 
30pl of lx  Sequencing Gel Loading Buffer (see Section 7.21.6) and then separated in a 
denaturing polyacrylamide (see Section 7.21.6) gel along with samples from 
footprinting reactions.
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CHAPTER 8: Materials
8.1. Cell lines, media and tissue culture supplies.
The ELM cell lines and all the MS-5 stromal feeder cell line were obtained from Dr. W. 
Ostertag in Heinrich-Pette Institute for Experimental Virology and Immunology, 
University of Hamburg, Germany. The K562, HL60, KG-1 and Molt-4 cells were taken 
from laboratory stocks. The quail Q2BN cells were kindly given by Dr. J. Frampton in 
Univeristy of Oxford, England. Recombinant human erythropoietin (Boehringer 
Mannheim) was the generous gift of Dr. T. Holyoake in the Western Infirmary, 
Glasgow.
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland 
Chicken serum
Dulbeco’s Modified Eagle’s Medium (DMEM) 
a-Minimal Essential Medium (a-MEM)
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England 
Donor horse serum
Supplier: TCS Biologicals Ltd., Buckingham, UK 
Foetal calf serum
8.2. Mice.
Female C3H mice were purchased from Harlem-Olac and housed by S. Bell and injected 
by T. Hamilton from the Beatson Animal Laboratory Services. The Beatson Institute’s 
Alycon II Teletherapy Unit was used for all irradiation procedures.
8.3. Bacterial hosts and media.
E.coli host strain DH5a was obtained from laboratory stock held by Fiona McGreger. 
Terrific broth and L-broth were prepared according to Sambrook et al. (1989).
8.4. Nucleotides, polynucleotides, DNA, DNA/RNA markers.
Supplier: Amersham International pic, Little Chalfont, Buckinghamshire, England 
[a-32P]dCTP ~3000Ci/mmol 
[y-32P]dATP ~5000Ci/mmol
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L-[35S] methionine >1000Ci/mmol
Supplier: Bethesda Research Laboratory, Gibco Ltd., Paisley, Scotland
DNA markers (lpg/pl): lkb ladder and bacteriophage Oxl74DNA (Hae Ill-cut) 
0.24-9.5kb RNA markers (lpg/pl)
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England 
Calf liver tRNA
Supplier: Pharmacia Ltd., Milton Keynes, Buckinghamshire, England 
Poly (dl-dC)
Ultrapure dNTP Set (lOOmM)
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England
Sonicated and denatured salmon testes DNA (lOmg/ml)
8.5. Plasmids.
Plasmid Suppliers
pCR-TA Invitrogen Corporation, San Diego, California, USA
pCR-Scrip™. Amp. SK(+) Stratagene Ltd. UK, Cambridge, England
a-globin Dr. R. Nibbs (Beatson Institute)
pSSF V(neo-bcl-2) Dr. S. Korsmeyer, Washington University, Missouri, USA
7s r RNA Dr. L. Wu (Beatson Institute)
pRC-CMV(erg) Dr. R. Nibbs (Beatson Institute)
pRC-CMV(/7/-7) Dr. C. Bartholomew (Beatson Institute)
pRC-CMV (DNM1) Dr. C. Bartholomew (Beatson Institute)
pRC-CMV (DNM2) Dr. C. Bartholomew (Beatson Institute)
bcl-x Dr. J. Reed, La Jolla Cancer Research Foundation, USA
scl Dr. A.R. Green, University of Cambridge, England
pXP2 (h250) Dr. J. Frampton, University of Oxford, England
pXP2 (h600) Dr. J. Frampton, University of Oxford, England
pGL2 (basic) Dr. C. Bartholomew (Beatson Institute)
pGL2 (min. tk) Dr. C. Bartholomew (Beatson Institute)
pGL2 (3xE74+min.tk) Dr. C. Bartholomew (Beatson Institute)
PGK (p -gal) Dr. J. Frampton, University of Oxford, England
pHSV (p-soO J. O’Prey (Beatson Institute)
pRXV (V-zal) Dr. J. Frampton, University of Oxford, England
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8.6. Enzymes and enzyme inhibitors.
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland 
All restriction endonucleases with lOx reaction buffers 
DNase I (2mg/l 62jul)
Proteinase K
T4 DNA ligase (lU/pl) and 5x ligation buffer
Taq DNA polymerase (10U/pl) and lOx PCR reaction buffer
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England 
Calf intestinal alkaline phosphatase (lU/pl)
DNase-free RNases 
RNases A
Supplier: Northumbria Biologicals Ltd. (NBL), Cramlington, Northumberland, England 
Klenow DNA polymerase (lU/pl)
T4 polynucleotide kinase (lOU/pl) and lOx kinase buffer
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England 
Aprotinin Leupeptin
Benzamidine Pepstatin A
Levamisole
Supplier: Stratagene Ltd. UK, Cambridge, England
Pfu DNA polymerase (2.5U/pl) and lOx reaction buffer
8.7. Antibodies and control peptides
Rabbit-anti-mouse Fli-1 anti-serum was a kind gift from Dr. C. Bartholomew.
Supplier: Amersham International pic, Little Chalfont, Buckinghamshire, England 
Rabbit IgG, horseradish peroxidase-linked whole antibody (donkey)
Supplier: PharMigen Deutschland GmbH, Hamburg, Germany 
Rabbit-anti-mouse Bcl-2 anti-serum
Bestatin
Diethylpyrocarbonate (DEPC) 
p -glycerophosphate
PMSF
Sodium butyrate 
Sodium orthovanadate
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Supplier: Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA 
Purified polyclonal rabbit-anti-human Erg antibody (lOOpg/ml)
Bcl-2 control peptides (100p,g/0.5ml)
Erg control peptides (100pg/0.5ml)
8.8. Molecular biology kits.
Supplier: Amersham International pic, Little Chalfont, Buckinghamshire, England 
ECL™ Western Blotting Analysis System
Suppler: Applied Biosystems, Warrington, UK
Dyedeoxy Terminator Cycle Sequencing Prism Kit
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England 
Random-primed DNA labelling kit
Supplier: FMC BioProducts Europe, Vallensbaek Strand, Denmark 
SpinBind DNA recovery system for agarose gels
Supplier: Invitrogen Corporation, San Diego, California, USA 
TA cloning kit
Supplier: Promega, Madison, Wisconsin, USA
TNT® T7 Quick Coupled Transcription/Translation System 
Luciferase assay system
Supplier: Stratagene Ltd. UK, Cambridge, England 
PCR-Script™.Amp.SK(+) cloning kit
8.9. Membranes.
Supplier: Amersham International pic., Little Chalfont, Buckinghamshire, England 
Hybond™ N nylon membrane (fingerprint grade)
ECL™ nitrocellulose membrane
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8.10. Chemicals and water.
Supplier: Bethesda Research Laboratory, Gibco Ltd., Paisley, Scotland 
TRIzol reagent
Distilled water for buffers and general solutions was obtained from a Millipore MilliRO 
15 system. Water for protein/enzyme work or recombinant DNA protocols was further 
purified on a Millipore MilliQ system to 18MQcm.
8.11. Equipment.
Suppler: Applied Biosystems, Warrington, UK 
ABI 3 73A DNA Sequencer
Supplier: BioRad Laboratories, Richmond, California, USA 
BioRad Gene Pulser™ with capacitance extender
Supplier: Eppendorf, Hamburg, Germany 
Eppendorf Multipette® 4780
Supplier: Flowgen Instruments, Ltd., Lichfield, Staffordshird, UK 
EasyjecT Plus
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PART III: RESULTS
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CHAPTER 9: Cellular and Molecular Events in ELM-D Cells 
upon stroma-withdrawal
9.1. Viability assay of ELM-D cells upon stroma-withdrawal.
As mentioned in Chapter 6, one of the unusual features of the ELM system is that the 
erythroleukaemia cells growing in vivo in the spleen cannot be maintained in vitro 
except in contact with bone marrow-derived stromal cells. The stroma-dependence of 
the cell line (ELM-D) derived from the primary tumour has been rigorously tested by 
serial re-cloning experiments in the presence or absence of stromal cells (Prof. W. 
Ostertag, personal communication). The results confirmed that ELM-D cells show a 
strict dependence on stromal cells for long-term growth and survival, but are capable of 
proliferative cell expansion for a short term without stroma (2-3 weeks). However, their 
experiments also indicate that the ELM-D cell population contains a small proportion of 
cells that can grow without stromal cells and the frequency of occurence of stroma- 
independent clones (ELM-Is) is approximately 10'5.
As large number of cells are required for more detailed cellular and molecular 
characterisation, the stroma-dependence of ELM-D cells has to be reproduced in mass 
culture experiments. In order to do so, ELM-D cells were cultured in the presence of 
stromal cells in the ELM growth medium containing 16% horse serum (see Methods 
and Materials). They were grown to confluence when they were shaken off from the 
stromal cells. They were then centrifuged and the pellet resuspended in fresh medium at 
a density of 105 per ml and re-seeded into flasks with or without stromal cells. To 
eliminate the stromal cell contamination which would affect the viability of ELM-D 
cells in stroma-withdrawal experiments, the cell suspension was transferred to a new 
flask every hour for 3-4h. In this way, the adherent stromal cells were eliminated, 
whereas ELM cells, which are suspension cells, only loosely attached to the bottom of 
the flask and were lifted up by gentle agitation of the medium. It has been confirmed 
that, in this way, the stromal cell contamination can be eliminated almost completely. 
As a control, the stroma-independent ELM-I/2 cells were also grown on the stromal 
cells and subject to the same manipulation as ELM-D cells. The viability of ELM-D and 
ELM-I/2 cells in the presence or absence of the stromal cells was measured by the trypn 
blue exclusion method (see Methods and Materials) every day over a week period.
It can be seen from Figure 9.1 that the viability of ELM-D cells in the presence of the 
stromal cells (open square) remained constant up to day 3, after which it declined 
slightly, presumably due to confluence of the culture. On the contrary, the viability of 
ELM-D cells deprived of the stromal cells (solid square) decreased gradually over the
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Figure 9.1. Viability assays of ELM-D cells upon stroma-withdrawal.
The ELM-D cells and ELM-I/2 cells were cultured to sub-confluence on the stroma 
in the ELM growth medium containing 16% serum. They were then shaken off from 
the stroma and re-seeded into flasks with or without stromal cells. The viability of 
ELM-D and 1/2 cells in the presence or absence of the stroma was measured by the 
trypan blue exclusion method (see Methods and Materials). Each experiment was 
carried out in triplicates, and the graph shows the means and standard deviation of 
two independent experiments.
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period of experiments. The viability dropped to about 50% at day 6. The viability of 
ELM-I/2 cells in the presence (open circle) or absence (solid circle) of stromal cells was 
similar to that of ELM-D cells in the presence of stroma, indicating that the decline in 
viability observed in ELM-D cells in the absence of stroma was not due to experimental 
manipulation. When the culture of ELM-D cells in the absence of the stroma was 
maintained continuously, it was found to be able to be grow for an extended period of 
time.
The fact that only 50% of ELM-D cells die a week after stroma-withdrawal and the 
whole culture can never die out does not necessarily mean that our data is contradictory 
to that of the serial re-cloning experiments and overthrows the established fact that 
ELM-D cells are stromal dependent. It should bear in mind that the growth conditions in 
serial re-cloning experiments is much more stringent than that in the mass culture. 
Moreover, given that ELM-D cells are fairly heterogenous, and a small number of 
clones have been derived in the absence of stromal cells even in serial re-cloning 
experiments (Prof. W. Ostertag, personal communication), it is possible that the small 
number of stroma-independent cells present in the ELM-D cell population can 
proliferate rapidly, and sooner or later will take over in the mass culture. In addition, it 
is also possible that the strictly stroma-dependent ELM-D cells die only slowly in the 
absence of the stromal cells and can still proliferate, to some extent, over a limited 
period under the culture condition. This is reminiscent of the fact that, in the serial re­
cloning experiments, there are clones of ELM-D cells grown up in the absence of the 
stroma, which can grow for 2-3 weeks yet disintegrate afterwards.
In order to establish the culture conditions under which growth of ELM-D cells is more 
stringently stroma-dependent, attempts were made to culture ELM-D cells in the 
reduced levels of serum. Serum contains various survival and proliferation that might 
keep ELM-D cells alive and stimulate proliferation in the absence of stromal cells. The 
ELM-D cells were grown in the medium containing 16%, 8% or 4% horse serum. By 
visual observation of the cultures under the light microscope, it was noted that ELM-D 
cells grown in 16% and 8% serum could grow and reach confluence at a similar rate. 
Measurement of the numbers of ELM-D cells maintained in 16% and 8% serum further 
confirmed that cells proliferate similarly at both serum conditions (Figure 9.2). 
However, cells maintained in 4% serum grew at a much reduced rate and still remained 
pretty sparse when the stromal layer reached confluence at 4-5 days. Regardless of the 
issue if ELM-D cells grown at 4% serum were healthy and could be mamintained for a 
long term, they fact that they grew too slow eliminated the possibility of growing cells at 
this level of serum.
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Similar viability assays were performed in the stroma-withdrawal experiments when 8% 
serum was used as the culture condition. Figure 9.3 shows that the viability of ELM-D 
cells decreased dramatically upon stroma-withdrawal (solid square) and it dropped to 
approximately 10% at day 6, whereas ELM-D cells grown on the stroma (open square) 
maintained the high viability. The control experiments showed that the viability of 
ELM-I/2 cells either in the presence or absence of stromal cells remained constantly 
high over the period of the assays. Thus, using 8% horse serum as the culture condition 
largely reduces the viability of ELM-D cells upon stroma-withdrawal.
9.2. Characterisation of the growth of ELM-D cells in the absence of stromal cells 
in 8% horse serum.
To further characterise the growth of ELM-D cells in the absence of the stroma, similar 
stroma-withdrawal experiments were carried out in 8% serum, but the actual number of 
viable cells instead of viability was measured. It can be seen from Figure 9.4 (a and b) 
that, upon stroma-withdrawal, the total number of viable ELM-D cells decreased 
dramatically. It dropped to approximately 1/10th of the original number at day 3 and 
1/100th at day 7. The number of viable cells remained relatively constant for the 
following 9 days, after which it increased logarithmically (Figure 9.4b). Calculations of 
the total number of viable cells have taken account of the dilutions of cells during 
passage.
The timing and extent of this later outgrowth of stroma-independent cells were 
dependent on the level of serum. At day 8 after the removal of stroma, half of the cells 
was passaged into medium containing 16% horse serum. It can be seen that the 
outgrowth of the stroma-independent cells in 16% serum (dotted line) started at day 12 
instead of day 17. Furthermore, the proliferation rate of those cells in 16% serum was at 
least twice as much as that in 8% serum.
The above evidence further confirms that, in 8% serum, ELM-D cells are truly stroma- 
dependent, and majority of the population dies out following stroma-withdrawal. 
However, 16% serum allows a high background of stroma-independent growth.
9.3. Effects of serum levels on the long-term growth of ELM-D cells on the stroma.
It is critical that cells grown in 8% serum can not only proliferate at a similar rate but 
also maintain their biological features. The most important feature of ELM-D cells is 
that they are stroma-dependent and the stromal cells are able to maintain their survival 
and growth for a long term. Therefore, it is crucial to test whether the reduced level of 
serum affects the ability of stromal cells to maintain the long-term growth of ELM-D
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Figure 9.4. Characterisation of the growth of ELM-D cells in the absence of stroma 
in 8% serum.
The ELM-D cells were cultured to sub-confluence on the stroma in the ELM growth 
medium containing 8% serum. They were then shaken off from the stroma and 
re-seeded into flasks with or without stromal cells. The viability of ELM-D cells in 
the presence or absence of the stroma was measured by the trypan blue exclusion 
method (see Methods and Materials). Total number of viable cells was calculated 
taking account of the dilution of cells during each passage. At day 8 after the 
removal of stroma, half of the cells was passaged into medium containing 16% horse 
serum. The dotted line represents the total number of viable cells (in logarithm) 
maintained in 16% serum. Arrows indicate when cells were passaged.
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cells. For this purpose, serial re-cloning experiments were performed. The ELM-D cells 
were grown to sub-confluence on the stroma in the ELM growth medium containing 
16% or 8% horse serum. They were then shaken off from the stroma and cloned by end­
point dilution into 96-well plates containing a monolayer of stromal cells. After every 2- 
3 weeks, the number of clones grown out were counted, and 8-16 clones were picked 
and subsequently re-cloned. Table 9.1 shows the results of four rounds of such cloning 
experiments which lasted for 3 months.
Table 9.1. Comparison of the cloning efficiency (C.E.) and colony size of ELM-D cells 
cloned in the presence of stromal cells in serial re-cloning experiments in 16% and 8% 
serum. Colony size represents the total number of cells within each colony and is an 
average of 10 randomly picked colonies. After each round of cloning, colonies were 
counted and cloning efficiency calculated; then 10 colonies were picked randomly, the 
total number of cells within each colony counted using a haemocytometer, and 
subsequently re-cloned. The data of the first three rounds of cloning experiments was a 
combination of three independent experiments. The fourth round of cloning was only 
performed in one occasion due to the large amount of work involved.
Serum level 16% 8%
C.E. Size (x 103) C.E. Size (x 103)
1st round Mean 40.5% n.d. 35.6% n.d.
S.D. 9.8% n.d. 13.2% n.d.
2nd round Mean 15.9% 30.4 18.9 21.8
S.D. 10.1% 17.6 9.3% 14.1
3rd round Mean 8.3% 24.7 8.9% 15.9
S.D. 5.1% 14.6 6.4% 10.0
4th round Mean 15.6% 34.4 14.0% 30.8
S.D. 10.7% 14.4 11.2% 14.5
It can be seen that the cloning of ELM-D cells on the stroma, in terms of both cloning 
efficiency and colony size, was not significantly different under different serum 
conditions used. More importantly, apart from the second round of cloning (see below), 
there was no decline in cloning efficiency of ELM-D cells in 8% serum over the period 
of experiments (3 months). This suggests that ELM-D cells are able to grow in a long 
term on the stroma in 8% horse serum.
The cloning efficiency of ELM-D cells in the first round of cloning was much higher 
than subsequent rounds. It should be noted that the first round of cloning involved cells 
maintained in a mass culture, which are generally cloned better than cloned cells. 
Another feature of such serial re-cloning experiments, which is also reflected by the data
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shown in the table, is the large variation in terms of both cloning efficiency and colony 
size between different clones. The only way to get around this problem so as to obtain 
statistically significant results is to select a large number of clones and repeat the 
experiment several time, as was done in the experiments presented.
Thus, the lowered serum level (i.e. 8%) does not affect the long-term maintenance of 
ELM-D cells by the stroma and, therefore, can be used as the culture condition for 
further cellular and molecular characterisation.
9.4. Morphological studies of ELM-D cells upon stroma-withdrawal.
To characterise the features of the cell death that ELM-D cells undergo upon stroma- 
withdrawal, Giemsa staining and microscopy analysis were performed (see Methods and 
Materials). Briefly, ELM-D cells were grown in the presence of stroma to sub­
confluence in 8% serum, and were then shaken off from the stroma and re-seeded into 
flasks without the stromal cells. Four days later, cells were harvested and centrifuged 
onto microscope slides using a cytospin centrifuge, and stained with a Giemsa solution. 
Cells that had just been shaken off from the stroma were also stained for comparison.
The ELM-D cells just shaken off from the stroma displayed typical morphology of pro­
erythroblasts or basophilic erythroblasts with some differentiation to orthorchromatic 
erythroblasts (Harrison et a l , 1973) (Figure 9.5a). However, it can be seem from Figure 
9.5b showed that ELM-D cells removed from the stroma for 4 days displayed membrane 
blebs, cytoplasmic vacules, chromosome condensation and classical apoptotic bodies 
(indicated by arrows). This suggests that, as a result of stroma-withdrawal, ELM-D cells 
die with the characteristics of apoptosis. This has been confirmed by our collaborator, 
Prof. W. Ostertag, by using "TUNEL" assays, which showed that ELM-D cells removed 
from stroma exhibit DNA strand breaks, which is the most prominent feature of 
apoptosis (Savill et a l, 1993).
9.5. Changes in gene expression of ELM-D cells upon stroma-withdrawal.
For most cell types, the above features observed, in particular, the existence of apoptotic 
bodies and DNA strand breaks, are sufficient for diagnosis of apoptosis. However, the 
situation is not so simple for erythroid cells since chromosome condensation and DNA 
strand breaks also appear in cells that undergoing erythroid differentiation. During this 
process, the nucleus and the associated chromosomes are condensed, ultimately 
degraded and exocytosed out of the cell (Harrison et a l , 1973). It has also been reported 
that DNA isolated from differentiating erythroid cells also appears in a pattern of 
laddering in agarose gel electrophoresis (Savill et a l , 1993), which is normally observed
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Figure 9.5. Giemsa staining of ELM-D cells after stroma-withdrawal.
(a) ELM-D cells that had just been shaken off from the stromal cells;
(b) ELM-D cells that had been removed from the stroma for 4 days. 
(Scale bar = lOjim)
(a)
(b)
#
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in apoptotic cells. Therefore, to define the nature of the cell death of ELM-D cells upon 
stroma-withdrawal, it is necessary to perform experiments to distinguish whether 
apoptosis or erythroid differentiation is in fact occurring. In order to do so, the a-globin 
and bcl-2 expression was analysed as markers for erythroid differentiation and 
apoptosis, respectively. As mentioned in Chapter 5, bcl-2 is the founding member of an 
expanding family of genes that are involved in the regulation of apoptosis. It is able to 
protect cells from apoptosis during development in vivo and in many culture systems in 
vitro, and has been found to be up-regulated as a cellular response to apoptosis stimuli 
(Vaux et a l, 1988). Briefly, ELM-D cells grown on stroma were shaken off from the 
stroma and transferred at 105 cells per ml to flasks containing no stromal cells. Any 
contamination of the stromal cells was eliminated as described previously (see Section
9.1). Cells were harvested at various time points after stroma-withdrawal, total RNA 
was extracted and analysed by Northern blotting (see Methods and Materials). The 
same blot was successively probed with a mouse bcl-2 cDNA fragment and a-globin 
genomic fragment (spanning exon 1 and 2 of the gene). The RNA loadings were 
assessed by stripping the blot and re-probing it with a 7s rRNA genomic fragment.
9.5.1. Changes in the a-£lobin and bcl-2 mRNA expression in ELM-D cells upon 
stroma-withdrawal in 16% serum.
Figure 9.6 shows the changes in a-globin and bcl-2 expression of ELM-D cells upon 
stroma-withdrawal in 16% serum. It can be seen that ELM-D cells deprived of the 
stroma displayed a gradual increase in a-globin expression, which peaked at day 5 and 
reached approximately 9 fold as the original level, indicating that ELM-D cells 
underwent erythroid differentiation upon stroma-withdrawal. Thereafter, the expression 
of a-globin decreased to about the same as the control level at 14 days after stroma- 
withdrawal. The occurrence of spontaneous erythroid differentiation in ELM-D cells 
after the stroma was removed implies that the stroma is able to block an intrinsic 
differentiation program within, at least, a sub-population of the cells. This can be one of 
the mechanisms whereby the stroma maintains the long-term survival and growth of 
ELM-D cells. The later decline of the a-globin expression within the population may be 
a result of the outgrowth of another sub-population of the cells which is stroma- 
independent and does not differentiate in the absence of it. Cells that underwent terminal 
erythroid differentiation would ultimately die and be eliminated from the population. On 
the other hand, those that did not differentiate and therefore expressed low levels of a- 
globin would grow out. As a consequence, the overall a-globin expression would 
decrease eventually.
In addition, the expression of bcl-2 also displayed an early increase, which peaked at day 
5 to about 5 fold as the original level, and a later decline. The significance and
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implication of the changes in bcl-2 expression are difficult to interpret. It is possible that 
the increase in bcl-2 expression was due to the deprivation of various survival and 
proliferation signals that are normally provided by the stromal cells. Alternatively, since 
the bcl-2 expression increased and decreased in parallel with that of a-globin, it is 
possible that the Bcl-2 protein may positively regulate erythroid differentiation. To 
distinguish these possibilities, ELM-D cells should be induced to differentiate in the 
presence of the stromal cells (also see Chapter 12).
9.5.2. Changes in die a-slobin and bcl-2 expression of ELM-D cells upon stroma- 
withdrawal in 8% serum.
Figure 9.7 shows the data of a similar stroma-withdrawal experiment but the serum 
condition used was 8% rather than 16%. It can be seen that ELM-D cells also 
differentiate upon stroma-withdrawal in 8% serum, but to a much larger degree. At day 
1 after stroma-withdrawal, the expression of a-globin increased to approximately 32 
fold as that when the stroma was just removed. The fact that the increase in a-globin 
expression of ELM-D cells occurred more rapidly and to a larger extent in 8% serum 
may be due to the effects of serum on various sub-populations of the cells. First of all, 
the majority of the population, which is truly stroma-dependent, had less proliferation 
capability in lower serum and therefore their expansion was limited and differentiation 
enhanced. In the meanwhile, the proliferation of the stroma-independent sub-population 
of ELM-D cells was also largely reduced.
Changes in the gata-1 mRNA expression was also measured. Gata-1 is a transcription 
factor that positively regulates erythroid differentiation (see Section 2.2.1). It has been 
reported that the gata-1 expression is up-regulated at an early stage in erythroid 
differentiation (Bockamp et al., 1994). It can be seen that the expression of gata-1 
mRNA was transiently up-regulated as early as 6h after stroma-withdrawal.
On the other hand, although the bcl-2 expression displayed a slight increase reaching 
about 2.6 fold as the original level at day 1, it decresed thereafter and remained at more 
or less the normal level. It should be noted that the maximum level of a-globin 
expression in ELM-D cells upon stroma-withdrawal was 31 fold in 8% serum, in 
contrast to 9 fold in 16% serum. On the other hand, the maximum level of bcl-2 
expression in ELM-D cells upon stroma-withdrawal was 2.6 fold in 8% serum, but 4.6- 
fold in 16% serum. If Bcl-2 indeed plays a positive role in erythroid expression it would 
be expected that, upon stroma-withdrawal, ELM-D cells grown in 8% serum, which 
differentiated 3.5 times better than that in 16% serum, would display more increase in 
the bcl-2 expression. This is in contrary to what was observed. Therefore, it seems 
unlikely that Bcl-2 plays a positive role in erythroid differentiation. Rather, the increase
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Figure 9.7. Changes in the a-globin, gata-1 and bcl-2 mRNA expression in 
ELM-D cells after stroma-withdrawal in 8% serum by Northern blotting 
analysis. The figures below the lanes are the relative levels of gene expression 
after calibration with the 7s rRNA loading control.
Serum
condition
a-globin
ELM-D cells: time after stroma-withdrawal 
MS-5 0 0 6h 1 day 2 day 3 day
16% 16% 8% 8% 8% 8% 8%
bcl-2
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in bcl-2 expression in ELM-D cells upon stroma-withdrawal may indeed be a response 
to the deprivation of survival and proliferation signals. Factors in the serum may 
augment this response in favour of survival and growth of the cells.
In conclusion, ELM-D cells undergo terminal erythroid differentiation upon stroma- 
withdrawal. The bcl-2 expression is only slightly up-regulated, which seems to be a 
result of the deprivation of the survival and proliferation signals that are normally 
provided by the stromal cells.
9.6. Conclusions.
Mass culture experiments have demonstrated that ELM-D cells are stroma-dependent. 
Upon stroma-withdrawal, the majority of the population dies out in the form 
characteristic of apoptosis. However, the fact that the a-globin expression in ELM-D 
cells is largely increased upon stroma-withdrawal points out that ELM-D cells undergo 
erythroid differentiation in the absence of stroma. The bcl-2 expression in ELM-D cells 
only increases slightly at the early stage of stroma-withdrawal, and this may be a result 
of the deprivation of the survival and proliferation signals that are normally provided by 
the stroma.
In addition, the kinetics of cell death and differentiation, and the changes in gene 
expression in the stroma-withdrawal experiments are largely affected by the level of 
serum used. The reduced level of serum (8% instead of 16%) does not affect the ability 
of stromal cells to maintain the long-term growth of ELM-D cells but largely facilitates 
cellular and molecular studies.
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CHAPTER 10: Gene Expression Studies of the ELM system
As mentioned in Chapter 6, various ELM cell lines are different in stroma-dependence, 
differentiation potential and tumorigenicity. This provides us a unique opportunity to 
identify genetic events involved in generating these different phenotypes. The genes that 
have been studied can be divided into four categories: (1) genes involved in the 
induction of erythroleukaemia (the ets family members, in particular, erg and fli-1 , also 
see Chapter 4); (2) genes involved in the control of cell survival, especially when in the 
absence of survival and proliferation signals that are normally present {bcl-2 and bcl-x, 
also see Chapter 5); (3) genes that play a crucial role in the regulation of erythroid 
differentiation {gata-1 and scl, see Section 2.2); and (4) a gene that serves as a erythroid 
differentiation marker {a-globin).
For the gene expression studies, the stroma-dependent (ELM-D) and -independent cells 
(ELM-I/1, 2, 5 and 6) were used. They were seeded at a density of 105 per ml in the 
ELM growth medium containing 16% horse serum (see Methods and Materials) and 
harvested 3 days later, when they were still in logarithmic growth. Total mRNA and 
protein were isolated for Northern and Western blot analysis (see Methods and 
Materials). The ELM-D cells were grown on the MS-5 stromal cells, and at the time of 
harvest they were shaken off from the stroma. In this way, it is able to recover >90% of 
ELM-D cells with few stromal cell contamination. Even though, MS-5 cells were also 
included in gene expression studies.
10.1. Gene expression studies at the mRNA level.
In Northern blotting analysis, 20pg of total RNA was used and the blot was probed with 
32P-radiolabelled DNA fragments from the genes of interest (see Methods and 
Materials). RNA loading was assessed by stripping the blot of the radiolabelled probes 
and reprobing it with a 7s rRNA genomic fragment. Autoradiographs were scanned and 
quantitated by laser densitometer (see Methods and Materials). Relative levels of gene 
expression were calculated after calibration with the loading control. Representative 
blots were shown in Figure 10.1 and Table 10.1 summaries the relative levels of gene 
expression in the ELM system.
It can be seen from Figure 10.1 and Table 10.1 that, as reported by Dr. Nibbs (Nibbs et 
a l , 1993), that the stroma-independent variants (ELM-I/1, 2, 5 and 6) express an 
elevated level of erg in comparison to their stroma-dependent parent (ELM-D). More 
significantly, the expression offli-1 in ELM-I/1 cells is highly activated while the other 
ELM cells do not express fli-1 at all.
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Table 10.1. Relative levels of gene expression in the ELM system. The figures given 
have been calibrated with the 7s rRNA loading control. The means and standard 
deviation are results of at least three independent experiments.
MS-5 ELM-D ELM-I/1 ELM-I/2 ELM-I/5 ELM-I/6
erg 0 1 6.0 5.5 5.4 7.3
fli-1 0 0 +++ 0 0 0
bcl-2 0.5±0.1 1 11.3±4.6 2.6±0.8 3.1±2.7 3.1±1.0
bcl-x 1.7 1 0.3 0.4 0.4 0.4
gata-1 0 1 4.5±0.9 1.9±0.4 4.8±2.4 3.8±2.2
scl 0 1 8.4±3.5 0.4±0.3 7.8±2.1 1.5±0.7
a-globin 0 1 0.2±0.1 0.3±0.2 0.5±0.3 2.6±2.0
The second most significant feature of gene expression in the ELM system is that the 
bcl-2 expression in ELM-I/1 cells is also highly up-regulated. It is approximately 11 fold 
as that in ELM-D cells, and about 4-5 fold as that in the other ELM-I cells. The 
expression of bcl-x in ELM-D is approximately 2.5-3 fold as that in ELM-I cells.
Differences in the gata-1 and scl expression also exist among different ELM cell lines 
but the significance of them is difficult to assess. It is intriguing that ELM-I/1 cells, 
which are blocked in differentiation, express the highest levels of gata-1 and scl mRNA. 
It would be interesting to see if this correlates with the expression at protein level, and if 
there is any mutations in these genes. It is possible that differentiation arrest in ELM-I/1 
cells results from either a lack of transcription factors that positively regulate erythroid 
differentiation, such as gata-1 and scl, or aberrant functional activities of those factors 
(discussed in detail in Chapter 13).
The expression of a-globin in ELM-I/1,1/2 and 1/5 cells is only l/5th to one-half of that 
in ELM-D cells, indicating that they are in a less differentiated state. The ELM-I/6 cells 
express higher levels of a-globin than that in ELM-D cells.
Characterisation of gene expression at the mRNA level had allowed us to postulate 
theories with regard to the molecular mechasisms of the stroma-dependent growth, 
differentiation arrest and tumourgenicity of the ELM system. It is possible that the 
elevated expression of erg in ELM-I cells is associated with the occurence of stroma- 
independent growth. Indeed, it has also been found that, upon stroma-withdrawal, the 
erg expression at the mRNA level in ELM-D cells was up-regulated (Nibbs et al., 
1993). Furthermore, activation offli-1 and up-regulation of bcl-2 may be responsible for 
the differentiation arrest and increased tumorigenicity in ELM-I/1 cells. The fact that 
there are many potential Ets binding sites in a very important regulatory element (i.e.
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NRE) within the bcl-2 promoter (see Chapter 5.3) further points to a link between the 
activation of fli-1 and bcl-2. To further pursue these possibilities, functional studies are 
desired and it is necessary that comparative studies of gene expression in the ELM 
system was extended to the protein level.
10.2. Gene expression studies at the protein level.
To determine whether differences in gene expression at the mRNA level observed in the 
ELM system correlate with the expression of proteins, the levels of Erg, Fli-1 and Bcl-2 
proteins were analysed by Western blotting. Cells were cultured and harvested and total 
protein isolated as described earlier on in the chapter (also see Methods and Materials). 
20pl of total protein extracts (10 cells / lOOpl) were used for detection of the proteins 
in Western blotting analysis (see Methods and Materials), and the results are shown in 
Figure 10.2 and 10.3. It can be seen that ELMI/1 cells also express high levels of Fli-1 
and Bcl-2 proteins. The Fli-1 and Bcl-2 proteins in other ELM cells are not readily 
detectable.
The expression of Erg proteins was detected by using a polyclonal rat-anti-human Erg 
antibody purchased from Santa Cruz, which recognises the human Erg, but not other Ets 
proteins. Its ability to cross-react with the murine Erg had not been tested. In order to 
test the cross-reactivity of the antibody, protein extracts from the human cells lines with 
known Erg expression profiles were included as controls. The KG-1 and Molt-4 cells, 
which express the Erg proteins (Prasad et a l, 1994), were used as the positive controls, 
whereas HL-60 and K562 cells, which do not express the Erg proteins, were used as the 
negative controls (Rao et al., 1987; Duterque-Coquillaud et a l, 1993). Figure 10.3 
shows the Erg protein expression in the ELM system. The Erg protein can be expressed 
in three different isoforms with molecular weights of 41 kD, 52 kD (normally occurs as 
a doublet) and 59 kD (Reddy and Rao 1991; Murakami et al., 1993; Siddique et a l, 
1993), respectively. It can be seen from Figure 10.3(a) that there were two bands (or a 
doublet) around 52 kD in all the ELM cells, MS-5 cells, the two positive controls (KG-1 
and Molt-4) and one of the negative controls (K562). Only the bottom band of the 
doublet was present in the other of the negative control (HL60). In addition, there are 
two bands around 41 kD in the two positive controls and, furthermore, the bottom one 
migrated at a similar position as the bottom band in ELM-I/1 cells. These two bands 
were not present in any of the other cell lines. The results with regard to the Erg 
expression in the positive control cell lines are consistent with what have been reported 
(Siddique et a l, 1993). However, the fact that the doublet around 52 kD was present in 
virtually all the cell lines including the negative controls raises the doubt with regard to
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Figure 10.2. Expression studies of the Fli-l (a) and Bcl-2 (b) proteins in the
ELM system
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Figure 10.3. Expression of the Erg proteins in the ELM system.
(a) Western blotting analysis of total protein extracts from the ELM cells;
(b) Immuno-depletion and Western blotting analysis of the Erg expression in the 
ELM cells. The Erg protein was detected in Western blotting using the antibody 
that had been pre-incubated with the Erg control peptide (left panel) or an irrelevant 
peptide (right panel).
The ELM cell lines: ELM-D, ELM-I/1, 1/2,1/5 and 1/6 
The stromal cell line: MS-5 
Positive control cell lines: KG-1 and Molt-4 
Negative control cell lines: HL60 and K562
(b)
Antibody was pre-incubated Antibody was pre-incubated
with the Erg control peptide with an irrelevant peptide
CJ S  CJ *->
0 ^ - 7 : sD
^  ^  hJ*  UJ S  u  W
52 kD 
41 kD
97
whether or not these bands represented the Erg expression or, rather, they were non­
specific.
The specificity of the antibody was further characterised by immuno-depleting the 
antibody with the human Erg control peptide (Santa Cruz) which was used as the 
antigen to generate the antibody. Immuno-depletion was carried out by incubating the 
antibody with 50pg of the control peptide on ice for 30min prior to application in the 
Western blotting analysis. As a control, an aliquot of the antibody was incubated with 
the same amount of an irrelevant peptide {bcl-2 peptide) which was synthesised and 
purified in the same way by the same company. Figure 10.3(b) shows the results of such 
immuo-depletion and Western blotting analysis. The right panel shows that pre­
incubating the antibody with irrelevant peptides gave the same banding pattern as that in 
Figure 10.3(a). The left panel shows that after immuno-depleting the antibody with the 
Erg control peptide, the top band of the doublet around 52 kD persisted, indicating that 
it was non-specific, whereas all the other bands disappeared. Although the result further 
confirms that the bands around 41 kD are likely to be specific, it still does not provide 
convincing evidence with regard to the specificity of the bottom band of the doublet 
around 52 kD. This is because that not only this band was present in the negative control 
(Figure 10.3b, right panel) but also it disappeared when the antibody was immuno- 
depleted with the Erg control peptide (Figure 10.3b, left panel). It is more likely that it is 
non-specific. Therefore, in conclusion, none of the ELM cells apart from ELM-I/1 
express detectable levels of the Erg protein. In ELM-I/1 cells, an Erg protein of 
approximately 41 kD is expressed.
10.3. Conclusions.
The most significant results from the gene expression studies of the ELM system can be 
summarised as the following: (1) The stroma-independent cells (ELM-I/1, 2, 5 and 6) 
express an elevated level of the erg mRNA in comparison to their stroma-dependent 
parent (ELM-D). However, only the Erg protein in ELM-I/1 cells is readily detectable; 
(2) The expression of fli-1 at both mRNA and protein levels in ELM-I/1 cells is 
significantly activated but is absent in all the other ELM cells; (3) The bcl-2 expression 
at the mRNA level in the stroma-independent cells is higher than that in ELM-D cells, 
especially in ELM-I/1 cell line which is the only cell line wherein the Bcl-2 protein is 
expressed at a detectable level.
These conclusions have led to three lines of potential functional work. The first aimed 
at clarifying the possible roles of Erg in confering stroma-dependent growth. The 
second was to test the possible involvement of Bcl-2 and Fli-1 in differentiation arrest 
and increased tumorigenicity in ELM-I/1 cells. The functional studies involving Fli-1
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have been carried out by Dr. Bartholomew in the laboratory. These could be carried out 
either by over-expression or antisense approaches. The third was to test whether or not 
Fli-1 can transactivate the bcl-2 promoter and is responsible for the up-regulation of bcl- 
2 in ELM-I/1 cells.
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CHAPTER 11: Molecular Mechanisms of bcl-2 Up-regulation
in ELM-I/1 Cells.
11.1. Transactivation of the bcl-2 promoter by Fli-1,
11.1.1. Transactivation o f  the bcl-2 promoter by Fli-1 in a quail fibroblast assay system.
It has been established that in ELM-I/1 cells, fli-1  and bcl-2 are significantly up- 
regulated at both mRNA and protein levels (see Chapter 10). This, together with the fact 
that an important regulatory element (NRE) in the bcl-2 promoter contains multiple 
potential Ets-binding sites (EBS) (see Figure 5.1), suggested that it might be worthwhile 
to determine whether Fli-1 can transactivate the bcl-2 promoter, and whether Fli-1 is 
responsible for the up-regulation o f bcl-2 expression in this particular cell line. A 
murine fli-1  expression vector, pRC-CM W-fli-1, was used in transient transfection 
assays, where expression o f the fli-1  cDNA is driven by the cytomegalovirus promoter. 
Two truncated Fli-1 mutants, DNM1 and DNM2, were also used (Figure 11.1): DNM1 
includes the last 175 amino acids from the carboxyl-terminal, which contains the DNA- 
binding domain and the minor carboxyl-transactivation domain; while DNM2 contains 
the DNA-binding domain only. It was expected that DNM1 retains part o f the 
transactivation activity compared with the full length Fli-1 protein, whereas DNM2 
should not have any transactivation activity at all.
Figure 11.1 Schematic representation o f the functional domains o f the murine 
Fli-1 protein and its two truncated mutants.
ATD
Full Length Fli-1
Fli-1 DNM1
Fli-1 DNM2
ATD: Amino-terminal transactivation domain
EBD: £/s-binding domain
CTD: Carboxy-terminal transactivation domain
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To check that the assay system was functional correctly, the transactivation activity of 
the full length Fli-1 protein and its truncated mutants thus generated was first tested 
using reporter vectors containing the luciferase cDNA under the control of the 
minimum herpes thymidine kinase (tk) promoter with or without insertions of three 
copies of the E74 target sequence upstream of the tk promoter. The E74 oligonucleotide 
contains the consensus sequence required for binding to the Drosophila E74 protein 
(Umess and Thummel, 1990). A number of Ets proteins, including the human Erg-1, 
Erg-2, Ets-1, Ets-2, Fli-1 and Spi-l/PU.l, can bind to and transactivate through this 
sequence (Reddy and Rao, 1991; Chang et a l, 1993; Rao et a l, 1993). A mutant E74 
sequence (mE74) has also been derived where the core consensus sequence GGAA is 
mutated to CAA, which abolishes its binding activity to the Ets proteins (Nibbs et a l, 
1993). Thus, the E74 sequence provides a very useful tool for assaying the 
transactivation activity of Fli-1. The fli-1 expression vector and the E74 reporter 
construct were co-transfected into a quail fibroblast cell line, Q2BN. Q2BN has been 
chosen because it is highly transfectable, and Dr. Frampton has successfully applied this 
system in his studies on a variety of both chicken and murine Ets proteins. On the other 
hand, transfection efficiency of the ELM system was too low to conduct such assays.
In order to be certain that any changes in the reporter gene expression was due to the 
specific effect of co-transfection of the expression vector of fli-1 or its truncated 
mutants, rather than due to differences in transfection efficiency or any other artefacts, a 
P-galactosidase expression vector, pRSV(p-g«/), was co-transfected to serve as an 
internal control, in which the p-gal cDNA is driven by the promoter of Rous Sarcoma 
Virus. It had been confirmed that co-expressing the fli-1 expression vector, over the 
range applied in our assays, i.e. 0-1 pg, does not have considerable effect on the RSV 
promoter (Figure 11.2a). However, it does have significant effects on the HSV and GK 
promoters (Figure 11.2b and 11.2c). Based on this analysis, lpg of the pRSV(p-gaZ) 
vector was co-transfected to serve as an internal control in all the assays, unless 
otherwise indicated.
Figure 11.3a shows the luciferase expression from various reporter constructs when co­
expressed with either the expression vectors (pRC-CMV(fli-1) or pRC-CMV) or a non­
expression vector (the Bluescript vector, Promega). The use of the Bluescript vector 
served as an additional control to test whether the expression vectors used had brought 
about certain artefacts. It shows that expression of the Fli-1 protein led to an average of 
2-fold increase in the luciferase expression (Figure 11.3a) from the reporter construct 
pGL2(min.tk+3xE74) containing the minimum tk promoter linked to three copies of 
E74 sequences, compared with the negative controls where either the empty expression 
vector (pRC-CMV) or a non-expression vector (Bluescript) was used (Figure 11.3a).
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Figure 11.2. Effects of Fli-1 on the expression of a p-galactosidase ((3-gal) reporter 
gene driven by (a) RSV, (b) HSV, and (c) GK promoters.
To test the effect of Fli-1 on the expression of p -gal by various expression 
constructs and, therefore, the validity of choosing a particular construct in transient 
transfection studies as the internal control, lpg  of p -gal expression vectors 
(pRCV(p-gtf/), pHSV(p-gfl/) and pGK(p-g<z/)) and various amounts (0-5|ig) of the 
///-/expression vector (pRC-CMV-fli-1) were co-transfected into Q2BN cells by the 
traditional calcium-phosphate method (see Methods and Materials). Carrier DNA, 
the pRC-CMV vector, was used so that the same amount of DNA was used in each 
transfection. Cells were harvested after 48h and the p -gal assays performed (see 
Methods and Materials). Cell lysates prepared from pRSV(P-gal) transfectants 
were incubated with the substrates of P-gal for 25 min before reactions were 
stopped and OD(420nm) was read, whereas in the case of pHSV(P-gal) and 
pGK(p-gal), an incubation time of 90 min was used since the p-gal expression 
driven by the HSV and GK promoters was less efficient. The results represent the 
means and standard deviation of two independent experiments, each performed in 
triplicates.
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Figure 11.3. Effects of Fli-1 and its truncated mutants, DNM1 and DNM2, on the 
activity of the E74-linked minimum thymidine kinase (tk) promoter.
The wild-type Fli-1 protein (a) but not its truncated mutants (b) can transactivate the 
minimum tk promoter via the linked three copies of E74 sequences, (c) When co­
expressed with wild-type Fli-1 protein, the Fli-1 truncated mutant, DNM2, which only 
contains the DNA-binding domain, can act as a dominant negative mutant and reduce 
the transactivation of the E74-linked minimum tk promoter by Fli-1. lpg of pRSV(P- 
gal) was co-transfected as the internal control for transfection efficiency. The luciferase 
activity was then divided by the p-galactosidase activity to normalise transfection 
efficiency. The results represent the means and standard deviation of two independent 
experiments, each performed in triplicates.
(a) 250ng of reporter constructs (pGL2(3xE74+min.TK), pGL2(min.tk) or 
pGL2(promoter-less)) and 150ng of the fli-1 expression vector ($RC-CMW-fli-1) were 
co-transfected into Q2BN cells by the traditional calcium-phosphate method (see 
Methods and Materials). The negative controls include using the empty expression 
vector (pRC-CMV, indicated as “pRC (no fli-1)”) or a non-expression vector plasmid 
(the Bluescript vector). Cells were harvested 48h post-transfection and luciferase assays 
performed (see Methods and Materials).
(b)150ng of the E74-linked minimum tk promoter-reporter construct (pGL2(3xE74+ 
min.tk)) and 350ng of the pRC-CMV expression vectors, containing either fli-1 , DNM1 
or DNM2, were co-transfected into Q2BN cells. The empty expression vecotr, pRC- 
CMV (indicated as “pRC (no fli-1)”) was included as the negative control. Cells were 
harvested and assayed for luciferase activity as above.
(c) Left panel: 150ng of the E74-linked tk promoter-reporter construct (pGL2(3xE74+ 
min.tk)) and various amounts (0-5 pg) of the DNM2 expression vector were co­
transfected into Q2BN cells, and cells were harvested and assayed for luciferase activity 
as above.
Right panel: 150ng of the E74-linked minimum tk promoter-reporter construct 
(pGL2(3xE74+ min.tk)), 350ng of the wild-type fli-1 expression vector (pRC-CMV-fli- 
1) and various amounts (0-5 pg) of the DNM2 expression vector (pRC-CMV-DNM2) 
were co-transfected into Q2BN cells, and cells were harvested and assayed for luciferase 
activity as above. Carrier DNA (pRC-CMV) was used so that the same amount of DNA 
was used in each transfection.
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This increase was not observed with the reporter construct where the 3xE74 sequences 
are deleted (pGL(min.tk)), or with the promoter-less reporter where both 3xE74 and the 
minimum tk promoter were deleted (pGL2(promoter-less)) (Figure 11.3a). This 
indicates that the increase in the reporter gene expression observed is a specific effect 
due to the interaction between Fli-1 and the 3xE74 sequence. Similar experiments using 
the Fli-1 truncated mutants showed that DNM1, which retains the DNA-binding domain 
and the minor carboxyl-terminal transactivation domain, had reduced transactivation 
activity; while DNM2, which contains the DNA-binding domain only, did not have any 
transactivation activity at all (Figure 11.3b). Furthermore, DNM2 had, indeed, a 
dominant negative effect on the full length Fli-1 protein. It can be seen from Figure 
11.3c (right panel) that, with increasing amount of the DMN2 expression vector, the 
transactivation activity of full length Fli-1 protein was reduced, and completely 
abolished when 5pg of the DNM2 vector was used. The control experiment presented in 
the left panel shows that, in the range used (i.e. 0-5pg), DNM2 on its own had no 
significant effect on the E74 reporter. Taken together, the various Fli-1 expression 
vectors can produce the Fli-1 proteins (i.e. the full length Fli-1, DNM1 and DNM2) 
with expected transactivation activity
In order to test whether Fli-1 can transactivate the bcl-2 promoter, we had tried to obtain 
the murine genomic bcl-2 clone from the laboratory that originally cloned and 
characterised the gene but were fruitless. Attempts had also been made to isolate the full 
length bcl-2 promoter from murine genomic DNA by the PCR approach but these 
proved unsuccessful, possibly due to the high GC content of the sequence. Instead, a 
partial bcl-2 promoter containing 518bp upstream of the ATG start codon was isolated. 
Since this region of the bcl-2 promoter displays the highest nucleotide sequence 
homology between mice and human in the non-coding regions, and it also contains the 
P2 promoter and a very important regulatory element implicated in transcriptional 
control of the gene (Young and Korsmeyer, 1993 and Miyashita et al., 1994; also see 
Figure 5.1 and Figure 11.6), we decided to use this region as a starting point in the 
studies. The promoter-reporter construct (pXP2(m500)) was generated, which contains 
the luciferase cDNA under control of the partial bcl-2 promoter, and the promoter-less 
reporter (pXP2) was used as the negative control. The left panel of Figure 11.4 indicates 
that the various fli-1 expression vectors did not have any effect on the promoter-less 
reporter construct (pXP2). However, expression of the full length Fli-1 protein led to an 
average of 5.5-fold increase in the bcl-2 promoter activity in comparison to the empty 
expression vector (pRC-CMV) (Figure 11.4, right panel). Both the two truncated 
mutants, DNM1 and DNM2, had a reduced transactivation activity towards the bcl-2 
promoter (Figure 11.4, right panel). It is surprising that DNM2 had any transactivation 
activity at all since, as described earlier that, it only contains the DNA-binding domain. 
Such effects of the wild-type and mutant Fli-1 proteins on the bcl-2 promoter activity
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Figure 11.4. (a) Effects of Fli-1 and its truncated mutants, DNM1 and DNM2, on the 
activity of a partial bcl-2 promoter, (b) Schematic representation of the bcl-2 promoter. 
The partial bcl-2 promoter covers the 518bp region upstream of the ATG start codon.
150ng of the reporter constructs (either the promoter-less reporter, pXP2, or the bcl-2 
promoter-reporter, pXP2(m500)) and 350ng of either of the expression vectors were co­
transfected into Q2BN cells by the traditional calcium-phosphate method (see Methods 
and Materials). The empty expression vector, pRC-CMV (as indicated by "None") was 
used in the negative controls. Cell were harvested 48h post-transfection and luciferase 
assays performed (see Methods and Materials). The results represent the means and stan­
dard deviation of three independent experiments, each performed in triplicate.
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can also be observed when in a range of expression vectors was used. Figure 11.5a 
shows the results of titration experiments using various amounts (i.e. 0-1 pg) of Fli- 
7/DNM1/DNM2 expression vectors with a fixed amount of reporter construct. It can be 
seen that, with increasing amounts of wild-type Fli-1 expression vector, the bcl-2 
promoter activity increased initially, peaked at around 200-500ng, and then decreased 
when more expression vector was used (Figure 11.5a, left panel). This bell-shaped curve 
of promoter activity in such expression vector titration experiments is typical, and 
presumably is due to the "squelching" effect. This occurs when over-expression of a 
transcription factor leads to its non-specific interaction with basal transcription factors, 
thereby sequestering them and thus reduce the promoter activity. Both DNM1 and 
DNM2, at various amounts used, had much reduced transactivation activity towards the 
bcl-2 promoter (Figure 11.5a, middle and right panel). A different way of plotting 
Figure 11.5a gives clearer comparison of transactivation activity of the wild-type Fli-1 
protein and its truncated mutants at various amounts of expression vector used (Figure 
11.5b).
In order to define the minimum promoter region required for Fli-1 transactivation, 
deletion mutagenesis was desired to generate a shorter murine bcl-2 promoter. As the 
518bp region of the bcl-2 promoter we had focused on in this study is 77.6% 
homologous to the human counterpart (Figure 11.6). Furthermore, the important 
regulatory element of the bcl-2 promoter, which begins at 287bp upstream of the start 
codon, is 80.5% homologous between murine and human. Therefore, we took advantage 
of the fact that the promoter reporter constructs (pXP2(h300) and pXP2(h600)) were 
readily available, which contain the partial human bcl-2 promoter 300bp and 646bp 
upstream of the start codon, and used them for comparison of their activity in response 
to the Fli-1 expression. Figure 11.7 shows that Fli-1 was able to transactivate the h300 
and h600 promoters equally well. This indicates that the major elements required for the 
Fli-1 transactivation of the partial human bcl-2 promoter lies in the 300bp region 
upstream of the start codon, which conincides with the important regulatory element 
previously reported (Young et al., 1993 and Miyashita et al., 1994). The high homology 
of this region between the murine and human sequence also suggests the importance of 
this element in the transcriptional regulation of the gene, and that the minimum bcl-2 
promoter for murine may also lie in this region. Interestingly, there are seven potential 
^ -b in d in g  sites in this region (Figure 5.1) and, consequently, we attempted to map the 
Fli-1 activating sites within this region by DNase I footprinting analysis and gel 
retardation analysis.
107
Figure 11.5. Titration experiments of the effects of Fli-1 and its truncated mutants, 
DNM1 and DNM2, on the bcl-2 promoter activity.
150ng of the bcl-2 promoter reporter constructs (pXP(m500)) and various amounts of 
(0 -lpg) expression vectors (either pRC-CMV-fli-1, -DNM1, or DNM2) were 
co-transfected into Q2BN cells by the traditional calcium-phosphate method (see 
Methods and Materials). Carrier DNA (pRC-CMV) was used so that the same amount 
of DNA was used in each transfection. Cells were harvested 48h post-transfection and 
luciferase assays performed (see Methods and Materials). The results represent the 
means and standard deviation of four independent experiments, each performed in 
triplicates. It should be noted that (a) and (b) are based on the same data but plotted in 
different ways.
DNM2DNM1
Amount of activator 
lOOng lOOOnj;
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Figure 11.6 Sequence alignment between the murine and human bcl-2 promoters 
studied. The region in bold indicates the regulatory element that is crucial for the 
transcriptional regulation of bcl-2. This region has been focused in subsequent DNase I 
footprinting and gel retardation analysis. The arrow indicates the transcriptional start 
site. The ATG start codons are boxed.
m.bcl-2 1162 AAC
1 f
1164
h.bcl-2 813
1 I 
GAC 815
m.bcl-2 1165 TCCCGATTCATT.GCAAGTTGTAAAGAAGCTTATACAAGGAGACTTCTGA
ill i i i i i i i i i i i i i i ill ill i i i i i i i i i i i i i i
1213
h.bcl-2 816
III 1 1 1 1 1 1 1 1 1 1 1 1 1 1 III III 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TCCTGATTCATTGGGAAGTTTCAAATCAGC.TATAACTGGAGAGTGCTGA 864
m-bcl-2 1214 AGATCGATGGTGTGGTTGCCTTATGTATTTGTTTGGGTTTTACCAAAAAA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1263
h.bcl-2 865 AGATTGATGGGATCGTTGCCTTATGCATTTGTTTTGGTTTTACAAAAA.. 912
m. bcl-2 1264 GGGTAAACTTGACAGAAGATCATGCCGTCCTTAGAAAATAC.AGTAAGTT
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
..GGAAACTTGACAGAGGATCATGCTGTACTTAAAAAATACAAGTAAGT.
1312
h.bcl-2 913 959
m.bcl-2 1313 CTTTGCACAGGAATTTTGTTTAATATAACTTTCCATGGACGCGTTTGAAA 
1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
.CTCGCACAGGAAATTGGTTTAATGTAACTTTCAATGGAAACCTTTGAGA
1362
h.bcl-2 960 1008
m.bcl-2 1363 TATTTTTTTACTTCAAGTGCATTCAAGCAAATTTCATTTCCAGACAGTTT 
1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 III II 
...TTTTTTACTTAAAGTGCATTCGAGTAAATTTAATTTCCAGGCAGCTT
1412
h.bcl-2 1009 1055
m.bcl-2 1413 AATGCA...TTTTTAAACGTGTAACTTGTAGCGGATATACCTTTCTTACC 
1 1 1 II 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 
AATACATTGTTTTTAGCCGTGTTACTTGTAGTGTGTATGCCCTGCTTTCA
1459
h.bcl-2 1056 1105
m.bcl-2 1460 C TAAATATATAAAGGAAAACACAC C T GA.TTTTAACTTCCTAGGTCGTCC
II 1 1 1 II III 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 III 1 II
CTCAGTGTGTACAGGGAAACGCACCTGATTTTTTACTTATTAGTTTGTTT
1508
h.bcl-2 1106 1155
m.bcl-2 1509 CGCCTCTTCACCTTTCAGCATTGCGGAGGAAGTAGACTGATATTAACAAA
II II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
TTTCT.TTAACCTTTCAGCATCACAGAGGAAGTAGACTGATATTAACAAT
1558
h.bcl-2 1156 1204
m.bcl-2 1559 GCTTAATA..AATAATGTACCTCATGAAATAAAAAGCAGAAAGGAATTTG
i i i i ii i i i i i ii i i i i i i i i i i i i i i i i i I i i i i i i i i i
1606
h.bcl-2 1205
1 1 II II 1 1 1 1 1 II 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ACTTACTAATAATAACGTGCCTCATGAAATAAAGATCCGAAAGGAATTGG 1254
m.bcl-2 1607 AATAAAAATTTCCTGCATCTCATGCCAACGGGGAAACACCAGAATCAAGT
1 II II 1 II 1 1 II 1 1 1 1 1 1 1 1 1 1 II 1 1 1 II 1 1 1 1 II 1 1 1 II 1 II 1 1 II
AATAAAAAT TTCCTGCGTCT CAT GC CAAGAGGGAAACAC CAGAAT CAAGT
1656
h .bcl-2 1255 1304
m.bcl-2 1657 gttcggtgtaactaaagacaccccttcatccaagaatgcaaagcacatcc
1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
GTTCCGCGTGATTGAAGACACCCCCTCGTCCAAGAATGCAAAGCACATCC
1706
h.bcl-2 1305 1354
m.bcl-2 1707 AATAAAAGAGCTGGATTATAACTATTCTTTTTTTTTTTTTTTTCTTTCGG
1 1 1 1 1 1 1 1 II 1 1 1 II 1 1 1 1 1 1 1 II II 1 1 1 1 1 1 II
AATAAAATAGCTGGATTATAACTCCTC.......... TTCTTTCTCTGGG
1756
h .bcl-2 1355 1394
m.bcl-2 1757
. T
GGCCGTGGGGCGGGAGTCGGGACTTGAAGTGCCATTGGTACCTGCAGCTT
1111111 i i  i 11111 111 i 11 11111 1111 m i  1111
ggccgtggggtgggagctggggcgagaggtgccgttggcccccgttgctt
1806
h.bcl-2 1395 1444
m. bcl-2 1807 CTTTTCGGGGAAGdATGl
1 II 111111II11 
TTCCTCTGGGAAGG|ATG|
1823
h.bcl-2 1445 1461
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11.1.2. The Bcl-2 promoter activity in the ELM system.
The above evidence demonstrates that Fli-1 can transactivate the bcl-2 promoter in a 
quail fibroblast assay system. As the first step to prove that this is also the case in the 
ELM system, the bcl-2 promoter activity was compared in ELM-I/1 cells that express 
the Fli-1 protein and 1/2 cells that do not. 25pg of the bcl-2 promoter reporter construct, 
pXP2 (m500), was transfected into ELM-I/1 and 1/2 cells by electroporation and cells 
were harvested after 48h for luciferase assay (see Methods and Materials). The 
transfection efficiency of ELM cells was poor but had been optimised to an acceptable 
degree to perform the assay. 25pg of the luciferase expression construct, pGL2 (min.tk), 
was used in parallel as a control for transfection efficiency, since the transfection 
efficiency was not high enough to enable the p -gal expression to be detectable using 
pRSV(P-gaZ) while luciferase assays are much more sensitive. It was demonstrated 
earlier (Figure 11.3a, middle panel) that Fli-1 has no considerable effects on the 
minimum tk promoter.
Figure 11.8 shows that the tk promoter activity as measured by luciferase activity was 
similar in ELM-I/1 and 1/2 cells. However, the bcl-2 promoter acitivity in ELM-I/1 cells 
was approximately 4 times as that in 1/2 cells. It is likely that transcription factor(s) that 
are present in ELM-I/1 but not 1/2 cells are responsible for this difference. In light of the 
fact that Fli-1 can transactivate the bcl-2 promoter in the quail system, the Fli-1 protein 
is a very likely candidate.
11.2. Preparation and characterisation of the nuclear extracts from ELM-1/1 and 
1/2 cells: quantitation and expression of the Fli-1 protein.
Nuclear extracts were prepared from ELM-I/1 cells, which express the Fli-1 protein, and 
ELM-I/2 cells, that do not. As DNA-binding activity of the ELM-I/1 and 1/2 nuclear 
extracts will be compared in both footprinting and gel retardation analysis, quantitation 
of the extracts is important. This was carried by a combination of the BCA protein 
assays and gel retardation analysis using the CAAT oligonucleotide as the probe. The 
BCA assay is an accurate and reproducible method for quantitating total proteins. 
However, nuclear protein preparations unavoidably contain contaminations of 
cytoplasmic proteins, and the extent of contaminations can vary among different 
preparations. One way to compensate for this is to combine the BCA assays with gel 
retardation analysis using the CAAT oligonucleotide as the probe, which binds to 
ubiquitous transcription factor(s) and, therefore, can be used as the loading control of 
nuclear proteins (Plumb et al., 1989). Figure 11.9a shows the CAAT-binding of nuclear 
proteins from various preparations. The amount of nuclear proteins loaded had been 
adjusted according to the calculated protein concentrations as a result of BCA assays,
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Figure 11.9. Quantitation of nuclear proteins utilising the CAAT oligonucleotide which 
binds to ubiquitous nuclear protein(s) in gel retardation assays.
(a) Large scale nuclear protein extracts were prepared from ELM-I/1 and 1/2 cells on two 
different occasions (the year of which, 1994 and 1996, are indicated in brackets). The 
protein concentrations were quantitated by the BCA assay (see Methods and Materials) 
followed by gel retardation analysis using the CAAT oligonucleotide (see Section 11.2). 
The intensity of the retarded bands was quantitated by densitometry. The calculated 
figures were shown below each lane, which were then used to further standardise the 
protein loadings.
(b) Confirmation of equal protein loadings after quantitation by the BCA assays and 
CAAT-binding assays (see above). The gel retardation assay using the CAAT oligonu­
cleotide was performed as in (a) but using the amounts of extracts that were calculated 
to give the same CAAT-binding. The intensity of the bands, which was indicated below 
each lane, shows equal loadings from different protein preparations, and therefore the 
reliability of the quantitation results.
(a) Before correction for CAAT-binding activity
Nuclear extracts 
CAAT-binding
VO VO o o
On ON ON On ON ON ON ON
w w w w
— ,—i <N <N —H _ <N 04
Free probe 
Band intensity 2.2 3.8 4.0 4.5 4.9 5.1 3.0 4.6
(b) After correction for CAAT-binding activity
Nuclear extracts 
CAAT-binding ■
Free probe 
Band intensity
but it seems that there were still differences in the CAAT-binding from various protein 
preparations. The retarded bands resulting from the CAAT-binding were subsequently 
scanned by densitometry and their optical density calculated. The differences in the 
loadings in Figure 11.9a were then further corrected according to the calculated optical 
density of the bands, and Figure 11.9b shows the CAAT-binding activity of nuclear 
proteins from various preparations after such correction. It can be seen from the 
quantitated CAAT binding activity that proteins were equally loaded in Figure 11.9b. 
The results of such quantitation were used in the subsequent Western blotting, 
footprinting and gel retardation analysis.
To be certain that the methods used for the large scale nuclear protein preparations can 
successfully extract the Fli-1 protein from ELM-I/1 cells, the nuclear extracts were 
analysed by Western blotting using a Fli-1-specific antibody, lpg and lOpg of the ELM- 
I/1 and 1/2 nuclear extracts prepared in two separate occasions were used. It can be seen 
in Figure 11.10 that the antibody recognised the Fli-1 protein in the ELM-I/1 nuclear 
extracts, and resulted in a doublet with the molecular weights of 48 kD and 51 kD. The 
intensity of the bands representing Fli-1 further confirms the reliability of the protein 
quantitation.
11.3. In vitro DNase I footprinting analysis of the minimum bcl-2 promoter region.
To determine the Fli-1 activating sites within the minimum bcl-2 promoter, in vitro 
DNase I footprinting studies were performed with various fragments of the region 
suitable for identifying any protein-binding sites (Figure 11.11a and 11.11b). The 
promoter fragments used in footprinting analysis were generated by PCR from mouse 
genomic DNA, which were subsequently cloned into the vector pCR-Script.Amp.(SK+) 
(Stratagene) (see Methods and Materials). By using probes 1 and 2 labelled on 
complementary strands of the minimum Fli-1-responsive bcl-2 promoter region 
identified, six fooprints (FPs) were identified with both ELM-I/1 and 1/2 nuclear extracts 
(Figure 11.1 la). FP3 and FP4 were close to the top of the gels and were not resolved as 
clearly as the other FPs. In order to improve the resolution of FP3 and FP4, similar 
foorprinting reaction was performed with probe 2 but the sequencing gel was run much 
longer (Figure 11.11b).
Figure 11.12 shows the positions of these FPs alongside the sequence of the promoter 
fragment used. Four FPs (FP2, FP3, FP4 and FP6) contain potential binding sites for the 
Ets family of transcription factors. The two potential ^ -b in d in g  sites (EBS) in FP2 and 
FP4 are palindromically arranged. This is potentially interesting as it has been reported 
that, at least in some cases, efficient DNA-binding and transactivation by the Ets 
proteins require two EBS arranged in an inverted configuration, whereas the
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Figure 11.11 In vitro DNase I footprinting analysis of the minimum bcl-2 promoter 
region, (a) Footprinting analysis using probes 1 and 2 as described below; (b) Similar 
footprinting analysis using probe 2 but the gel was run much longer in order to reveal 
the FP3 and FP4 more clearly.
Footprinting probes were prepared by 5'-end labelling (indicated by the star) of DNA 
restriction fragments with T4 polynucleotide kinase and [a-32P]ATP, and isolated after 
secondary restriction digest (see Methods and Materials). DNA:protein binding 
reactions were carried out in the presence of poly(dI-dC)-poly(dI-dC) with the nuclear 
protein extracts from ELM-I/1 and ELM-I/2 cells. After partially digested with DNase I, 
the nucleic acid was purified and resolved by 6% denaturing polyacrylamide gel 
electrophoresis and autoradiography (see Methods and Materials). A control reaction 
(O) was included, where protein extracts were omitted. A+G chemical sequencing 
reactions (see Methods and Materials) of the probes, together with the position of the 
sequence relative to the transcription initiation site, are included. The positions of the 
footprints (FP1-FP6) referred to in the text are marked. The putative EA-binding sites 
are underlined. The TATA, CAAT and Oct-1 motifs are also indicated.
The numbering of the sequence is based on the bcl-2 genomic sequence published by 
Negrini et al. (1987).
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Figure 11.11 (b)a
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Figure 11.12 Positions of the six footprints (FP1-FP6, underlined) alongside the 
sequence of the bcl-2 promoter fragment used in DNase I footprinting analysis. The 
potential binding ^ -b in d in g  sites (EBS) are boxed. The Oct-1, TATA and CAAT 
motifs are also indicated.
1491 TAACTTCCTA
1501 GGTCGTCCCG CCTCTTCACC TTTCAGCATT GCGGAIGGAa Ig TAGACTGATA
EBS1
1551 TTAACAAAGC TTAATAAATA ATGTACCTCA TGAAATAAAA AGCAGAAAlGGl
FP1 EBS2
1601  IaaIt t t g a a t a  AAAATfft c c It g c a t c t c a t g  ccaacggIgga aIacaccagaa  
FP2 EBS3 EBS4
1651  TCAAGTGTTC GGTGTAACTA AAGACACCCC TTCATCCAAG AATGCAAAGC 
FP3 O c t -1
1701  ACkTcc&ATA a a a g a g c tI g g  a t I t a t a a c t a  TTCTTTTTTT TTTTTTTTTC 
EBS5 /CAAT FP4 EBS6/TATA
1751 TTTCGGGGCC GTGGGGCGGG AGTCGGGACT TGAAGTGCCA TTGGTACCTG
FP5
1801 CAGCTTCTTT TCGdGGA^GG ATGGCGCAAG CCGGGAGAAC AGGGTATGAT
EBS7 FP6
1851 AACCGGGAGA
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oligonucleotide containing the two EBS in the same orientation binds 10-fold less 
proteins (Seth et al., 1993). FP6 is the most interesting because there is an obvious 
difference in the footprinting patterns between the ELM-I/1 and 1/2 nuclear extracts and 
the fact that it contains a potential EBS.
11.4. Gel retardation analysis of the identified footprints in the minimum bcl-2 
promoter region.
11.4.1. Nuclear factor/s) in the ELM-I/1 and 1/2 nuclear extracts can bind specifically to 
all the footprints.
In order to identify the nuclear factor(s) binding to FP1-FP6, gel retardation analysis was 
performed with the ELM-I/1 and 1/2 nuclear extracts. The 5’-boundary of FP2 is 
somewhat ambiguous, and so two oligonucleotides (FP2L and FP2S) varying at 5’-end 
were synthesised and used in gel retardation analysis (see Methods and Materials). 
Figure 12.13 shows that nuclear factor(s) in the ELM-I/1 and 1/2 nuclear extracts can 
bind to all the footprints. There was no significant difference in protein-binding between 
the two different forms of FP2 and, therefore, the longer version of FP2 (i.e. FP2L) was 
used in the subsequent gel retardation assays. Furthermore, the bindings of all FPs were 
specific as judged by self-competition experiments where a 250-fold excess of 
unlabelled FP oligonucleotides were used (Figure 11.13 and 11.14). FP3 and FP6 are 
more potentially interesting since, in each case, an additional band was observed with 
the ELM-I/1 nuclear extracts (each indicated by an arrow in the figure), which did not 
appear with the ELM-I/2 extracts. Competition between different FP oligonucleotides 
was tested and, in all cases, the ELM-I/1 and 1/2 nuclear extracts were used for 
comparison, and the autorads were exposed for the same length of time in the same 
cassette. It can be seen from Figure 11.14 (a-f) that there were competitions between 
certain FP oligonucleotides for protein-binding in gel retardation assays (summarised in 
Table 11.1). For example, either FP1 or FP4 was able to compete with FP2 and, 
similarly, FP5 with FP4. It seems that FPs adjacent to one another (e.g. FP1 and FP2 or 
FP4 and FP5) are more likely to compete with each other for protein-binding.
11.4.2. None of the ets oligonucleotides, E74. Ets-3. Fli. PEA3 or PU.l, competes 
significantly with the six FPs for protein-binding.
Competition experiments using the ets oligonucleotides were also carried out. These ets 
oligonucleotides, including E74, Ets-3, Fli, PE A3 and PU.l, contain the binding sites 
for certain Ets proteins. In particular, the Fli oligonucleotide has been reported to be 
able to bind to the Fli-1 protein in gel retardation analysis (Bosselut et al., 1993).
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Figure 11.14. Gel retardation analysis of nuclear protein-binding to oligonucleotides 
(FP1-FP6) from the six footprinted regions: competitions between FPs and the estab­
lished ets oligonucleotides, E74, Ets-3, Fli, PEA3 and PU .l.
Gel retardation experiments with the ELM-I/1 and 1/2 nuclear extracts were performed 
as described in Methods and Materials. The labelled oligonucleotides and nuclear 
extracts used in each reaction are indicated. The unlabelled competitor oligonucleo­
tides used are indicated above individual lane: (0) indicates no competitor; when com­
petitors were included, 250-fold excess was used. Arrows indicate the bands that are 
unique to ELM-I/1 nuclear extracts. Free probes, which were not bound to any pro­
teins in the extracts, are seen at the bottom of the autoradiographs.
(a) Probe: FP1
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Figure 11.14. (Continued, see the previous page for the legend)
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Table 11.1 Summary of gel retardation and competition analysis of the six footprint 
oligonucleotides (FP1-FP6). Note that FP1-FP6 in the first row indicates the probes 
used. FP1-FP6 along with other oligonucleotides in the first column are used as 
unlabelled competitors.
Probes FP1 FP2L FP3 FP4 FP5 FP6
Positions 1538-
1582
1575-
1631
1626-
1688
1686-
1736
1772-
1807
1805-
1840
Length 45 bp 57 bp 63 bp 51 bp 36 bp 36 bp
Potential
Ets-sites
0 Ets©
Ets®
Ets® Ets®
Ets®
0 Ets®
Differential
binding3
no no yes no no yes
Potential
interest15
* *** * ***
FP1 +++ +++ - - - +++/-
FP2L ++/- +++ - - - ++/-
FP3 +++ - +++ - - +++/-
FP4 +++/- +++ +? +++ +++/- ++/-
FP5 - - - +++ +++ ++/-
FP6 - - - - +++/- +++/-
E74 ++/- + - - - +/-
mE74 ++/- +++ ? - - +/-
Fli - - - - - -
Pea3 - - _ - - -
PU.l +/- - - - - +/-
a “Differential binding” indicates if there is any difference between the ELM-I/1 and 1/2 
nuclear extracts in binding to the footprint oligonucleotides in gel retardation analysis. 
b “Potential interest” grades the possibility of each footprint in light of Fli-1 activation 
based on (1) if it contains potential ^ -b in d in g  sites and (2) if it displays differential 
binding to the ELM-I/1 and 1/2 nuclear extracts.
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However, none of these ets oligonucleotides, apart from E74, was able to compete with 
FP1-FP6 for protein-binding (Figure 11.14 (a-f)). E74 was able to compete with either 
FP1, FP2 or FP6, indicating that the Ets proteins might bind to these footprints. 
Consistent with this possibility is the fact that, in both FP2 and FP6, there are potential 
EBS. However, the mutated E74 oligonucleotide (mE74), in which the ^ -b in d in g  site 
is mutated, was also able to compete with FP1, FP2 and FP6, suggesting that the 
competition effects observed with E74 may be an artefact.
The lack of significant competition of E74 and Fli oligonucleotides with all the six FPs 
could be due to differences in binding affinity: if the Ets proteins bind to FPs with high 
affinity then it may be difficult to detect competition by E74 or Fli even when excess 
amount is used. To exclude this possibility, gel retardation analysis was performed using 
either E74 or Fli oligonucleotides as probes and the six FPs as competitors. The results 
showed that none of the FP was able to compete with E74 or Fli for protein-binding 
when the ELM-I/1 nuclear extracts were used (Figure 11.15). It is important to point out 
that although the presence of competition between the FPs and ets oligonucleotides may 
indicate the involvement of Ets proteins in DNA-binding, the lack of it does not 
necessarily exclude this possibility.
In summary, competition experiments using ets oligonucleotides do not provide a strong 
evidence for the involvement of Ets proteins in binding to the footprints (summarised in 
Table 11.1).
11.4.3. In vitro synthesised Fli-1 protein can bind to the E74 and Fli oligonucleotides 
but none of the six FPs in gel retardation analysis.
As discussed above, although competition experiments have given negative results, they 
do not necessarily exclude the involvement of Fli-1 in binding to the FPs. An alternative 
approach to demonstrate that Fli-1 can bind to any of the FPs is to use in vitro 
synthesised Fli-1 protein. For in vitro synthesis of Fli-1, the pRC-CMV-fli-1 expression 
vector was used in a transcription and translation coupled rabbit reticulocyte system, and 
aliquots were used in Western blotting and gel retardation analysis. This was compared 
with aliquots of the "mock" transcription/translation (TNT) mix where the empty 
expression vector, pRC-CMV, was used.
Figure 11.16 shows the Western blotting analysis of the in vitro synthesised Fli-1 
protein, where the total cell lysates from ELM-I/1 cells were used as the positive 
control. It can be seen that the Fli-1 protein in 1/1 cells exists as a doublet with the 
molecular weights of 48 kD and 51 kD. In the transcription/translation mix where the 
fli-1 expression vector was used, there were two weak bands migrating at the similar
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positions, which were not present in the "mock" transcription/translation mix where the 
pRC-CMV vector was used. This demonstrates that the transcription/translation system 
can produce the Fli-1 protein in vitro with the correct molecular weight. However, the 
amount is poor compared to that present in ELM-I/1 cells.In order to demonstrate that 
the proteins synthesised in this way are functional in terms of their DNA-binding 
activity, gel retardation analysis was performed to test whether the in vitro synthesised 
Fli-1 protein could bind to either E74 or Fli oligonucleotides as expected. It has been 
shown in Section 11.1.1 that a minimum tk promoter can be transactivated by Fli-1 via 
the associated three copies of the E74 sequence. In addition, the Fli oligonucleotide has 
been reported to be able to bind to the Fli-1 protein in gel retardation analysis (Bosselut 
et al., 1993). Figure 11.17 shows that factors in the “mock” reaction mix were able to 
form complexes with both E74 (lane 1) and Fli oligonucleotides (lanes 7 and 8). The 
binding of E74 seemed to be specific as judged by the fact that it was competed by 250- 
fold excess of unlabelled E74 (lane 2), but not the mE74 oligonucleotide (lane 3). As 
mentioned before, the mE74 oligonucleotide is a mutated form of E74, where the core 
consensus ^ -b in d in g  site GGAA is mutated to CAA thereby abolishing the binding by 
the Ets proteins. The binding of the Fli oligonucleotide seemed to be non-specific as 
judged by the self-competition experiment (lane 9).
When the Fli-1 transcription/translation mix was used, additional bands appeared with 
both E74 and Fli oligonucleotides. In the case of E74 (lane 4), three additional band (C, 
D and E) were detected as well as the two that were detected with the "mock" reaction 
mix (A and B) were detected as well as another three bands (C, D and E). The binding 
between the in vitro synthesised Fli-1 protein and E74 oligonucleotide was specific, 
since the bands were competed by 250-fold excess of unlabelled E74 (lane 5) but not 
mE74 (lane 6). When the Fli-1 TNT mix was incubated with the labelled Fli 
oligonucleotdies, there were two extra bands (G and H, in lanes 10 and 11) in addition 
to the one observed with the "mock" reaction mix (lanes 7 and 8), and the binding was 
also specific (lane 12). The reason for the existence of multiple bands is not clear. It is 
possible that the higher mobility complexes were due to the binding of degraded or 
incompletely synthesised Fli-1 proteins. Alternatively, the lower mobility complexes 
may be the results of binding between the oligonucleotides and the Fli-1 oligomers. 
Finally, the Fli-1 protein may also form complexes with other proteins in the lysates, 
and different co-factors may be involved for different oligonucleotides. This can explain 
not only the existence of multiple bands but also why the mobility of protein:DNA 
complexes with the E74 and Fli oligonucleotides was different.
However, when the six FP oligonucleotides were used as probes in similar gel 
retardation assays, it was not able to reveal any binding between in vitro synthesised Fli- 
1 and any of the FPs. Figure 11.18 shows that factor(s) in the "mock" reaction mix
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Figure 11.17. Gel retardation analysis showing the binding of in vitro synthesised 
Fli-1 protein to the E74 and Fli oligonucleotides.
In vitro synthesis o f Fli-1 protein was carried out in a coupled transcription and 
translation (TNT) system from rabbit reticulocytes using a Fli-1 expression vector 
(pRC-CM V-fli-l) (see Methods and Materials). Aliquots (5pl or lOpl) were used 
directly in gel retardation analysis. As a negative control, “mock” transcription and 
translation reactions were carried out where the empty expression vector, pRC- 
CMV, was used. Gel retardation analysis was carried out as described in Methods 
and Materials.
The unlabelled competitor oligonucleotides used were indicated above individual 
lane: (0) indicates no competitor; when competitors were included, 250-fold excess 
was used. Free probes, which were not bound to any proteins in the extracts, are 
seen at the bottom of the autoradiograph. Note that the free labelled Fli oligonucleo­
tides had run off the bottome of the gel.
Probe E74 Fli
Cold competitor----------—— — ------— —— ------- —--------------------------------
(250x) 0 E74 mE74 0 E74 mE74 0 0 Fli 0 0 Fli
In vitro synthesised
Fli-1 (pi) 0 0 0 5 5 5 0 0 0 5 10 10
“mock” TNT
mix (pi) 5 5 5 0 0 0 5 10 10 0 0 0
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were able to bind to all of the FPs. In vitro sythesised Fli-1 did not alter the intensity of 
the bands, nor did it give rise to any additional bands. It is possible that in vitro 
synthesised Fli-1 could form complex(es) with FPs, but the complex(es) had the same 
mobility in gel retardation assays as those of FPs and some unknown factors in the 
“mock” reaction mix. This possibility can be tested in “supershift” analysis using a Fli- 
7-specific antibody (see Section 11.4.5). Alternatively, the data may also indicate that in 
vitro synthesised Fli-1 protein cannot bind to any of the six FP oligonucleotides. 
However, it must be remembered that, in the absence of other co-factors, the DNA- 
binding activity of a protein produced in an unphosphorylated state in vitro could exhibit 
completely different properties as that in the context of a total nuclear protein extract 
prepared from growing cells. Indeed, a recurring theme with many Ets proteins is that 
their ability to recognise certain DNA sequences is altered by phosphorylation and 
protein:protein interaction with either Ets or non-£te transcription factors (discussed in 
detail in Section 13.4). Therefore, the lack of binding between in vitro synthesised Fli-1 
and the FP oligonucleotides does not necessarily exclude the possibility that the Fli-1 
protein present in nuclear extracts can bind to the FPs.
11.4.4. The Fli-1-specific antiserum works in “supershift” analysis either when in vitro 
synthesised Fli-1 or ELM-I/1 nuclear extracts are used.
To further investigate the involvement of the Ets proteins, in particular Fli-1, in binding 
to the FPs, "gel supershift” analysis was performed using the rabbit-anti-mouse Fli-1 
antiserum generated in our laboratory. In "gel supershift” analysis, if an antibody 
recognises the specific protein bound to a probe, then either the mobility of the 
protein:DNA complex(es) will be further retarded, or the intensity of the band(s) will be 
altered. In order to test whether or not the Fli-1 antiserum is able to recognise Fli-1 
bound to oligonucleotides in gel retardation assays, in vitro synthesised Fli-1 protein 
was incubated with either radiolabelled E74 or Fli in the presence of the antiserum. Pre- 
immune serum was included in the control reactions. Figure 11.19a shows that the Fli-1 
anti-serum was able to give rise to “supershifted” bands (lanes 6 and 12). Consequently, 
bands B, C, D and F, which either completely disappeared (C and D) or had decreased 
intensity (B and F), corresponded to the genuine Fli-1 :DNA complexes. It is surprising 
that band G, which only appeared with in vitro synthesised Fli-1, was not affected by the 
antibody. It is possible that this band was due to the binding of the Fli oligonucleotide 
with a partially degraded Fli-1 protein which has lost the epitope and therefore can not 
be recognised by the antibody. The “supershif’ effects were due to the specific 
recognition of the Fli-1 antibody and the in vitro synthesised Fli-1 protein because: (1) 
“Supershift” was not detected with the pre-immune (lanes 5 and 11); and (2) The Fli-1 
anti-serum did not give rise to any “supershifted” bands in the control experiments 
where the "mock" translation mix was used (lanes 3 and 9). Taken together, the Fli-1
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antiserum generated in our laboratory can recognise in vitro synthesised Fli-1 protein in 
complexes with E74 or Fli oligonucleotides and give rise to “supershifted” bands in gel 
retardation assays.
To further determine whether the Fli-1 anti-serum can also recognise the Fli-1 protein 
present in the ELM-I/1 nuclear extracts, similar “supershift” assays were performed. In 
vitro synthesised Fli-1 was used in parallel as the positive control. It can be seen in 
Figure 11.19b that the E74 oligonucleotide was able to bind to nuclear protein(s) in both 
ELM-I/1 and 1/2 extracts (lanes 19 and 22). However, the Fli-1 anti-serum gave rise to a 
“supershifted” band only when the ELM-I/1 extracts were used (lanes 21 and 24). The 
“supershift” resulted in a slight decrease in the intensity of band I, indicating that band I 
may represent the Fli-1:E74 complexes. This, together with the fact that ELM-I/1 but 
not 1/2 cells express the Fli-1 protein, indicates that the Fli-1 anti-serum can indeed 
recognise the Fli-1 protein in the ELM-I/1 nuclear extracts. Pre-immune serum did not 
has any effects on the banding patterns (lanes 20 and 23). Similar results were obtained 
with the Fli oligonucleotide (Figure 11.19c). It can be seen that nuclear factor(s) in both 
EM-I/1 and 1/2 extracts were able to bind to the Fli oligonucleotide and gave rise to 
band J (lanes 31 and 34). However, factor(s) in the ELM-I/1 extracts also gave rise to 
an extra band (K) (lane 31), which was “supershifted” when the Fli-1 anti-serum was 
included (lane 33). The anti-serum had no effects on band J with either ELM-I/1 or 1/2 
nuclear extracts (lanes 33 and 36). Although the pre-immune serum gave rise to band L, 
it did not have any effects on the intensity of bands J and K, nor did it cause any 
“supershift” (lanes 32 and 35). Band L may be a result of interaction of the Fli 
oligonucleotide with some non-specific factor(s) in the serum. Thus, the above evidence 
suggests that the “supershift” effects observed was due to the specific interaction 
between the Fli-1 anti-serum and the Fli-1 protein present in ELM-I/1 nuclear extracts. 
Therefore, the Fli-1 anti-serum can not only recognise in vitro synthesised Fli-1 protein 
but also the Fli-1 protein present in ELM-I/1 nuclear extracts in gel retardation analysis, 
and give rise to “supershifted” bands.
Since it was thus established that in vitro synthesised Fli-1 can bind to either E74 or Fli 
oligonucleotides in gel retardation assays, it was interesting to determine if any of the 
FPs can compete with E74 or Fli for Fli-1 binding. As shown in Figure 11.20 that this is 
not the case. In the meanwhile, controls reactions including the Fli-1 antibody were 
performed to reveal the Fli-1 binding to either radiolabelled E74 or Fli, so were self­
competition reactions and cross-competition between E74, mE74 and Fli.
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11.4.5. The Fli-1-specific antiserum does not reveal a direct interaction between Fli-1 
and any of the six FP oligonucleotides.
However, when “supershift” analysis was performed using ELM-I/1 and 1/2 nuclear 
extracts and the six FP oligonucleotides as probes, we were not able to reveal any 
“supershifted” bands (Figure 11.21). This excludes the possibility that the complexes of 
FPs and in vitro synthesised Fli-1 had the same mobility in gel retardation assays as 
those of FPs and some unknown factors in the “mock” reaction mix (see Section 11.4.3, 
in particular, Figure 11.18). The results imply that either the assay conditions are not 
suitable for detecting the interaction between Fli-1 and FPs, or Fli-1 does not bind to 
any of the six FPs (discussed in detail in Section 13.4). If the latter is true, then the 
transactivation of the partial bcl-2 promoter by Fli-1 may be due to some indirect effects 
(discussed in detail in Section 13.4).
11.5. Conclusions.
Transient transfection assays have demonstrated that:
(1) Fli-1 can transactivate a partial bcl-2 promoter in a quail fibroblast cell line and a 
minimum promoter region has been defined;
(2) The Bcl-2 promoter activity is higher in ELM-I/1 cells, which express high levels of 
Fli-1 protein, than that in ELM-I/2 cells, which do not express fli-1 at all.
The attempts to map the Fli-1 activation site(s) within the minimum bcl-2 promoter by 
DNA footprinting, gel retardation and “supershift” analysis have demonstrated that:
(1) Six footprints (FP1-FP6) have been identified within the minimum bcl-2 promoter 
region with ELM-I/1 and 1/2 nuclear extracts, two of which (FP3 and FP6) are different 
between the two cell lines;
(2) Nuclear factors in the ELM-I/1 and 1/2 extracts can bind to all the six foorprints in a 
specific manner as judged by self-competition experiments;
(3) Nuclear factor(s) specifc in ELM-I/1 extracts can bind to the FP3 and FP6 
oligonucleotides and give rise to bands that are not present with ELM-I/2 extracts;
(4) Out of all the ets oligonucleotides (E74, Ets-3, Fli, PEA3 and PU.l) tested, only E74 
can significantly compete with some of the FPs (i.e. FP1, FP2 and FP6) for protein- 
binding. However, this competition may not be relevant as the mutated E74 
oligonucleotide (mE74), in which the Ets-binding site is mutated, can can also compete 
in each case;
(5) None of the FP oligonucleotides can compete with labelled E74 or Fli for protein 
binding either when the ELM nuclear extracts or in vitro synthesised Fli-1 were used;
(6) The E74 and Fli oligonucleotides, but none of the six FPs, can form complexes with 
the in vitro synthesised Fli-1 protein;
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(7) “Supershift” analysis using a Fli-1-specific antibody was not able to reveal the 
binding between Fli-1 and any of the six FPs.
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CHAPTER 12: Correlation of Bcl-2 Up-regulation with 
Differentiation Arrest and Increased Tumourigenicity
12.1. Changes in the bcl-2 expression in ELM cells undergoing erythroid 
differentiation induced by erythropoietin (Epo).
As mentioned in Chapter 5, bcl-2 is the founding member of an expanding family of 
genes that are involved in the regulation of apoptosis in development in vivo and many 
tissue culture systems in vitro (Vaux et al., 1988; Hockenbery et al., 1990). However, 
differentiation, in particular terminal differentiation, and apoptosis have been found to 
be related processes. Furthermore, the expression of bcl-2 family of genes is 
developmentally regulated (Hockenbery et a l, 1991) and is also seen to be altered in 
differentiating cells (Hockenbery et a l,  1991; Gratiot-Deans et a l, 1993; Kozopas et a l , 
1993; Lin et a l, 1993; Merino et a l, 1994; Marthinuss et a l, 1995; Zhang et a l, 1996). 
In light of these, it is intriguing that in ELM-I/1 cells, which are blocked in 
differentiation, the bcl-2 expression is significantly up-regulated (Figure 10.1). It is 
envisaged that dysregulation of the bcl-2 expression may contribute to the 
differentiation arrest in ELM-I/1 cells. As a starting point to address the possible role of 
Bcl-2 in erythroid differentiation, changes in the bcl-2 expression in ELM cells 
undergoing erythroid differentiation were studied.
It has been demonstrated in Chapter 9 that the bcl-2 and a-globin expression increases 
in ELM-D cells upon stroma-withdrawal (Figure 9.6). It is possible that Bcl-2 may be 
directly involved and play a positive role in erythroid differentiation. Alternatively, up- 
regulation of bcl-2 expression may be a response of ELM-D cells to the withdrawal of 
survival and proliferation signals that are normally presented by the stromal cells. In 
order to distinguish these two possibilities in an attempt to address the roles of Bcl-2 in 
erythroid differentiation, ELM-D cells were induced to differentiate with Epo in the 
presence of stromal cells. Furthermore, ELM-I cells were also induced to differentiate 
with Epo and changes in the bcl-2 expression studied.
12.1.1. Changes in the bcl-2 expression in ELM-D cells undergoing Eno-induced 
erythroid differentiation in the presence of stroma.
The ELM-D cells were maintained in the presence of the stroma and grown to sub- 
confluence. They were then trypsinised and 9 volumes of the ELM medium were added 
containing lU/ml of Epo. Cells were harvested at 0, 6h, 1 day and 3 days post-induction. 
By shaking the flasks, ELM-D cells can be separated from the stroma, and it has been 
tested that ELM-D cells isolated in such a way contain negligible number of the stromal
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cells. The cell pellets of ELM-D cells harvested at day 1 and 3 were red, indicating that 
ELM-D cells, when grown in the presence of the stroma, can also differentiate in 
response to Epo. To quantitate this effect and analyse the changes in bcl-2 expression 
during this process, total RNA was extracted and analysed by Northern blotting (see 
Methods and Matierials). The same blot was successively probed with a mouse bcl-2 
cDNA fragment and a-globin genomic fragment. RNA loading was assessed by 
stripping the blot of the radiolabelled probes and reprobing it with a 7s rRNA genomic 
fragment.
It can be seen from Figure 12.1 that, in response to Epo in the presence of stroma, ELM- 
D cells undergo erythroid differentiation, as indicated by an increase in the a-globin 
mRNA,. The increase in the a-globin expression reached approximately 3 fold at day 3 
post-induction. During this process, the bcl-2 mRNA decreased and, at day 3 post­
induction, it was only 10% as the original level.
Although ELM-D cells can undergo erythroid differentiation in response to either 
stroma-withdrawal or Epo-addition in the presence of stromal cells, the molecular 
events were not entirely the same. First of all, it seems that ELM-D cells, in response to 
Epo in the presence of stromal cells, did not differentiate as well as in response to 
stroma-withdrawal. In the former situation, the a-globin mRNA increased to about 3 
fold at day 3 post-induction by Epo (Figure 12.1); while in the latter, the a-globin 
expression increased to about 11 fold at day 3 after stroma-withdrawal (Figure 9.6). This 
confirms the earlier discovery (Chapter 9.5) that the stroma is able to block 
differentiation of the ELM cells, and further indicates that Epo can, to some extent, 
override this blockage. Secondly, the bcl-2 expression underwent a transient increase 
followed by a later decline in ELM-D cells upon stroma-withdrawal (Figure 9.6); while 
the bcl-2 expression decreased in ELM-D cells in response to Epo (Figure 12.1). It is 
possible that the initial increase in bcl-2 expression is a response of ELM-D cells to the 
removal of survival and proliferation signals that are normally provided by the stromal 
cells. This effect can be so dramatic that it masks the decrease in bcl-2 expression 
associated with erythoid differentiation. Alternatively, it is also possible that the 
population of cells with increased bcl-2 expression upon stromal withdrawal was 
distinctive to those that underwent erythroid differentiation and had decreased levels of 
bcl-2 expression. No matter what the explanation is, one thing that seems to be clear is 
that there are multiple cellular events in ELM-D cells upon stroma-withdrawal and the 
molecular changes (e.g. in the bcl-2 expression) observed are a result of the combined 
effects. On the other hand, the cellular events of ELM-D cells in response to Epo are 
much simpler. Finally, as mentioned in Chapter 9.5, the observation that, upon stroma- 
withdrawal, ELM-D cells differentiate much better in 8% than 16% serum, but the 
increase in bcl-2 expression was less in 8% serum (Figure 9.6 and 9.7), also points out
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Figure 12.1. Changes in the a-globin and bcl-2 mRNA expression of ELM-D 
cells in response to erythropoietin (Epo) in the presence of the stroma.
The ELM-D cells were cultured on the stroma in the presence of Epo. At 0, 6h, 
1 day and 3 days post-induction, ELM-D cells were shaken off from the stroma, 
total RNA extracted and analysed in Northern blotting. The figures below the 
lanes are the relative levels of gene expression after calibration with the 7s rRNA 
loading control.
Time after addition of Epo (1 U/ml)
0 3h 6h 1 day 3 day
that the bcl-2 up-regulation may not be associated with erythroid differentiation. 
Therefore, the decrease in bcl-2 expression observed in ELM-D cells in response to Epo 
in the presence of stroma can be regarded as a direct correlation with erythoid 
differentiation.
12.1.2. Changes in the bcl-2 expression in ELM-I cells undergoing Epo-induced 
erythroid differentiation.
Similar induction experiments were carried out in ELM-I cells and gene expression 
studied. In contrast to ELM-I/1 cells, the cell pellets of ELM-I/2 and 1/6 cells harvested 
at day 3 post-induction were red, indicating that ELM-I/2 and 1/6 but not 1/1 cells 
differentiate in response to Epo. To quantitate this effect and analyse the changes in bcl- 
2 expression during this process, total RNA was extracted and analysed by Northern 
blotting as described above (see Section 12.1.1).
Figure 12.2 (a and b) shows that, in response to Epo, both ELM-I/2 and 1/6 cells 
displayed an increase in the a-globin expression, which occurred as early as 6h post­
induction. In the meanwhile, the bcl-2 expression underwent a transient decrease 
followed by a later increase. The later increase in bcl-2 expression occurred at day 2 
post-induction, presumably at a time when the cells had underwent full differentiation. 
On the contrary, ELM-I/1 cells did not differentiate in response to Epo as indicated by 
the lack of increase in the a-globin expression (Figure 12.2c). Moreover, the bcl-2 
expression did not change at all during the period of experiment.
The above evidence suggests that there seems to be a correlation between the changes in 
the bcl-2 expression and erythroid differentiation. Quantative changes in the expression 
of bcl-2 and related genes have also been reported in other differentiation systems 
(Hockenbery et a l , 1991; Gratiot-Deans et al., 1993; Kozopas et al., 1993; Lin et al., 
1993; Merino et al., 1994; Marthinuss et al., 1995; Zhang et al., 1996) and have been 
suggested to be necessary for cell differentiation. In ELM cells, it is possible that the 
early decrease in bcl-2 expression is necessary for the cells to initiate differentiation 
program, in which case a constitutive up-regulation of the bcl-2 expression, as seen in 
ELM-I/1 cells, may be responsible for differentiation arrest. Alternatively, changes in 
the bcl-2 expression may be just a consequence of differentiation.
It is intriguing that, in ELM-D cells undergoing Epo-induced erythroid differentiation in 
the presence of stroma, the decrease in bcl-2 expression was not followed by a later 
increase as observed with ELM-I/2 and 1/6 cells. It is possible that the stromal cells may 
be able to block the increase in bcl-2 expression. This hypothesis is consistent with that
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fact that, upon stroma-withdrawal, there was an increase in the bcl-2 expression in 
ELM-D cells.
In summary, the bcl-2 expression is decreased in ELM-D cells undergoing Epo-induced 
erythroid differentiation in the presence of the stroma. On the other hand, in the 
differentiating ELM-I/2 and 1/6 cells in response to Epo, the bcl-2 expression undergoes 
an early decline followed by a later increase. The bcl-2 expression in ELM-I/1 cells, 
which express high levels of bcl-2 and are blocked in differentiation, is not affected by 
the presence of Epo.
12.2. Bcl-2 up-regulation and differentiation arrest in ELM-I cells.
In order to test whether the early decline in bcl-2 expression in differentiating ELM cells 
is necessary and if constitutive up-regulation of bcl-2 is responsible for differentiation 
arrest in ELM-I/1 cells, the bcl-2 expression vector, pSFFV(neo-bcl-2), was stably 
transfected into ELM-I/2 and 1/6 cells which do not express high level of bcl-2. The 
vector contains the full length cDNA of bcl-2 and the neomycin-resistant gene driven by 
the promoter in the LTR of spleen focus-forming virus (SFFV), and has been reported to 
achieve high levels of bcl-2 expression when transfected into cells (Bissonnette et al., 
1992). The control vector, pSSFV(«eo), was used in parallel as a control for any 
artefacts that can be caused by transfection and the subsequent drug selection. 
Transfection was carried out by electroporation and neomycin-resistant clones were 
isolated (see Methods and Materials).
The efficiency of stable transfection (EST) can be calculated as the number of clones 
obtained in drug selection divided by the total number of cells seeded. The EST can be 
used not only as a measure of the transfection efficiency, but also as a way to detect any 
growth advantages or disadvantages of the cells caused by introducing the transgene. 
The EST of ELM-I/2 and 1/6 cells when using the vectors pSSFV(neo) or pSSFV(«eo- 
bcl-2) is shown in Table 12.1. It can be seen that there is no dramatic difference in the 
EST when using pSSFV(weo) and pSSFV(neo-bcl-2), and this is the case for both ELM- 
I/2 and 1/6 cells, indicating that over-expression of bcl-2 does not confer any growth 
advantages or disadvantages to the cells.
Table 12.1. Comparison of the efficiency of stable transfection of ELM-I/2 and 1/6 cells 
when using either pSSFV(«eo) or pSSFV(neo-bcl-2). The figures are results of three 
independent experiments. ________________________ _________________________
pSSFV(«eo) pS SFV (neo-bcl-2)
ELM-I/2 0.45% 0.31%
ELM-I/6 0.05% 0.02%
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The expression of the bcl-2 transgene at the mRNA and protein levels in individual 
clones was analysed by Northern and Western blotting analysis, respectively (see 
Methods and Materials). It can be seen from Figure 12.3 and 12.4 that high levels of bcl- 
2 expression was achieved in ELM-I/6 and 1/2 transfectants at both mRNA and protein 
levels. The top two bands on the Northern blots (Figure 12.3a and 12.4a) reflect the two 
isoforms of endogenous bcl-2 mRNA, which are 7.5kb and 2.4kb, respectively. The 
band below is the exogenously expressed bcl-2 mRNA. It can be seen that the level of 
exogenous bcl-2 mRNA was expressed at a much higher level than that of the 
endogenous transcripts, and this was consistent with the expression of Bcl-2 protein. 
Figure 12.3b and 12.4b shows that the clones that expressed exogenous bcl-2 mRNA 
also expressed the Bcl-2 protein at a level much higher than that in ELM-I/1 cells. The 
Bcl-2 protein in the untransfected ELM-I/6 and 1/2 cells was not readily detectable using 
this antibody, and those clones that did not express exogenous bcl-2 mRNA did not 
express Bcl-2 protein at a detectable level, as seen in the parental cells.
Clones that express high levels of exogenous Bcl-2 protein were used in the
differentiation induction experiments to see whether constitutive up-regulation of bcl-2 
is sufficient to induce differentiation arrest. Clones that did not express exogenous bcl-2 
at neither mRNA nor protein levels were used in parallel as controls. Cells were treated 
with lU/ml of Epo and harvested at day 3 post-induction for analysis of a-globin 
mRNA induction as described previously (see Section 12.1.1). It can be seen from 
Figure 12.5 (a and b) that all clones, apart from one (i.e. 6C2), were still able to 
differentiate in response to Epo, as indicated by a significant increase in the a-globin 
mRNA expression. Although there was variation between clones in their differentiation 
capacity, with some clones having higher a-globin induction than the others, this 
variation showed no correlation with the level of bcl-2 expression.
It can be concluded that the decline in bcl-2 expression is not necessary for erythroid
differentiation, and constitutive up-regulation of the bcl-2 expression on its own is not 
sufficient to block differentiation in ELM-I/2 and 1/6 cells and thus cannot explain the 
differentiation arrest in El cells. If Bcl-2 is involved in differentiation arrest in ELM-E1 
cells at all, other co-factors are required (discussed in detail in Section 13.3.1).
12.3. Bcl-2 up-regulation and increased tumorigenicity of ELM-I cells.
It has been noted that the original ELM tumour can be passaged in vivo and that both 
ELM-D and ELM-E1 cells are tumorigenic (Itoh et al., 1988). However, ELM-E1 cells, 
which have constitutive up-regulation of Jli-1 and bcl-2 expression, display the highest 
tumorigenicity in the ELM system (Nibbs et a/., 1993). In order to test whether
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Figure 12.3. Screening of the stably transfected ELM-I/6 clones that express high levels 
of exogenous bcl-2 at both mRNA and protein levels by Northern (a) and Western (b) 
blotting analysis.
The bcl-2 expression vector, pSSFV(neo-bcl-2), was used to generate stably transfected 
ELM-L/6 clones that expressed high levels of bcl-2. The control vector, pSSFV(rt^>), 
was used in parallel as a control for any artefacts that can be caused by transfection and 
the subsequent drug selection. The endogenous (endo.) and exogenous (exo.) bcl-2 
transcripts are indicated by arrows in (a). In Western blotting analysis of Bcl-2 protein 
expression (b), total protein extracts from a myeloid cell line, Ml, was used as a 
positive control for the bcl-2 antibody.
Clones transfected with pSSF\ {neo-bcl-2): 6B2, 6B3, 6B4, 6B5, 6B7, 6B10, 6B16
and 6 B 18
Clones transfected with pSSF\{neo): 6C2, 6C12, 6C13 and 6C14
(a) Northern blotting
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Figure 12.4. Screening of the stably transfected ELM-I/2 clones that express high levels 
o f exogenous bcl-2 at both mRNA and protein levels by Northern (a) and Western (b) 
blotting analysis.
The bcl-2 expression vector, pSSFV(neo-bcl-2), was used to generate stably transfected 
ELM-I/2 clones that expressed high levels of bcl-2. The control vector, pSSFV{neo), 
was used in parallel as a control for any artefacts that can be caused by transfection and 
the subsequent drug selection. The endogenous (endo.) and exogenous (exo.) bcl-2 
transcripts are indicated by arrows in (a).
Clones transfected with pSSF\(neo-bcl-2): 2B1, 2B3, 2B4, 2B5, 2B6, 2B7, 2B8, 2B9 
2B10, 2B11, 2B13, 2B14, 2B16, 2B18, 2B19, 2B21, 2B22, 2B23, 2B25, and 2B26 
Clones transfected with pSSFY(neo): 2C1, 2C3, 2C5, 2C6, 2C8 and 2C9
(a) Northern blotting
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Figure 12.5. Differentiation capability of the stably transfected ELM-I/6 (a) and 1/2 (b) 
clones that constitutively express high levels of exogenous Bcl-2 protein. The transfec- 
tants were cultured in the presence of Epo, harvested at day 3 post-induction, total RNA 
extracted and analysed by Northern blotting.
(a) ELM-I/6 transfectants
Clones 1/6
Exogenous 
Bcl-2 expression 
Epo (1 U/rnl)
a-globin
6C2 6B2
+
6B3
+
6B18
+
6B5
+
- + + + + + +
mm mm mm m • • •
Clones 6C12 6C13 6C14 6B7 6B10 6B16
Exogenous 
Bcl-2 expression
Epo (1 U/ml) + + - + + - + +
a-globin m m * *  • m
7s rRNA
(b) ELM-I/2 transfectants
Clones 1/2 2C3 2B6 2B1 2B4 2B9 2B10 2B4
Exogenous 
Bcl-2 expression 
Epo (1 U /m l) 
a-globin
7s rRNA
Clones 1/2 2B11 2B19 2B26 2B14 2B21 2B25
Exogenous 
Bcl-2 expression 
Epo (1 U/ml)
a-globin
7s rRNA m «•
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constitutive up-regulation of bcl-2 expression is sufficient to induce increased 
tumorgenicity in ELM cells, ELM-I/2 and 1/6 cells that had been stably transfected with 
the bcl-2 expression vector and expressed high levels of the Bcl-2 protein were used in 
tumorgenicity assays in vivo. Clones that had been transfected with the control vector, or 
do not express exogenous bcl-2 mRNA were used as controls. Un-transfected ELM-I/1, 
1/2 and 1-6 cells were also used in parallel for comparison. In the in vivo tumorgenicity 
assays, 10 viable cells were injected via the tail vein into syngeneic C3H mice that had 
been immuno-suppressed by irradiation with 300 Rads of y-rays. The viability of cells 
injected was checked by the trypan blue exclusion assay (see Methods and Materials) so 
that the same number of viable cells were used. 4-5 clones were selected from each 
transfection and separately injected into groups of 9 mice. Mice were sacrificed at 26-30 
days post-injection, when their spleens were weighed as a measure of leukaemogenicity. 
Mice injected with the bcl-2 transfectants were sacrificed at the same time as the 
equivalent controls.
Figure 12.6a and 12.6b show the weight of spleens from mice injected with transfectant 
clones isolated from ELM-I/2 and 1/6 cells, respectively, as a measure of the 
tumorigenicity of individual clones, and Figure 12.6c shows the average spleen weight 
as a result of 4-5 clones tested. It can be seen that, although there is variations among 
the tumorigenicity of individual clones, ectopic expression of high levels of bcl-2 do not 
confer increased tumorigenicity in vivo in those cells.
12.4. Conclusions
In summary, even though changes in the bcl-2 expression are associated with erythroid 
differentiation, they are not absolutely necessary. In addition, constitutive up-regulation 
of bcl-2 is not sufficient to induce differentiation arrest or increased tumorigenicity in 
ELM-I/2 and 1/6 cells.
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Figure 12.6. Tumorigenicity of the stably transfected ELM-I/2 (a) and 1/6 (b) clones 
that constitutively express high levels of exogenous Bcl-2 protein.
Tumorigenicity of the stably transfected ELM-I/2 (a) and ELM-I/6 (b) clones was 
measured by the weights of spleens from mice sacrificed 26-30 days after injection 
with these cells. Tumorigenicity of un-transfected ELM-I/2 and 1/6 cells is also 
included. Presence (+) or absence (-) of exogenous bcl-2 expression in each clone is 
indicated.The average spleen weights as a result of 4-5 clones tested are shown in (c). 
"1/2 controls" and "116 controls" represent ELM-I/2 and ELM-I/6 clones that are either 
stably transfected with the bcl-2 expression vector but do not express exogenous 
bcl-2, or stably transfected with the empty vector. "1/2 +bcl-2" and "\16+bcl-2" 
represent ELM-I/2 and 1/6 clones stably transfected with bcl-2 expression vector and 
express high levels of exogenous bcl-2 (see Figure 12.3 and 12.4).
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CHAPTER 13: Discussion and Future Prospects
13.1. The ELM system as a model for the study of erythropoiesis.
The ELM erythroleukaemia is a very attractive model system to investigate 
erythropoiesis and erythroleukaemia for the following reasons. First of all, its origin 
appears to be unique as it was reportedly induced with X-ray irradiation, which usually 
generates leukaemias derived from other blood cell lineages. Secondly, both the primary 
tumour and the cell line (ELM-D) subsequently derived are strictly dependent on direct 
contact with a bone marrow-derived stromal cell layer for long-term growth and survival 
(Itoh et al., 1988b). Thirdly, ELM-D cells and all the stroma-independent variants apart 
from one (ELM-I/1) are still able to undergo erythroid differentiation in response to 
physiological inducers, such as Epo and IL-3. Thus, in contrast to various retrovirally- 
induced erythroleukaemias, the ELM cells appear to be much less advanced in terms of 
their loss of normal erythroid progenitor characteristics. Therefore, the ELM system 
provides a more "normal'' model system for studying the stromal control of 
erythropoiesis. Identifying the growth factors and other regulatory molecules produced 
by the stroma, and defining their roles in supporting the growth of ELM-D cells, have 
obvious implications in our understanding of the control of normal and malignant 
erythropoiesis and the nature of cellular interactions involved. Furthermore, the fact that 
the various ELM cell lines (ELM-D, 1/1, 1/2, 1/5 and 1/6) have different properties in 
their stroma-dependence, differentiation capacity and tumorigenicity also provides a 
unique opportunity to identify genetic alterations responsible for generating these 
different phenotypes (also see Section 13.3). This should give an insight into the nature 
of intracellular signalling pathways and further our knowledge of the molecular 
mechanisms of erythropoiesis and leukaemia progression.
By utilising the ELM system, it was demonstrated that a bone marrow-derived stroma 
pre-adipocyte cell line is able to support the long-term growth and survival of erythroid 
progenitor cells, and allow erythroid differentiation in response to growth factors. This 
implies that, although bone marrow is not a major erythropoietic organ in mice, its 
stromal cells can support erythropoiesis in vitro (also see below). This conclusion is 
consistent with the studies using the Dexter type long-term bone marrow cultures 
(LTBMCs), which are murine bone marrow primary cultures and contain several cell 
types including fibroblasts, pre-adipocytes, adipocytes, endothelial cells, osteogenic 
cells and macrophages (reviewed by Quesenberry, 1992). It has been demonstrated that, 
apart from supporting differentiation along myeloid pathways, LTBMCs can also 
support erythropoiesis (Humphries et a l, 1979), especially by the addition of Epo 
(Eliason et a l, 1979) or the transfection of the Epo cDNA to the marrow stromal cells
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(Corey et al., 1990). Although LTBMCs reconstitute a haemopoietic microenvironment 
that is a close approximation of the situation in vivo, their heterogeneity unavoidably 
brings about a high level of complexity and has hindered a detailed analysis of the 
molecular nature of cellular interactions. This has led to the studies, such as ours, which 
establish bone marrow cell lines from LTBMCs that can support haemopoiesis in vitro. 
However, studies using cloned stromal cell lines have the obvious drawbacks since 
immortalised or transformed cells are used and, moreover, haemopoiesis is analysed 
under circumstances where progenitor cells are interacting with only one type of stroma 
cells. Nevertheless, a more complete picture is likely to emerge when the two strategies 
are combined.
The significance of the ELM system as a model system for studying the stromal control 
of erythropoiesis is further reinforced by the research carried out in Dr. M. Obinata’s 
laboratory. They demonstrated that stromal endothelial (Yanai et al., 1989; Yanai et a l, 
1991) and epithelial-like cell lines (Ohneda et al., 1990) derived from mouse spleen and 
foetal liver, respectively, are able to support large erythroid colony formation and mimic 
erythropoiesis in vivo. Furthermore, various lines of evidence showed that this kind of in 
vitro microenvironment seems to be created by direct contact and/or short range 
communication between erythroid progenitor cells and the stromal cell layer (see 
Section 2.1). This is exactly reminiscent of how the bone marrow-derived stromal cell 
line supports the long-term growth and survival of ELM-D cells. An intriguing question 
is whether or not stromal cells in bone marrow, spleen and foetal liver can all support 
and regulate erythropoiesis in vivo and, if so, whether they utilise similar cellular and 
molecular mechanisms. It is worthwhile noting that cultured stromal cells seem to have 
lost organ specificity. This is exemplified by the long-term culture for T-cell precursors 
in that the stromal cell clone used to initiate the cultures could be either bone marrow- 
or thymus-derived (Zipori and Tamir, 1989). The ability to support precursor T-cell 
growth is therefore not a property exclusive to the thymic stromal cells. Similarly, the 
ability to support the stem cell growth and long-term myelopoiesis was exhibited not 
only by endothelial-adipocytes from mouse bone marrow but also by a clone of thymic 
stromal cells (Zipori and Tamir, 1989). Two potential explanations may be considered: 
it is possible that following culture in vitro, stromal cells lose their organ specificities; 
alternatively it is also possible that a variety of stromal cell types exist, each present in 
all organs but at different frequencies.
Finally, it should be emphasised that any conclusions derived from in vitro studies may 
not be valid when extrapolating to the situations in vivo. Therefore, it is very important 
that studies of the ELM system are complemented with in vivo experiments. This can be 
carried out by the use of congenitally anaemic mutant mouse strains with inherited
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environment deficiencies, in vivo administration of antibodies and the transgenic 
approaches.
13.2. Stromal control of the long-term growth of ELM-D cells.
It has been demonstrated in Chapter 9 that, upon stroma-withdrawal, ELM-D cells 
undergo terminal erythroid differentiation. Moreover, although ELM-D cells grown on 
the stroma can differentiate in response to Epo, the extent of differentiation is a lot less 
than that occurs when the stromal cells are removed (see Section 9.5 and Section 
12.1.1). This implies that the stromal cells can block differentiation of ELM-D cells, 
which, to a small extent, can be overridden by Epo, and at least one mechanism whereby 
the stroma maintains the long-term growth of ELM-D cells is to prevent them from 
further maturation. Consistent with our finding, Weber and Tykocinski (1994) also 
demonstrated that a bone marrow-derived fibroblastic cell line can block leukaemic cell 
differentiation. A role of stroma in inhibiting differentiation may have its physiological 
significance in vivo. It may be a mechanism whereby haemopoietic cells in circulation 
are tightly controlled so that only cells leaving the bone marrow in response to 
appropriate cues can survive and proliferate, whereas those getting into circulation 
“accidentally” due to loss of adhesion to the stroma, would terminally differentiate and 
die, and therefore would not expand abnormally. On the other hand, those that are 
induced to differentiate in order to perform certain specific functions may also receive 
cues to leave the bone marrow and get into circulation where they can differentiate 
better and are positioned within appropriate tissues.
It would be interesting to identify the molecules involved in differentiation blockage by 
the MS-5 stromal cells. As discussed in Section 6.2, the stroma-dependence of ELM-D 
cells strictly requires direct cell-cell contact, suggesting the involvement of cell 
membrane and adhesion molecules. Indeed, several lines of evidence indicate that the 
interaction between the transmembrane form of stem cell factor (mSCF) and its 
receptor, c-Kit, is important in maintaining the long-term growth of ELM-D cells. 
Antibodies against either SCF or c-Kit do not affect adhesion between ELM-D and the 
stroma, whereas they significantly reduce the growth of ELM-D cells on stroma by 
greater than 60% relative to the untreated controls (J. O’Prey and Prof. W. Ostertag, 
personal communication). Moreover, mutant S l/S f  stromal cells that produce only the 
soluble form of SCF (Flanagan et a l, 1991) are able to support transient but not long­
term growth of ELM-D cells (Prof. W. Ostertag, personal communication). The role of 
SCF/c-Kit interaction in inhibiting differentiation is further highlighted by the fact that, 
in the ELM-I/1 cells which are blocked in erythroid differentiation, the c-Kit receptor is 
constitutively phosphorylated and activated (Dr. N. Leslie, personal communication, 
also see Section 13.3.4). It would be interesting to see whether over-expression of this
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mutated c-Kit in ELM-D cells can prevent them from differenting in the absence of 
stroma and confer stroma-independent growth. However, the fact that all the other 
stroma-independent variants (ELM-I/2, 1/5 and 1/6) do not contain constitutively 
activated c-Kit suggests that, even if constitutive activation of c-Kit is involved in 
stroma-independent growth, other mechanism(s) also exist.
The hypothesis that the stromal cells maintain the long-term growth of ELM-D cells by 
preventing them from further maturation does not exclude the possibility that the 
stromal cells also provide survival and proliferation signals. Indeed, a block in 
differentiation in ELM-D cells in the absence of stroma may not be sufficient for their 
survival and proliferation. It is likely that a combination of mechanisms are at play in 
coffering stroma-independent growth.
Other molecules that are also involved in the maintenance of long-term growth of ELM- 
D cells by the stroma are insulin growth factor-1 (IGF-1) and integrin a l .  Neutralising 
antibody against IGF-1 reduces the long-term growth of ELM-D cells on the stroma by 
50%, and so does blocking antibody against integrin a l ,  although to a less degree (J. 
O’Prey, personal communication). Furthermore, when both antibodies against c-Kit and 
IGF-1 are applied, the growth of ELM-D cells on the stroma is completely abolished, 
suggesting that interactions of SCF and IGF-1 with their respective receptors contribute 
to the majority of the stromal cell activity in maintaining the long-term growth of ELM- 
D cells.
13.3. Genetic characterisation and functional analysis of the ELM system.
As mentioned above, the various ELM cell lines differ in stroma-dependence, 
differentiation potential and tumorigenicity and thus provide us a unique opportunity to 
identify genetic events involved in generating these different phenotypes. Indeed, it has 
been demonstrated that different ELM cell lines have different gene expression profiles 
(see Chapter 10).
13.3.1. fli-1 and bcl-2.
Most significantly, it was found that expression of bcl-2 and fli-1 at both mRNA and 
protein levels is largely elevated in one of the stroma-independent variants, ELM-I/1, 
which is the only clone that is blocked in erythroid differentiation in response to various 
inducers and also displays the highest tumorigenicity. When the changes in bcl-2 
expression in differentiating ELM cells were studied (see Section 12.1), it was found 
that, in ELM-D cells undergoing Epo-induced erythroid differentiation in the presence 
of stromal cells, the expression of bcl-2 mRNA is stably decreased. Furthermore, in
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response to Epo, the differentiation of ELM-I/2 and 1/6 cells is also accompanied by an 
early decline in the bcl-2 mRNA expression, which is followed by a later increase. In 
contrast, the expression of bcl-2 mRNA in ELM-I/1 cells is not affected by Epo. This, 
together with the quantitative changes of bcl-2 expression during cell differentiation 
observed in other laboratories (Hockenbery et al., 1991; Gratiot-Deans et al., 1993; 
Merino et al., 1994; Marthinuss et al., 1995; Zhang et al., 1996), prompted us to address 
a role of Bcl-2 in erythroid differentiation. It was proposed that a decline in the bcl-2 
expression is necessary for ELM cells to undergo erythroid differentiation, and therefore 
in ELM-I/1 cells, where the bcl-2 expression is constitutively elevated, the 
differentiation program is blocked. Then the question is: is bcl-2 up-regulation the only 
factor responsible for the differentiation arrest in ELM-I/1 cells? In another words, is 
bcl-2 up-regulation sufficient to induce differentiation arrest in ELM-I cells? In order to 
test this, a bcl-2 expression vector was transfected into ELM-I/2 and 1/6 cells, and stably 
transfected clones selected. However, clones that ecotopically express high levels of bcl- 
2 are still able to differentiate in response to Epo (see Section 12.2), and do not display 
significantly elevated tumorigenicity in vivo (see Section 12.3). This implies that either 
Bcl-2 is not involved in inducing differentiation arrest and increased tumorigenicity, or 
that over-expression of bcl-2 on its own is not sufficient. The latter possibility may 
exemplify the requirement for oncogene co-operation in tumorigenesis. Indeed, bcl-2 
was one of the first oncogenes where this requirement was documented on the basis of 
the fact that cross-breeding bcl-2 and c-myc transgenic mice induces a rapidly emerging 
undifferentiated haemopoietic leukaemia (Strasser et a l , 1990).
The possibility that Bcl-2 requires other co-factors to generate the full phenotype in 
ELM-I/1 cells is further supported by the fact that fli-1, like bcl-2, is over-expressed in 
ELM-I/1 cells, and the finding that the Fli-1 protein can transactivate the bcl-2 promoter 
and may well be directly responsible for the increased expression of bcl-2 in ELM-I/1 
cells. As a member of a family of multi-functional transcription factors, it is most likely 
that Fli-1 has a number of target genes and its activation in ELM-I/1 cells may alter the 
expression of several other genes apart from bcl-2. It is anticipated that, to achieve the 
full phenotype of the ELM-I/1 variant, multiple genetic changes are required. It would 
be interesting to see if over-expression of fli-1 in ELM-I/2, 5 and 6 cells can induce 
differentiation arrest and increased tumorigenicity, which is an ongoing project being 
carried out by Dr. C. Bartholomew in our laboratory. Conversely, it would also be 
worthwhile to perform expression- or functional “knockout” experiments of bcl-2 or fli- 
1 in ELM-I/1 cells, and see whether or not the phenotypes are somewhat reversed. This 
can be carried out either by an antisense approach or, in the case of fli-1, by over­
expressing the cDNA of a fli-1 dominant negative mutant which consists of the DNA- 
binding domain only and can act as a competitive inhibitor of the normal protein (see 
Section 11.1.1). This kind of “knockout” approaches can be more informative because if
155
several factors are necessary to generate a phenotype then eliminating any one of them 
at a time is likely to see a partial reversion.
In search of other factors that may be responsible for the differentiation arrest and 
increased tumorigenicity in ELM-I/1 cells, c-myc and c-myb are of particular interest. C- 
myc and c-myb are proto-oncogenes that play an important role in regulating cell 
proliferation, differentiation and apoptosis. As mentioned above, bcl-2 and c-myc 
display potent synergy in tumour development in transgenic mice. Furthermore, it has 
been well documented that the expression of c-myc and c-myb mRNA shows a rapid 
biphasic change in murine erythroleukaemia cells (MEL) induced to differentiate, and 
constitutive expression of either of them results in differentiation arrest (Dmitrovsky et 
al., 1986; Clarke et al., 1988). Moreover, the Ets proteins have been implicated in 
transcriptional regulation of the c-myc expression (Roussel et al., 1994). In addition, c- 
myb can co-operate with the Ets proteins in transcriptional activation (see Section 4.1.2). 
It has been reported that c-Ets-2 does not activate the mim-1 promoter unless c-Myb is 
also present (Dudek et al., 1992). Furthermore, c-Myb can synergise with either c-Ets-1 
or c-Ets-2 to transactivate the promoter of an early myeloid gene (Shapiro, 1995). This 
co-operation between c-Myb and the Ets proteins is of particular interest in light of the 
fact that v-Myb can also transactivate the bcl-2 promoter, and over-expression of v-Myb 
leads to an up-regulation of the bcl-2 mRNA (Frampton et al., 1996). It would be 
interesting to see whether c-Myb and Fli-1 co-operate in up-regulating the bcl-2 
expression in ELM-I/1 cells.
13.3.2. ere.
As mentioned in Section 10.1, the stroma-independent variants (ELM-I/1, 1/2, 1/5 and 
1/6) express an increased level of erg mRNA in comparison to their stroma-dependent 
parent (ELM-D) (also see Nibbs et al., 1993). Furthermore, it has also been reported by 
Nibbs et a l (1993) that, upon stroma-withdrawal, the expression of erg mRNA in ELM- 
D cells is elevated. Therefore , it was postulated that erg up-regulation is associated with 
the stroma-independent growth and this is made permanent in ELM-I cells. However, 
preliminary studies of the expression of Erg protein using an anti-human Erg antibody 
demonstrated that the Erg protein is only readily detectable in ELM-I/1 cells. Based on 
this finding, the significance of the different levels of erg mRNA expression between 
ELM-D and ELM-I cells, and the up-regulation of erg mRNA in ELM-D cells upon 
stroma-withdrawal, becomes uncertain. Since it is very important to verily the 
expression of Erg protein in ELM cells, it may be worthwhile to check the expression of 
Erg protein using another Erg antibody. If our finding is confirmed, then it would be 
interesting to see whether, like Fli-1, Erg can up-regulate bcl-2, or whether Erg is 
responsible for the differentiation arrest and increased tumorigenicity in ELM-I/1 cells.
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On the other hand, if the expression of erg at the protein level is consistent with that at 
the mRNA level, then functional studies are desired to address a role of Erg in confering 
stroma-independent growth. This can be carried out by over-expressing erg in ELM-D 
cells to see if this can induce stroma-independent growth. Alternatively, an antisense 
approach or the approach involving dominant negative mutants of erg can be applied in 
ELM-I cells to see whether “knocking out” erg expression or functions can reverse these 
cells to become stroma-dependent.
13.3.3. sata-1 and scl/tal-l.
In addition to fli-1 and bcl-2 activation, a number of other genetic changes has also been 
identified in ELM-I/1 cells. Two transcription factors that are positive regulators of 
erythropoiesis, gata-1 and scl/tal-l (hereafter called scl), are expressed at an elevated 
level according to Northern blotting analysis (see Section 10.1). In order to pursue this 
further, it would first be essential to see if the expression of GATA-1 and SCL proteins is 
also significantly increased. If this is the case, it would appear paradoxical since ELM- 
I/1 cells are blocked in erythroid differentiation and the logical expectation would be 
that they lack certain positive regulators. However, it has been documented that ecotopic 
expression of scl in late myeloid progenitors and early leukaemic precursors induces a 
proliferative stimulus under sub-optimal culture conditions via an anti-apoptotic effect 
or stimulation of DNA synthesis, and these effects are accompanied by a marked 
inhibitory effect on differentiation (Condorelli et a l , 1997). It is well known that the 
specific effect of a multi-functional protein such as SCL is largely dependent upon a 
particular cellular context. Therefore, whether SCL promotes or inhibits erythroid 
differentiation in the ELM cells may also depend on other factors present. Moreover, the 
potential role of SCL in promoting proliferation may also underlie the molecular 
mechanisms responsible for the increased tumorigenicity associated with this particular 
cell line.
In addition, it is also possible that ELM-I/1 cells may express mutant forms of gata-1 or 
scl. The mutation could result in the expression of aberrant proteins that are defective in 
DNA-binding or transcriptional activity. Alternatively, the mutation could also cause a 
defect in post-translational regulation of the protein, in particular, by phosphorylation in 
response to differentiation inducers. It has been reported that both GATA-1 and SCL can 
be phosphorylated by differentiation inducers, such as DMSO and Epo (Crossley and 
Orkin, 1994; Prasad et a l , 1995). Such induced phosphorylation may trigger functional 
activation of the proteins as transcription factors and the subsequent involvement in 
erythroid differentiation. Finally , it is also important to determine the expression in 
ELM-I/1 cells of any of the co-factors that are known to interact with GATA-1 or SCL 
and work in conjunction to regulate erythropoiesis. It has been mentioned in Section 2.2
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that direct protein-protein interactions largely dictate the functional activity of GATA-1 
and SCL. In the case of SCL, it would be interesting to see if LMO-2 and Id  proteins are 
involved in the regulation of erythroid differentiation of ELM cells.
13.3.4. c-kit.
In parallel to the genetic characterisation work presented in this thesis, Dr. N. Leslie in 
our laboratory has also identified mutations in c-kit, which encodes the receptor for stem 
cell factor (SCF), in ELM-I/1 cells, but not in any other of the ELM cell lines. Although 
c-kit is expressed at a similar level in all the ELM cells tested (ELM-D, 1/1,1/2,1/5 and 
1/6), only the c-Kit protein in ELM-I/1 exhibits constitutive phosphorylation in the 
absence of growth stimuli. Under normal circumstances, phosphorylation of the c-Kit 
protein is induced by ligand-binding by SCF, which results in activation of the protein 
and subsequently initiates a series of signalling pathways leading towards promoting 
cell survival and proliferation. In light of that, it would be interesting to see whether 
certain target molecules downstream of c-Kit are also constitutively activated. It is 
anticipated that, as a result of constitutive activation of c-Kit, ELM-I/1 cells may reside 
in a hyper-proliferative status, which may be obstacle for differentiation. In order to test 
this, the mutant c-kit derived from ELM-I/1 cells has been over-expressed in other 
ELM-I cells to see whether or not this will induce differentiation arrest and increased 
tumorigenicity. This would be interesting in light of the fact that activation of the c-Kit 
signalling pathway has been implied as a necessary event in erythroleukaemia induction 
(Ben-David and Bernstein, 1991; also see Section 3.2.3).
13.4. Molecular mechanisms of transactivation of the bcl-2 promoter by Fli-1.
As mentioned above, ELM-I/1 cells display significantly elevated expression offli-1 and 
bcl-2 at both mRNA and protein levels. This, together with the fact that an important 
regulatory element (NRE) in the bcl-2 promoter contains multiple potential ^ -b in d in g  
sites (EBS) (see Figure 5.1), suggested that it might be worthwhile to determine whether 
Fli-1 can transactivate the bcl-2 promoter and is responsible for the up-regulation of bcl- 
2 expression in this particular cell line. As demonstrated in Chapter 11, Fli-1, but not 
its truncated mutant (DMN2), can transactivate a partial bcl-2 promoter in a quail 
fibroblast cell line, Q2BN. Moreover, when the bcl-2 promoter reporter construct was 
transfected into ELM-I/1 and 1/2 cells, it displayed higher activity in the former, in 
which endogenous fli-1 expression is significantly activated, than in the latter, which do 
not express fli-1 at all. DNase I footprinting analysis of a minimum bcl-2 promoter 
fragment has identified six footprints, four of which (FP2, 3, 4 and 6) contain potential 
EBS, and FP6 shows different footprinting pattern between the ELM-I/1 and 1/2 nuclear 
extracts. When oligonucleotides from the footprinted regions were analysed in gel
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retardation assays, it was found that FP3 and FP6 show differential binding to the ELM- 
I/1 nuclear extracts compared to the ELM-I/2 extracts. Although all the FP 
oligonucleotides seem to bind to the extracts specifically as judged by self-competition 
experiments, none of them can be competed significantly with oligonucleotides 
containing binding sites for known Ets proteins, including E74, Ets-3, Fli, PEA3 and 
PU.l. Finally, “supershift” analysis using Fli-1-specific antibody was not able to reveal 
the binding between Fli-1 and any of the six FPs.
There are several possibilities why gel retardation and “supershift” analysis did not 
reveal a direct interaction between Fli-1 and the six FP oligonucleotides. First, it is 
possible that Fli-1 can interact with the FP oligonucleotides, and this interaction results 
in a conformational change in the protein that masks the epitope which would normally 
bind to the Fli-1 antibody. To test this possibility, a panel of Fli-1-specific antibodies 
can be raised against various regions of the protein, and see whether any of them would 
have an effect on Fli-1-binding to the six FP oligonucleotides.
Secondly, it is possible that the Fli-1 antibody can recognise and bind to Fli-1 in a 
proteimDNA complex, but this interaction does not survive in the gel electrophoresis 
conditions used and the antibody is thus released, whereas Fli-1 remains in the complex. 
This possibility can be tested by using the biotinylated oligonucleotide capture approach 
developed by Dr. B. Ozanne in the institute, in which oligonucleotides are contemerised 
and bound to beads which are then incubated with nuclear extracts. Following 
centrifugation, the unbound fraction is removed, the proteimDNA complex recovered 
from the beads and subject to Western blotting analysis.
A third possibility is that binding of Fli-1 requires flanking sequences outside the actual 
footprinted regions. It should be bom in mind that that DNA secondary structure is 
important not only for protein recognition and binding but also for the stabilisation of 
the proteimDNA complex. Analysing short stretches of DNA sequence unavoidably 
destroys this structure. This hypothesis is supported by the evidence that adjacent FPs 
tend to compete with one another for protein binding in gel retardation assays (see 
Figure 11.14 and Table 11.1), which implies that some protein factors in the nuclear 
extracts can bind to several regions within the promoter, and it is likely that a “multi­
protein complex bridge” is built across these regions stablised by DNA secondary 
structure. Therefore, it is worthwhile to use longer oligonucleotides in gel retardation 
and “supershift” analysis, which contain two or more footprints.
However, it may also be actually true that Fli-1 does not transactivate the bcl-2 
promoter by directly binding to the DNA. The fact that neither E74 or Fli 
oligonucleotides competes with any of the FPs oligonucleotides, although they do bind
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to both in vitro translated Fli-1 and the Fli-1 protein present in the ELM-I/1 nuclear 
extracts, suggests that this might be the case. Instead, Fli-1 may bind to other protein 
factor(s) in a proteimDNA complex. Such an interaction between Fli-1 and another 
factor might not be resolved in gel retardation and “supershift” assays. There are several 
precedents for such interactions: since transactivation by many Ets proteins has been 
shown to require multiple co-factors that physically interact with them (see Section 
4.1.2). In particular, Elk-1 (Hipskind et a l , 1991), SAP1 (Dalton and Treisman, 1992) 
and Fli-1 (Watson et a l , 1997) can recognise and interact with the serum response 
factor (SRF) bound to the DNA, and form a stable ternary complex, but not the naked 
DNA. To determine whether Fli-1 was present in those multiple proteimDNA 
complexes responsible for the footprints observed in DNase I footprinting analysis, it 
would be worthwhile to perform immuno-depletion prior to footprinting assays and see 
if footprinting patterns are altered. However, it should bear in mind that since many 
protein factors can be involved in binding to a promoter region, the changes due to the 
lack of one protein may be subtle. To identity those unknown factor(s) that bind to the 
minimum bcl-2 promoter and Fli-1, and further dissect the molecular mechanisms 
whereby Fli-1 transactivates the bcl-2 promoter, the yeast one and two hybrid systems 
can be used.
The fact that the molecular mechanism(s) whereby Fli-1 transactivates the bcl-2 
promoter is still elusive does not exclude a regulatory role of Fli-1 in regulating the bcl- 
2 expression. This is emphasised by the discovery that the fli-1 and bcl-2 transgenic 
mice display certain similar phenotypes (see Section 4.2). These similarities indicate 
that these two proteins may have similar functional end points. One possibility, 
tentatively suggested by the present finding, is that Fli-1 and Bcl-2 are part of the same 
pathway and, in this scenario, it is possible that Fli-1 may lie upstream of Bcl-2 and 
regulate its activity, directly or indirectly. However, it is also possible that they act 
through distinct pathways which converge at some point.
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